NZ713074B2 - Bicyclic heterocycles as fgfr inhibitors - Google Patents

Bicyclic heterocycles as fgfr inhibitors Download PDF

Info

Publication number
NZ713074B2
NZ713074B2 NZ713074A NZ71307414A NZ713074B2 NZ 713074 B2 NZ713074 B2 NZ 713074B2 NZ 713074 A NZ713074 A NZ 713074A NZ 71307414 A NZ71307414 A NZ 71307414A NZ 713074 B2 NZ713074 B2 NZ 713074B2
Authority
NZ
New Zealand
Prior art keywords
alkyl
nrc6
aryl
cycloalkyl
independently selected
Prior art date
Application number
NZ713074A
Other versions
NZ713074A (en
Inventor
Chunhong He
Liang Lu
Dingquan Qian
Yaping Sun
Liangxing Wu
Meizhong Xu
Wenqing Yao
Fenglei Zhang
Jincong Zhuo
Ding Quan Qian
Original Assignee
Incyte Holdings Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Holdings Corporation filed Critical Incyte Holdings Corporation
Priority to NZ752422A priority Critical patent/NZ752422B2/en
Priority claimed from PCT/US2014/034662 external-priority patent/WO2014172644A2/en
Publication of NZ713074A publication Critical patent/NZ713074A/en
Publication of NZ713074B2 publication Critical patent/NZ713074B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

The present invention relates to bicyclic heterocycles of Formula IIIa, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.

Description

BICYCLIC HETEROCYCLES AS FGFR INHIBITORS FIELD OF THE INVENTION The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR—associated diseases such as cancer.
BACKGROUND OF ION The Fibroblast Growth Factor Receptors (FGFR) are receptor tyrosine kinases that bind to fibroblast growth factor (FGF) ligands. There are four FGFR proteins (FGFRl-4) that are capable of g ligands and are ed in the regulation of many physiological processes including tissue development, angiogenesis, wound healing, and metabolic regulation. Upon ligand binding, the receptors undergo zation and phosphorylation g to stimulation of the protein kinase activity and recruitment of many ellular docking proteins. These interactions facilitate the activation of an array of intracellular signaling ys including Ras-MAPK, AKT-PI3K, and phospholipase C that are important for cellular growth, eration and survival (Reviewed in Eswarakumar et al.
Cytokine & Growth Factor Reviews, 2005). Aberrant activation of this pathway either through overexpression of FGF ligands or FGFR or ting mutations in the FGFRs can lead to tumor development, progression, and ance to conventional cancer therapies. In human cancer, genetic alterations including gene amplification, chromosomal translocations and somatic mutations that lead to ligand-independent receptor activation have been described. Large scale DNA sequencing of thousands of tumor samples has revealed that ents of the FGFR pathway are among the most frequently mutated in human cancer.
Many of these ting mutations are identical to germline mutations that lead to skeletal sia syndromes. Mechanisms that lead to aberrant ligand-dependent signaling in human disease include overexpression of FGFs and changes in FGFR splicing that lead to receptors with more promiscuous ligand binding abilities (Reviewed in Knights and Cook Pharmacology & Therapeutics, 2010; Turner and Grose, Nature Reviews Cancer, 2010).
Therefore, development of inhibitors targeting FGFR may be useful in the al treatment of diseases that have elevated FGF or FGFR activity.
The cancer types in which FGF/FGFRs are ated include, but are not limited to: carcinomas (e. g., bladder, , cervical, colorectal, endometrial, gastric, head and neck, kidney, liver, lung, ovarian, prostate); hematopoietic malignancies (e. g., multiple a, chronic lymphocytic lymphoma, adult T cell leukemia, acute myelogenous leukemia, non— n lymphoma, myeloproliferative neoplasms, and Waldenstrom's Macroglubulinemia); and other neoplasms (e. g., glioblastoma, melanoma, and rhabdosarcoma). In addition to a role in oncogenic neoplasms, FGFR activation has also been implicated in skeletal and ocyte disorders including, but not limited to, achrondroplasia and craniosynostosis syndromes.
There is a continuing need for the pment of new drugs for the treatment of cancer and other diseases, and the FGFR inhibitors described herein help address this need.
SUMMARY OF INVENTION The present invention is directed to inhibitors of FGFR having Formula 1: R3 R5 \o )L N w R2 R6 \ R7 N [Tl/ R8 or a pharmaceutically acceptable salt thereof, wherein constituent variables are defined herein.
The present invention is further directed to pharmaceutical compositions comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and at least one ceutically acceptable r.
The present invention is further directed to methods of inhibiting an FGFR enzyme sing contacting the enzyme with a compound of Formula I, or a pharmaceutically acceptable salt thereof.
The present invention is r directed to a method of treating a disease associated with abnormal activity or expression of an FGFR enzyme, sing administering a compound of Formula I, or a pharmaceutically acceptable salt thereof, to a patient in need thereof.
The present invention is further directed to compounds of Formula I for use in treating a disease associated with abnormal ty or expression of an FGFR .
The t invention is further directed to the use of compounds of Formula I in the preparation of a medicament for use in therapy.
DETAILED PTION The present invention is ed to inhibitors of FGFR having Formula I: R3 R5 \o i N w R2 R6 \ R7 N [11/ R8 or a pharmaceutically able salt thereof, wherein: w is NR9, o, or CRloR"; R1 is C1_6 alkyl, C1_6haloalkyl, or c3_7 cycloalkyl, R2, R3, and R5 are each independently selected from H, halo, C1_6 alkyl, C2_6 alkenyl, 02.6 alkynyl, 01.6 haloalkyl, cyclopropyl, CN, OR", SR3, C(O)Rb, C(O)NRcRd, C(O)ORa, OC(O)Rb, OC(O)NRcRd, NRcRd, NRCC(O)Rb, NRCC(O)ORa, NRCC(O)NRcRd, C(=NRe)Rb, C(=NRC)NRcRd, NRC)NRcRd, NRCS(O)Rb, NRCS(O)2Rb, NRCS(O)2NRcRd, S(O)Rb, S(O)NRcRd, S(O)2Rb, and S(O)2NRCRd; R4 is H, halo, C1_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C1_6 haloalkyl, C3_7 cycloalkyl, 4-7 membered heterocycloalkyl, CN, 0R", SR‘", C(O)Rb1, C(O)NRC1R‘", C(O)ORal, OC(O)Rb1, OC(O)NR°1R‘", NRClel, NRC1C(O)Rb1, NRC1C(O)OR‘", NRclc(0)NRcle1, C(=NR€1)Rb1, C(=NR€1)NRC1R‘", NR"C(=NR€1)NR"R‘", NRCls(O)Rb1, NR"S(0)2R", NR"S(0)2NR01R‘" u 1, S(0)NR"R‘", S(O)2Rb1, and S(O)2NRC1Rd1; wherein said C1_6 alkyl, CM alkenyl, C2_6 alkynyl, C3_7 cycloalkyl, and 4-7 membered cycloalkyl are each optionally substituted With l, 2, or 3 substituents independently selected from halo, C1_6 alkyl, C2_6 alkenyl, 02.6 alkynyl, 01.6 haloalkyl, CN, N02, 0R", SR", C(O)Rb1, C(O)NRC1R‘", C(O)ORa1, OC(O)Rb1, OC(O)NRCle1, C(=NR61)NRC1R‘",NRC1C(=NR61)NRC1R‘",NRClR‘", NRC1C(O)Rb1, NRC1C(O)OR31, NRC1C(O)NRC1R‘", NR"S(0)R", )2R", NR"S(0)2NR01R", S(O)Rb1, C1R‘", S(O)2Rb1, and RC1R‘"; R6 is H, halo, C1_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C1_6 haloalkyl, C6_10 aryl, C3_10 cycloalkyl, 5—10 membered aryl, 4—10 membered heterocycloalkyl, CN, N02, ORaZ, SRaZ, C(O)Rb2, C(O)NRC2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRC2Rd2, NRcszz, NRC2C(O)Rb2, NRCZC(O)OR32, NRCZC(O)NR°2Rd2, C(=NR€2)Rb2, C(=NR62)NRCZRd2, NRC2C(=NR62)NRCZRd2, NRCZS(O)Rb2, NRCZS(O)2Rb2, NRCZS(O)2NRCZRd2, S(O)Rb2, S(O)NRC2Rd2, z, or S(O)2NRCZRd2; wherein said 01.6 alkyl, 02.6 alkenyl, 02.6 alkynyl, 06.10 aryl, C3_10cycloalkyl, —10 membered heteroaryl, and 4—10 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently ed from R63; wherein R6 is other than H when W is NR9; each R6a is ndently selected from Cyl, halo, C1_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, 01.6 haloalkyl, CN, N02, ORaZ, SRaZ, C(O)Rb2, C(O)NRC2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRC2Rd2, C(=NR€2)NRcsz2, NRC2C(=NR62)NR°2Rd2, NRcszz, NRC2C(O)Rb2, NRCZC(O)OR32, NRCZC(O)NRCZRd2, NRCZS(O)Rb2, NRCZS(O)2Rb2, NRCZS(O)2NRcsz2, S(O)Rb2, S(O)NRC2Rd2, S(O)2Rb2, and Rcsz2, wherein said 01.6 alkyl, 02.6 l, and CM alkynyl are each optionally substituted with 1, 2, or 3 tuents independently selected from Cyl, halo, CN, N02, ORaZ, SRaZ, C(O)Rb2, C(O)NRC2Rd2, C(O)OR"2, OC(O)Rb2, OC(O)NRCZRd2, C(=NR62)NRcsz2, NRC2C(=NR62)NRCZRd2, NRcszz, NRC2C(O)Rb2, NRCZC(O)OR32, NRC2C(O)NRCZRd2, NRCZS(O)Rb2, NRCZS(O)2Rb2, NRCZS(O)2NRCZRd2, S(O)Rb2, S(0)NR°2Rd2, S(O)2Rb2, and RCZRd2; R7 and R8 are each independently selected from H, C1_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, —C(O)RA, S(O)RA, A, 06.10 aryl, C3_1ocycloalkyl, 5—10 membered heteroaryl,4-10 membered heterocycloalkyl, C640 aryl-C1_4 alkyl, C340 cycloalkyl-C1_4 alkyl, (5-10 membered heteroaryl)-C1_4 alkyl, or (4-10 membered heterocycloalkyl)-C1_4 alkyl, n said C1_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C640 aryl, C340 cycloalkyl, 5-10 membered heteroaryl, 4—10 membered heterocycloalkyl, C640 aryl-C1_4 alkyl, C340 cycloalkyl-C1_4 alkyl, (5-10 membered heteroaryl)-C1_4 alkyl, and (4-10 membered heterocycloalkyl)-C1_4 alkyl are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from R73; each R7a is independently selected from Cyz, halo, C1_6 alkyl, C2_6 l, C2_6 alkynyl, 01.6 haloalkyl, CN, N02, 0R", S1133, C(O)Rb3, C(O)NRC3Rd3, C(O)ORa3, OC(O)Rb3, OC(O)NRC3Rd3, C(=NR€3)NRC3Rd3, NRc3C(=NRe3)NRc3Rd3, NRC3Rd3, O)Rb3, NRC3C(O)OR"3, NRC3C(O)NRC3Rd3, NRC3S(O)Rb3, NRC3S(O)2Rb3, NRC3S(O)2NRC3R‘B, S(O)Rb3, S(O)NRC3Rd3, S(O)2Rb3, and S(O)2NRC3Rd3, wherein said 01.6 alkyl, 02.6 alkenyl, and C2_6 alkynyl are each optionally substituted with l, 2, or 3 substituents independently selected from Cyz, halo, CN, N02, 0R", SRa3, C(O)Rb3, C(O)NRC3Rd3, C(O)OR"3, b3, OC(O)NRC3Rd3, C(=NRC3)NRC3Rd3, =NRC3)NRC3R‘B, NRC3Rd3, NRC3C(O)Rb3, NRC3C(O)OR"3, NRC3C(O)NRC3Rd3, NRC3S(O)Rb3, NRC3S(O)2Rb3, NR°3S(O)2NRC3R‘B, S(O)Rb3, S(0)NR°3Rd3, S(O)2Rb3, and S(O)2NRC3Rd3; R9 is H, C1_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C640 aryl, C3_10 cycloalkyl, 5-10 membered heteroaryl, 4—10 membered heterocycloalkyl, €6-10 aryl—C1_4 alkyl, €3-10 cycloalkyl— C1_4 alkyl, (5-10 ed heteroaryl)-C1_4 alkyl, or (4-10 membered heterocycloalkyl)—C1_4 alkyl, wherein said C1_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C640 aryl, C340 cycloalkyl, 5-10 membered heteroaryl, 4—10 membered heterocycloalkyl, €6-10 aryl—C1_4 alkyl, €3-10 cycloalkyl— C1_4 alkyl, (5-10 ed heteroaryl)-C1_4 alkyl, and (4-10 membered heterocycloalkyl)—C1_4 alkyl are each optionally substituted with l, 2, 3, 4, or 5 substituents independently selected from Rga; each R9a is independently selected from Cy3, halo, C1_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, 01.6 haloalkyl, CN, N02, 0R", SR", C(O)Rb4, C4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NR°4Rd4, C(=NR64)NRC4Rd4, =NRe4)NRc4Rd4, 4, NR°4C(O)Rb4, NRC4C(O)ORa4, NRc4C(0)NRc4Rd4, NR°48(O)Rb4, NR°48(O)2Rb4, NRC4S(O)2NRC4Rd4, S(O)Rb4, S(O)NRC4Rd4, S(O)2Rb4, and S(O)2NR°4Rd4, wherein said 01.6 alkyl, 02.6 alkenyl, and C2_6 alkynyl are each optionally substituted with l, 2, or 3 tuents independently selected from Cy3, halo, CN, N02, 0R", SR", C(O)Rb4, C4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NR°4Rd4, 4)NRC4Rd4, NRC4C(=NRC4)NRC4Rd4, 4, NRC4C(O)Rb4, NRC4C(O)ORa4, NRc4C(0)NR°4Rd4, O)Rb4, NRC4S(O)2Rb4, NRC4S(O)2NRC4Rd4, S(O)Rb4, S(0)NR°4Rd4, S(O)2Rb4, and S(O)2NRC4Rd4; R10 and R11 are each independently selected from H, C1_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C1_6 haloalkyl, C640 aryl, C3_10 cycloalkyl, 5-10 membered heteroaryl, 4—10 membered heterocycloalkyl, CN, N02, ORa4, SRa4, C(O)Rb4, C(O)NR°4Rd4, C(O)ORa4, OC(O)Rb4, R°4Rd4, NR°4Rd4, NRC4C(O)Rb4, NR°4C(O)ORa4, NR°4C(O)NR°4Rd4, C(=NR64)Rb4, C(=NR€4)NRc4Rd4, NRc4C(=NRe4)NRc4Rd4, NRC4S(O)Rb4, NRC4S(O)2Rb4, NRC4S(O)2NRC4Rd4, S(O)Rb4, S(O)NRC4Rd4, S(O)2Rb4, and S(O)2NRC4Rd4; wherein said 01.6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C640 aryl, C340 cycloalkyl, 5-10 membered heteroaryl, and 4— membered heterocycloalkyl are each optionally substituted with l, 2, 3, 4, or 5 substituents independently selected from Rloa; each R10a is independently selected from Cy3, halo, C1_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, 01.6 haloalkyl, CN, N02, 0R", SR", C(0)R", C(0)NR"R", C(0)0R", OC(O)R", OC(O)NR"R", C(=NR")NR"R", NR"C(=NR")NR"R", NR"R", NR"C(0)R", NR"C(0)0R", NR"C(0)NR"R", NR"S(0)R", O)2Rb4, NR"S(0)2NR"R", S(0)R", S(0)NR"R", S(O)2Rb4, and S(O)2NR°4Rd4, wherein said 01.6 alkyl, 02.6 alkenyl, and C2_6 alkynyl are each optionally substituted with l, 2, or 3 substituents independently selected from Cyz, halo, CN, N02, 0R", SR", C(0)R", C(0)NR"R", ", ", OC(O)NR"R", C(=NR")NR"R", NR"C(=NR")NR"R", NR"R", NR"C(0)R", NR"C(0)0R", NR"C(0)NR"R", NR"S(0)R", NR"S(0)2R", NR"S(0)2NR"R", S(0)R", S(0)NR"R", S(O)2Rb4, and S(0)2NR"R", or R10 and R11 er with the carbon atom to which they are ed form a 3-, 4-, —, 6—, or 7—membered cycloalkyl group or a 4—, 5—, 6—, or 7—membered heterocycloalkyl group, each optionally substituted with l, 2, or 3 substituents ndently selected from cy3, 01.6 alkyl, C1_6haloalkyl, halo, CN, 0R", SR", C(0)R", C(0)NR"R", ", OC(O)R", OC(O)NR"R", NR"R", NR"C(0)R", NR"C(0)NR"R", NR"C(0)0R", C(=NR")NR"R", NR"C(=NR")NR"R", S(0)R", S(0)NR"R", S(O)2Rb4, NR°48(O)2Rb4, NR"S(0)2NR"R", and S(O)2NRC4Rd4, wherein said 01.6 alkyl is optionally substituted by 1, 2, or 3 substituents independently selected from Cy3, halo, CN, ORa4, SRa4, C(O)Rb4, C(0)NR"R", ", OC(O)R", R"R", NR"R", NR"C(0)R", NR"C(0)NR"R", )0R", C(=NR")NR"R", NR"C(=NR")NR"R", S(0)R", S(0)NR"R", S(O)2Rb4, NR"S(0)2R", NR°48(O)2NR°4Rd4, and S(0)2NR"R", each RA is independently selected from H, C1_6 alkyl, C1_6 alkoxy, C640 aryl, C340 cycloalkyl, 5—10 membered aryl, 4-10 membered heterocycloalkyl, C640 aryl-C1_4 alkyl, C340 cycloalkyl-C14 alkyl, (5-10 membered heteroaryl)-C1_4 alkyl, and (4-10 membered heterocycloalkyl)-C1_4 alkyl, wherein said C1_6 alkyl, C1_6 alkoxy, C640 aryl, C3_10 cycloalkyl, —10 membered heteroaryl, 4—10 membered heterocycloalkyl, €6.10 aryl—C1_4 alkyl, €3.10 cycloalkyl-C14 alkyl, (5-10 membered heteroaryl)—C1_4 alkyl, and (4-10 membered cycloalkyl)-C1_4 alkyl are each optionally substituted with l, 2, or 3 substituents independently selected from R"; Cyl, Cyz, and Cy3 are each independently ed from C640 aryl, C3_10cycloalkyl, 5— membered heteroaryl, and 4—10 ed heterocycloalkyl, each of which is optionally substituted by l, 2, 3, 4, or 5 substituents independently selected from halo, C1_6 alkyl, C26 alkenyl, CM alkynyl, C1_6 haloalkyl, €6.10 aryl, €3.10 cycloalkyl, 5—10 ed heteroaryl, 3— membered heterocycloalkyl, CN, N02, 0R", SRaS, 5, C(O)NR°5Rd5, C(O)OR35, OC(O)Rb5, OC(O)NRC5Rd5, NRCSRdS, NRC5C(O)Rb5, NRCSC(O)OR"5, NRC5C(O)NR05Rd5, C(=NR€5)Rb5, 5)NRCSRd5, NRC5C(=NR65)NRCSRd5, NRCSS(O)Rb5, O)2Rb5, NRCSS(O)2NRCSRd5, S(O)Rb5, S(O)NRCSRd5, S(O)2Rb5, and S(O)2NRCSRd5; wherein said 01.6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C640 aryl, C340 cycloalkyl, 5-10 membered heteroaryl, and 4— ed heterocycloalkyl are each optionally substituted with l, 2, 3, 4, or 5 substituents independently selected from halo, C1_6 alkyl, CM alkenyl, CM alkynyl, C1_6 haloalkyl, CN, N02, 0R", SRaS, C(O)Rb5, C(O)NRC5Rd5, C(O)ORa5, OC(O)Rb5, OC(O)NRCSRd5, C(=NR€5)NRCSRd5, =NR65)NRCSRd5, NRCSRdS, NRC5C(O)Rb5, NRcsc(0)0R35, NR65C(O)NR05Rd5, NRCSS(O)Rb5, NRCSS(O)2Rb5, NRCSS(O)2NRCSRd5, S(O)Rb5, S(O)NR65Rd5, S(O)2Rb5, and S(O)2NRC5Rd5; each Ra, Rb, RC, and Rd is ndently selected from H, C1_6 alkyl, C1_4 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, and cyclopropyl, wherein said C1_6 alkyl, C2_6 alkenyl, C26 alkynyl, and cyclopropyl is ally substituted with l, 2, or 3 tuents independently selected from 01.4 alkyl, loalkyl, halo, CN, 0Ra6, SRa6, C(O)Rb6, C(O)NRC6Rd6, C(O)ORa6, b6, OC(O)NRC6Rd6, NRC6Rd6, NRC6C(O)Rb6, NRC6C(O)NRC6Rd6, NRC6C(O)ORa6, C(=NR€6)NRC6Rd6, NRC6C(=NRC6)NRC6Rd6, S(O)Rb6, S(O)NRC6Rd6, S(O)2Rb6, NRC6S(O)2Rb6, NRC6S(O)2NRC6Rd6, and S(O)2NRC6Rd6; each Ral, Rbl) Rel, Rdl) Ra2, sz) Rc2, Rdz) Ra3, Rb3, Rc3, Rd3, Ra4, Rb4, Rc4, and Rd4, Ra5, Rbs, R65, and Rds is independently ed from H, C1_6 alkyl, C1_4 haloalkyl, C2_6 alkenyl, C2. 6 alkynyl, €6.10 aryl, €3.10 cycloalkyl, 5—10 membered heteroaryl, 4—10 membered heterocycloalkyl, C640 aryl-C1_4 alkyl, C340 cycloalkyl-C1_4 alkyl, (5-10 ed heteroaryl)-C1_4 alkyl, or (4-10 membered heterocycloalkyl)-C1_4 alkyl, wherein said C1_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C640 aryl, C340 cycloalkyl, 5-10 membered aryl, 4—10 membered heterocycloalkyl, C640 aryl-C1_4 alkyl, C340 cycloalkyl-C1_4 alkyl, (5-10 membered heteroaryl)-C1_4 alkyl, and (4-10 membered heterocycloalkyl)-C1_4 alkyl is optionally substituted with l, 2, 3, 4, or 5 substituents independently selected from C1_4 alkyl, C1_4 haloalkyl, halo, CN, 0R", SRa6, C(O)Rb6, C(O)NRC6Rd6, C(O)ORa6, OC(O)Rb6, OC(O)NRC6Rd6, NRC6Rd6, NRC6C(O)Rb6, NRC6C(O)NRC6Rd6, NRc6C(0)0Ra6, C(=NR€6)NRC6Rd6, =NRC6)NRC6Rd6, S(O)Rb6, S(O)NRC6Rd6, S(O)2Rb6, NRC6S(O)2Rb6, NRC6S(O)2NRC6Rd6, and S(O)2NRC6Rd6; or any Rc and Rd together with the N atom to which they are attached form a 4-, 5-, 6-, or 7—membered heterocycloalkyl group optionally substituted with l, 2, or 3 substituents independently ed from C1_6 alkyl, C3_7 cycloalkyl, 4-7 membered heterocycloalkyl, C640 aryl, 5-6 membered heteroaryl, C1_6 haloalkyl, halo, CN, ORa6, SRa6, C(O)Rb6, C(O)NRC6Rd6, C(0)0R", OC(O)R", OC(O)NR"R", NR"R", NR"C(0)R", NR"C(0)NR"R", NR"C(0)0R", C(=NR")NR"R", NR"C(=NR")NR"R", S(0)R", S(0)NR"R", S(O)2Rb6, NR"S(0)2R", NR"S(0)2NR"R", and S(O)2NRC6Rd6, wherein said 01.6 alkyl, 03.7 cycloalkyl, 4-7 membered heterocycloalkyl, C640 aryl, and 5-6 membered heteroaryl are optionally substituted by l, 2, or 3 substituents independently selected from halo, CN, ORa6, SR", C(0)R", "R", C(0)0R", OC(O)R", OC(O)NR"R", NR"R", )R", NR"C(0)NR"R", NR"C(0)0R", C(=NR")NR"R", NR"C(=NR")NR"R", S(0)R", S(0)NR"R", b6, NR"S(0)2R", NR"S(0)2NR"R", and S(0)2NR"R", or any RC1 and Rdl together with the N atom to which they are attached form a 4-, 5-, 6—, or ered heterocycloalkyl group optionally substituted with l, 2, or 3 substituents independently selected from C1_6 alkyl, C3_7 cycloalkyl, 4-7 membered heterocycloalkyl, C640 aryl, 5-6 membered heteroaryl, C1_6 haloalkyl, halo, CN, ORa6, SRa6, C(O)Rb6, C(O)NRC6Rd6, C(0)0R", OC(O)R", OC(O)NR"R", NR"R", NR"C(0)R", )NR"R", NR"C(0)0R", C(=NR")NR"R", NR"C(=NR")NR"R", S(0)R", S(0)NR"R", S(O)2Rb6, NR"S(0)2R", NR"S(0)2NR"R", and S(O)2NRC6Rd6, wherein said 01.6 alkyl, 03.7 cycloalkyl, 4-7 membered heterocycloalkyl, C640 aryl, and 5-6 membered heteroaryl are optionally substituted by l, 2, or 3 tuents independently selected from halo, CN, ORa6, SR", C(0)R", C(0)NR"R", C(0)0R", ", OC(O)NR"R", NR"R", NR"C(0)R", NR"C(0)NR"R", NR"C(0)0R", C(=NR")NR"R", NR"C(=NR")NR"R", S(0)R", S(0)NR"R", S(O)2Rb6, NR"S(0)2R", )2NR"R", and S(0)2NR"R", or any RC2 and Rdz er with the N atom to which they are attached form a 4-, 5-, 6—, or 7—membered heterocycloalkyl group ally tuted with l, 2, or 3 substituents independently ed from C1_6 alkyl, C3_7 cycloalkyl, 4-7 membered cycloalkyl, C640 aryl, and 5-6 membered heteroaryl, C1_6 haloalkyl, halo, CN, ORa6, SRa6, C(O)Rb6, C(0)NR"R", C(0)0R", OC(O)R", OC(O)NR"R", NR"R", NR"C(0)R", NR"C(0)NR"R", NR"C(0)0R", C(=NR")NR"R", NR"C(=NR")NR"R", S(0)R", S(0)NR"R", S(O)2Rb6, NR"S(0)2R", NR"S(0)2NR"R", and S(0)2NR"R", wherein said C1_6 alkyl, C3_7 cycloalkyl, 4-7 membered heterocycloalkyl, C640 aryl, and 5—6 membered heteroaryl are optionally substituted by l, 2, or 3 tuents independently selected from halo, CN, 0R", SR", C(0)R", C(0)NR"R", C(0)0R", OC(O)R", R"R", NR"R", NR"C(0)R", NR"C(0)NR"R", NR"C(0)0R", C(=NR")NR"R", NRc6C(=NRe6)NRc6Rd6, S(O)Rb6, S(O)NRC6Rd6, S(O)2Rb6, NRC6S(O)2Rb6, NRC6S(O)2NRC6Rd6, and S(O)2NRC6Rd6; or any RC3 and Rd3 together with the N atom to which they are attached form a 4-, 5-, 6—, or 7—membered heterocycloalkyl group optionally substituted with l, 2, or 3 substituents independently ed from C1_6 alkyl, C3_7 cycloalkyl, 4-7 membered heterocycloalkyl, C640 aryl, 5-6 membered heteroaryl, C1_6 haloalkyl, halo, CN, ORa6, SRa6, C(O)Rb6, C(O)NRC6Rd6, C(O)ORa6, OC(O)Rb6, RC6Rd6, NRC6Rd6, NRC6C(O)Rb6, NRC6C(O)NRC6Rd6, NRC6C(O)OR36, C(=NRC6)NRC6Rd6, NRc6C(=NRe6)NRc6Rd6, S(O)Rb6, S(O)NRC6Rd6, S(O)2Rb6, O)2Rb6, NRC6S(O)2NRC6Rd6, and RC6Rd6, wherein said 01.6 alkyl, 03.7 cycloalkyl, 4-7 membered heterocycloalkyl, C640 aryl, and 5-6 membered heteroaryl are ally substituted by l, 2, or 3 substituents ndently selected from halo, CN, ORa6, SRa6, C(O)Rb6, C(O)NRC6Rd6, C(O)ORa6, OC(O)Rb6, OC(O)NRC6Rd6, NRC6Rd6, NRC6C(O)Rb6, NRC6C(O)NRC6Rd6, NRC6C(O)OR36, C(=NRC6)NRC6Rd6, NRC6C(=NRC6)NRC6Rd6, S(O)Rb6, S(O)NRC6Rd6, S(O)2Rb6, NRC6S(O)2Rb6, NRC6S(O)2NRC6Rd6, and S(O)2NRC6Rd6; or any RC4 and Rd4 together with the N atom to which they are attached form a 4-, 5-, 6—, or 7—membered heterocycloalkyl group optionally substituted with l, 2, or 3 substituents independently selected from C1_6 alkyl, C3_7 cycloalkyl, 4-7 membered heterocycloalkyl, C640 aryl, 5-6 membered heteroaryl, C1_6 haloalkyl, halo, CN, ORa6, SRa6, C(O)Rb6, C(O)NRC6Rd6, C(O)ORa6, OC(O)Rb6, RC6Rd6, NRC6Rd6, NRC6C(O)Rb6, NRC6C(O)NRC6Rd6, O)OR36, C(=NRC6)NRC6Rd6, NRc6C(=NRe6)NRc6Rd6, S(O)Rb6, S(O)NRC6Rd6, S(O)2Rb6, NRC6S(O)2Rb6, NRC6S(O)2NRC6Rd6, and RC6Rd6, wherein said 01.6 alkyl, 03.7 cycloalkyl, 4-7 membered heterocycloalkyl, C640 aryl, and 5-6 membered heteroaryl are optionally substituted by l, 2, or 3 substituents independently selected from halo, CN, ORa6, SRa6, C(O)Rb6, C6Rd6, C(O)ORa6, OC(O)Rb6, OC(O)NRC6Rd6, NRC6Rd6, NRC6C(O)Rb6, NRC6C(O)NRC6Rd6, NRC6C(O)OR36, C(=NR€6)NRC6Rd6, NRC6C(=NRC6)NRC6Rd6, 6, S(O)NRC6Rd6, S(O)2Rb6, NRC6S(O)2Rb6, NRC6S(O)2NRC6Rd6, and S(O)2NRC6Rd6; or any Rcs and Rds together with the N atom to which they are ed form a 4-, 5-, 6—, or 7—membered heterocycloalkyl group ally substituted with l, 2, or 3 substituents independently selected from C1_6 alkyl, C3_7 cycloalkyl, 4-7 membered heterocycloalkyl, C640 aryl, 5-6 membered heteroaryl, C1_6 haloalkyl, halo, CN, ORa6, SRa6, C(O)Rb6, C(O)NRC6Rd6, C(O)ORa6, b6, OC(O)NRC6Rd6, NRC6Rd6, NRC6C(O)Rb6, NRC6C(O)NRC6Rd6, NRC6C(O)OR36, 6)NRC6Rd6, NRc6C(=NRe6)NRc6Rd6, S(O)Rb6, S(O)NRC6Rd6, S(O)2Rb6, NRC6S(O)2Rb6, NRC6S(O)2NRC6Rd6, and S(O)2NRC6Rd6, wherein said 01.6 alkyl, 03.7 cycloalkyl, 4-7 ed heterocycloalkyl, C640 aryl, and 5-6 membered heteroaryl are optionally tuted by l, 2, or 3 substituents independently selected from halo, CN, ORa6, SRa6, C(O)Rb6, C(O)NRC6Rd6, C(O)ORa6, OC(O)Rb6, RC6Rd6, NRC6Rd6, O)Rb6, NRC6C(O)NRC6Rd6, NRC6C(O)OR36, C(=NR€6)NRC6Rd6, NRC6C(=NRC6)NRC6Rd6, S(O)Rb6, S(O)NRC6Rd6, S(O)2Rb6, NRC6S(O)2Rb6, NRC6S(O)2NRC6Rd6, and S(O)2NRC6Rd6; each R6, R61, R62, R63 and Res is independently selected from H, C1_4 alkyl, CN, , RC4, 0R", SRb6, S(O)2Rb6, C(O)Rb6, RC6Rd6, and C(O)NRC6Rd6; each R", Rb6, RC6, and Rd6 is independently selected from H, C1_4 alkyl, C1_4 haloalkyl, C2_4 l, and C2_4 alkynyl, wherein said C1_4 alkyl, C2_4 alkenyl, and C2_4 l, is optionally substituted with l, 2, or 3 substituents independently selected from OH, CN, amino, halo, C1_4 alkyl, C1_4 alkoxy, C1_4 alkylthio, C1_4 alkylamino, di(C1_4 alkyl)amino, C1_4 haloalkyl, and C1_4 haloalkoxy; or any RC6 and Rd6 together with the N atom to which they are attached form a 4-, 5-, 6—, or 7—membered heterocycloalkyl group optionally substituted with l, 2, or 3 substituents independently selected from OH, CN, amino, halo, C1_6 alkyl, C1_4 alkoxy, C1_4 hio, C1_4 alkylamino, di(C1_4 alkyl)amino, C1_4 haloalkyl, and C1_4 haloalkoxy; and each R66 is independently selected from H, C1_4 alkyl, and CN.
The present invention is directed to inhibitors of FGFR having Formula 1: R3 R5 \o i N w R2 R6 \ R7 N [11/ 1 or a pharmaceutically acceptable salt thereof, wherein: w is NR9, o, or ; R1 is 01.6 alkyl, C1_6haloalkyl, or 03.7 cycloalkyl; R2, R3, and R5 are each independently selected from H, halo, C1_6 alkyl, C2_6 alkenyl, 02.6 alkynyl, 01.6 haloalkyl, cyclopropyl, CN, OR", SR3, C(O)Rb, C(O)NRcRd, C(O)ORa, OC(O)Rb, OC(O)NRcRd, NRcRd, NRCC(O)Rb, NRCC(O)ORa, NRCC(O)NRcRd, C(=NRe)Rb, )NRcRd, NRCC(=NRC)NRcRd, NRCS(O)Rb, NRCS(O)2Rb, NRCS(O)2NRcRd, S(O)Rb, S(O)NRcRd, S(O)2Rb, and S(O)2NRCRd; R4 is H, halo, C1_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C1_6 haloalkyl, C3_7 cycloalkyl, 4-7 membered heterocycloalkyl, CN, 0R", SR‘", C(O)Rb1, C(O)NRC1R‘", al, OC(O)Rb1, OC(O)NR°1R‘", NRClel, NRC1C(O)Rb1, NRC1C(O)OR‘", NRclc(0)NRcle1, C(=NR€1)Rb1, C(=NR€1)NRC1R‘", NR"C(=NR€1)NR"R‘", NRCls(O)Rb1, NR"S(0)2R", NR"S(0)2NR"R‘", S(O)Rb1, S(0)NR"R‘", S(O)2Rb1, and S(O)2NRC1Rd1; wherein said 01.6 alkyl, 02.6 alkenyl, C2_6 alkynyl, C3_7 cycloalkyl, and 4-7 membered heterocycloalkyl are each optionally substituted With l, 2, or 3 substituents independently selected from halo, C1_6 alkyl, C2_6 l, 02.6 alkynyl, 01.6 haloalkyl, CN, N02, 0R", SR", C(O)Rb1, C(O)NRC1R‘", C(O)ORa1, OC(O)Rb1, OC(O)NRCle1, C(=NR€1)NRC1R‘", NRC1C(=NR61)NR°1R‘", NRClR‘", NRC1C(O)Rb1, NRC1C(O)OR"1, NRC1C(O)NRC1R‘", NRCls(O)Rb1, NR"S(0)2R", NR"S(0)2NRc1Rd1, S(O)Rb1, S(0)NR°1R‘", b1, and S(O)2NRC1Rd1; R6 is H, halo, C1_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C1_6 haloalkyl, C640 aryl, C340 lkyl, 5—10 membered heteroaryl, 4—10 membered heterocycloalkyl, CN, N02, ORaZ, SRaZ, C(O)Rb2, C(O)NRC2Rd2, C(O)ORa2, b2, OC(O)NRC2Rd2, NRcszz, NRC2C(O)Rb2, NRCZC(O)OR32, NRCZC(O)NRCZRd2, C(=NR€2)Rb2, C(=NR62)NRCZRd2, NRC2C(=NR62)NR°2Rd2, NRCZS(O)Rb2, NRCZS(O)2Rb2, O)2NRCZRd2, S(O)Rb2, S(O)NRC2Rd2, z, or S(O)2NRCZRd2; wherein said 01.6 alkyl, 02.6 alkenyl, 02.6 alkynyl, 06.10 aryl, C3_10cycloalkyl, 5—10 membered heteroaryl, and 4—10 membered heterocycloalkyl are each optionally substituted with l, 2, 3, 4, or 5 substituents independently selected from R6a; wherein R6 is other than H when W is NR9; each R6a is independently selected from Cyl, halo, C1_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, 01.6 haloalkyl, CN, N02, ORaZ, SRaZ, C(O)Rb2, C(O)NRC2Rd2, C(O)ORa2, b2, OC(O)NR°2Rd2, C(=NR€2)NRcsz2, NRC2C(=NR62)NRCZRd2, , NRC2C(O)Rb2, NRCZC(O)OR32, NRCZC(O)NRCZRd2, NRCZS(O)Rb2, O)2Rb2, O)2NRcsz2, S(O)Rb2, C2Rd2, S(O)2Rb2, and S(O)2NRcsz2, wherein said 01.6 alkyl, 02.6 alkenyl, and C2_6 alkynyl are each optionally substituted with l, 2, or 3 substituents independently selected from Cyl, halo, CN, N02, ORaZ, SRaZ, C(O)Rb2, C2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRCZRd2, C(=NR62)NRcsz2, NRC2C(=NR62)NRCZRd2, NRcszz, O)Rb2, NRCZC(O)OR32, NRC2C(O)NRCZRd2, O)Rb2, NRCZS(O)2Rb2, NRCZS(O)2NRCZRd2, S(O)Rb2, S(O)NRC2Rd2, S(O)2Rb2, and S(O)2NRCZRd2; R7 and R8 are each independently selected from H, C1_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, —C(O)RA, S(O)RA, S(O)2RA, 06.10 aryl, C3_1ocycloalkyl, 5—10 membered heteroaryl, 4—10 membered heterocycloalkyl, C640 aryl-C1_4 alkyl, C340 cycloalkyl-C1_4 alkyl, (5-10 ed heteroaryl)-C1_4 alkyl, or (4-10 membered heterocycloalkyl)-C1_4 alkyl, wherein said C1_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C640 aryl, C340 cycloalkyl, 5-10 membered heteroaryl, 4—10 membered heterocycloalkyl, C640 aryl-C1_4 alkyl, C340 cycloalkyl-C1_4 alkyl, (5-10 membered heteroaryl)-C1_4 alkyl, and (4-10 membered heterocycloalkyl)-C1_4 alkyl are each ally substituted with l, 2, 3, 4, or 5 substituents independently selected from R"; each R7a is independently selected from Cyz, halo, C1_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, 01.6 haloalkyl, CN, N02, 0R", S1133, C(O)Rb3, C3Rd3, C(O)ORa3, OC(O)Rb3, OC(O)NRC3Rd3, C(=NR€3)NRC3Rd3, NRC3C(=NRC3)NR°3R‘B, NRC3Rd3, NRC3C(O)Rb3, NRC3C(O)OR"3, NRC3C(O)NRC3Rd3, NRC3S(O)Rb3, NRC3S(O)2Rb3, NRC3S(O)2NRC3Rd3, S(O)Rb3, S(O)NRC3Rd3, S(O)2Rb3, and S(O)2NRC3Rd3, wherein said 01.6 alkyl, 02.6 alkenyl, and C2_6 alkynyl are each optionally substituted with l, 2, or 3 substituents independently selected from Cyz, halo, CN, N02, 0R", SRa3, 3, C(O)NR°3Rd3, C(O)ORa3, OC(O)Rb3, RC3Rd3, C(=NRC3)NRC3Rd3, NRC3C(=NRC3)NRC3R‘B, NRC3Rd3, NRC3C(O)Rb3, NRC3C(O)OR"3, NRC3C(O)NRC3Rd3, NRC3S(O)Rb3, NRC3S(O)2Rb3, NRC3S(O)2NRC3R‘B, S(O)Rb3, S(O)NRC3Rd3, S(O)2Rb3, and S(O)2NRC3Rd3; R9 is H, C1_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C640 aryl, C3_10 lkyl, 5-10 membered heteroaryl, 4—10 membered heterocycloalkyl, €6-10 aryl—C1_4 alkyl, €3-10 cycloalkyl— C1_4 alkyl, (5-10 membered heteroaryl)-C1_4 alkyl, or (4-10 membered heterocycloalkyl)—C1_4 alkyl, n said C1_6 alkyl, C2_6 l, C2_6 alkynyl, C640 aryl, C340 cycloalkyl, 5-10 membered heteroaryl, 4—10 ed heterocycloalkyl, €6-10 aryl—C1_4 alkyl, €3-10 cycloalkyl— C1_4 alkyl, (5-10 membered heteroaryl)-C1_4 alkyl, and (4-10 membered heterocycloalkyl)—C1_4 alkyl are each optionally substituted with l, 2, 3, 4, or 5 substituents independently selected from Rga; each R9a is independently selected from Cy3, halo, C1_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, 01.6 haloalkyl, CN, N02, 0R", SR", C(O)Rb4, C(O)NRC4Rd4, a4, OC(O)Rb4, OC(O)NR°4Rd4, C(=NR64)NRC4Rd4, NRc4C(=NRe4)NRc4Rd4, 4, NR°4C(O)Rb4, NRC4C(O)OR34, NRC4C(O)NR°4Rd4, NR°48(O)Rb4, NR°48(O)2Rb4, O)2NRC4Rd4, S(O)Rb4, S(O)NRC4Rd4, S(O)2Rb4, and S(O)2NR°4Rd4, wherein said 01.6 alkyl, 02.6 alkenyl, and C2_6 l are each optionally tuted with l, 2, or 3 substituents independently selected from Cy3, halo, CN, N02, 0R", SR", C(O)Rb4, C(O)NRC4Rd4, C(O)OR"4, OC(O)Rb4, OC(O)NR°4Rd4, C(=NR€4)NRC4Rd4, NRC4C(=NRC4)NRC4Rd4, NRC4Rd4, WO 72644 NR"C(0)R", NR"C(0)0R", NR"C(0)NR"R", NR"S(0)R", NR"S(0)2R", NR"S(0)2NR"R", S(0)R", S(0)NR"R", S(O)2Rb4, and S(0)2NR"R", R10 and R11 are each independently selected from H, C1_6 alkyl, C2_6 l, C2_6 alkynyl, C1_6 kyl, C640 aryl, C3_10 cycloalkyl, 5-10 membered heteroaryl, 4—10 membered heterocycloalkyl, CN, N02, ORa4, SRa4, C(O)Rb4, C(O)NR°4Rd4, C(O)ORa4, OC(O)R", OC(O)NR"R", NR"R", NR"C(0)R", NR"C(0)0R", )NR"R", C(=NR")R", C(=NR")NR"R", NR")NR"R", NR"S(0)R", NR"S(0)2R", NR"S(0)2NR"R", , S(0)NR"R", b4, and S(0)2NR"R", wherein said 01.6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C640 aryl, C340 cycloalkyl, 5-10 membered heteroaryl, and 4— 10 membered heterocycloalkyl are each optionally substituted with l, 2, 3, 4, or 5 substituents independently selected from Rloa; each R10a is independently selected from Cy3, halo, C1_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, 01.6 haloalkyl, CN, N02, 0R", SR", C(0)R", C(0)NR"R", C(0)0R", ", OC(O)NR"R", C(=NR")NR"R", NR"C(=NR")NR"R", NR"R", NR"C(0)R", NR"C(0)0R", NR"C(0)NR"R", NR"S(0)R", NR°48(O)2Rb4, NR"S(0)2NR"R", S(0)R", S(0)NR"R", S(O)2Rb4, and S(O)2NR°4Rd4, wherein said 01.6 alkyl, 02.6 alkenyl, and C2_6 l are each optionally substituted with l, 2, or 3 substituents independently selected from Cyz, halo, CN, N02, 0R", SR", C(0)R", C(0)NR"R", C(0)0R", ", OC(O)NR"R", C(=NR")NR"R", NR"C(=NR")NR"R", NR"R", NR"C(0)R", NR"C(0)0R", )NR"R", NR"S(0)R", )2R", NR"S(0)2NR"R", S(0)R", S(0)NR"R", S(O)2Rb4, and S(0)2NR"R", or R10 and R11 together with the carbon atom to which they are attached form a 3-, 4-, —, 6—, or 7—membered cycloalkyl group or a 4—, 5—, 6—, or 7—membered heterocycloalkyl group, each optionally substituted with l, 2, or 3 substituents independently selected from Cy3, 01.6 alkyl, C1_6haloalkyl, halo, CN, 0R", SR", C(0)R", C(0)NR"R", C(0)0R", OC(O)R", OC(O)NR"R", NR"R", NR"C(0)R", NR"C(0)NR"R", NR"C(0)0R", C(=NR")NR"R", NR"C(=NR")NR"R", S(0)R", S(0)NR"R", S(O)2Rb4, NR°48(O)2Rb4, NR"S(0)2NR"R", and S(O)2NRC4Rd4, wherein said 01.6 alkyl is optionally substituted by l, 2, or 3 substituents independently selected from Cy3, halo, CN, ORa4, SRa4, 4, C(0)NR"R", C(0)0R", OC(O)R", R"R", NR"R", NR"C(0)R", NR"C(0)NR"R", NR"C(0)0R", C(=NR")NR"R", NR"C(=NR")NR"R", S(0)R", S(0)NR"R", S(O)2Rb4, NR"S(0)2R", NR"S(0)2NR"R", and S(0)2NR"R", each RA is independently selected from H, C1_6 alkyl, C640 aryl, C3_10cycloalkyl, 5-10 membered heteroaryl, 4—10 membered heterocycloalkyl, €6-10 aryl—C1_4 alkyl, €3-10 cycloalkyl— C1_4 alkyl, (5-10 membered heteroaryl)-C1_4 alkyl, and (4-10 membered heterocycloalkyl)—C1_4 alkyl, wherein said C1_6 alkyl, C640 aryl, C340 cycloalkyl, 5-10 ed heteroaryl, 4-10 membered heterocycloalkyl, C640 aryl-C1_4 alkyl, C340 cycloalkyl-C1_4 alkyl, (5-10 membered heteroaryl)-C1_4 alkyl, and (4-10 membered heterocycloalkyl)-C1_4 alkyl are each optionally substituted with l, 2, or 3 substituents independently selected from R73; Cyl, Cyz, and Cy3 are each independently selected from C640 aryl, C3_10cycloalkyl, 5— membered heteroaryl, and 4—10 ed heterocycloalkyl, each of which is optionally tuted by l, 2, 3, 4, or 5 substituents independently selected from halo, C1_6 alkyl, CM alkenyl, CM alkynyl, C1_6 haloalkyl, €6.10 aryl, €3.10 cycloalkyl, 5—10 membered aryl, 3— 10 membered heterocycloalkyl, CN, N02, 0Ra5, SRaS, C(O)Rb5, C(O)NRC5Rd5, C(O)OR35, OC(O)Rb5, OC(O)NRC5Rd5, NRCSRdS, NRC5C(O)Rb5, NRCSC(O)OR"5, NRC5C(O)NR05Rd5, C(=NR€5)Rb5, C(=NR65)NRCSRd5, =NR65)NRCSRd5, NRCSS(O)Rb5, O)2Rb5, NRCSS(O)2NRCSRd5, S(O)Rb5, S(O)NRCSRd5, S(O)2Rb5, and RCSRd5; wherein said 01.6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C640 aryl, C340 cycloalkyl, 5-10 membered heteroaryl, and 4- 10 membered heterocycloalkyl are each optionally substituted with l, 2, 3, 4, or 5 substituents independently selected from halo, C1_6 alkyl, CM l, CM alkynyl, C1_6 kyl, CN, N02, 0R", SRaS, C(O)Rb5, C5Rd5, 35, OC(O)Rb5, OC(O)NRCSRd5, C(=NR€5)NRCSRd5, NRCSC(=NR65)NRCSRd5, S, NRC5C(O)Rb5, NR65C(O)OR35, NR65C(O)NR05Rd5, O)Rb5, NRCSS(O)2Rb5, NRCSS(O)2NRCSRd5, S(O)Rb5, S(O)NRCSRd5, S(O)2Rb5, and S(O)2NRcst5; each Ra, Rb, RC, and Rd is ndently selected from H, C1_6 alkyl, C1_4 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, and cyclopropyl, n said C1_6 alkyl, C2_6 alkenyl, C26 alkynyl, and cyclopropyl is optionally substituted with l, 2, or 3 substituents independently selected from 01.4 alkyl, C1_4haloalkyl, halo, CN, 0R", SRa6, C(O)Rb6, C(O)NRC6Rd6, C(O)ORa6, OC(O)Rb6, OC(O)NRC6Rd6, NRC6Rd6, NRC6C(O)Rb6, NRC6C(O)NRC6Rd6, NRC6C(O)ORa6, C(=NR€6)NRC6Rd6, NRC6C(=NRC6)NRC6Rd6, S(O)Rb6, S(O)NRC6Rd6, S(O)2Rb6, NRC6S(O)2Rb6, NRC6S(O)2NRC6Rd6, and S(O)2NRC6Rd6; each Ral, Rbl) Rel, Rdl) Ra2, sz) Rc2, Rdz) Ra3, Rb3, Rc3, Rd3, Ra4, Rb4, Rc4, and Rd4, Ra5, Rbs, R65, and Rds is independently selected from H, C1_6 alkyl, C1_4 haloalkyl, C2_6 alkenyl, C2. 6 alkynyl, €6.10 aryl, €3.10 cycloalkyl, 5—10 membered heteroaryl, 4—10 membered heterocycloalkyl, C640 aryl-C1_4 alkyl, C340 cycloalkyl-C1_4 alkyl, (5-10 membered heteroaryl)-C1_4 alkyl, or (4-10 membered heterocycloalkyl)-C1_4 alkyl, wherein said C1_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C640 aryl, C340 cycloalkyl, 5-10 membered heteroaryl, 4—10 membered heterocycloalkyl, C640 aryl-C1_4 alkyl, C340 cycloalkyl-C1_4 alkyl, (5-10 membered heteroaryl)-C1_4 alkyl, and (4-10 membered heterocycloalkyl)-C1_4 alkyl is optionally substituted with 1, 2, 3, 4, or 5 substituents independently ed from C1_4 alkyl, C1_4 haloalkyl, halo, CN, 0R", SR", C(0)R", C(0)NR"R", C(0)0R", OC(O)R", OC(O)NR"R", NR"R", NR"C(0)R", NR"C(0)NR"R", NR"C(0)0R", C(=NR")NR"R", NR"C(=NR")NR"R", S(0)R", S(0)NR"R", S(O)2Rb6, )2R", NR"S(0)2NR"R", and S(0)2NR"R"; or any Rc and Rd together with the N atom to which they are attached form a 4-, 5-, 6-, or 7—membered heterocycloalkyl group optionally substituted with 1, 2, or 3 tuents independently selected from C1_6 alkyl, C3_7 cycloalkyl, 4-7 membered heterocycloalkyl, C640 aryl, 5—6 membered heteroaryl, C1_6haloalkyl, halo, CN, 0R", SR", C(0)R", C(0)NR"R", C(0)0R", ", OC(O)NR"R", NR"R", NR"C(0)R", NR"C(0)NR"R", NR"C(0)0R", C(=NR")NR"R", NR"C(=NR")NR"R", S(0)R", S(0)NR"R", S(O)2Rb6, NR"S(0)2R", NR"S(0)2NR"R", and S(0)2NR"R", wherein said 01.6 alkyl, 03.7 lkyl, 4-7 membered heterocycloalkyl, C640 aryl, and 5-6 membered heteroaryl are optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, ORa6, SR", C(0)R", C(0)NR"R", C(0)0R", OC(O)R", R"R", NR"R", NR"C(0)R", NR"C(0)NR"R", NR"C(0)0R", C(=NR")NR"R", NR"C(=NR")NR"R", S(0)R", S(0)NR"R", b6, NR"S(0)2R", NR"S(0)2NR"R", and S(0)2NR"R"; or any RC1 and Rdl together with the N atom to which they are attached form a 4-, 5-, 6—, or 7—membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from C1_6 alkyl, C3_7 cycloalkyl, 4-7 membered cycloalkyl, C640 aryl, 5—6 membered heteroaryl, C1_6haloalkyl, halo, CN, 0R", SR", C(0)R", C(0)NR"R", C(0)0R", OC(O)R", OC(O)NR"R", NR"R", NR"C(0)R", NR"C(0)NR"R", NR"C(0)0R", C(=NR")NR"R", NR")NR"R", S(0)R", S(0)NR"R", b6, NR"S(0)2R", NR"S(0)2NR"R", and S(O)2NRC6Rd6, wherein said 01.6 alkyl, 03.7 cycloalkyl, 4-7 membered heterocycloalkyl, C640 aryl, and 5-6 membered heteroaryl are ally substituted by 1, 2, or 3 substituents independently selected from halo, CN, ORa6, SR", C(0)R", C(0)NR"R", C(0)0R", OC(O)R", OC(O)NR"R", NR"R", NR"C(0)R", NR"C(0)NR"R", )0R", C(=NR")NR"R", NR"C(=NR")NR"R", S(0)R", S(0)NR"R", S(O)2Rb6, NR"S(0)2R", NR"S(0)2NR"R", and S(0)2NR"R"; or any RC2 and Rdz together with the N atom to which they are attached form a 4-, 5-, 6—, or 7—membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents ndently ed from C1_6 alkyl, C3_7 cycloalkyl, 4-7 membered heterocycloalkyl, C640 aryl, and 5—6 membered heteroaryl, 01.6 haloalkyl, halo, CN, 0R", SR", C(0)R", C(0)NR"R", C(0)0R", OC(O)R", OC(O)NR"R", NR"R", NR"C(0)R", NR"C(0)NR"R", NR"C(0)0R", C(=NR")NR"R", NR")NR"R", , S(0)NR"R", S(O)2Rb6, )2R", NR"S(0)2NR"R", and S(0)2NR"R", wherein said C1_6 alkyl, C3_7 cycloalkyl, 4-7 membered heterocycloalkyl, C640 aryl, and 5—6 membered heteroaryl are optionally substituted by l, 2, or 3 substituents independently selected from halo, CN, 0R", SR", C(0)R", C(0)NR"R", C(0)0R", OC(O)R", OC(O)NR"R", NR"R", NR"C(0)R", NR"C(0)NR"R", NR"C(0)0R", C(=NR")NR"R", NR"C(=NR")NR"R", , S(0)NR"R", S(O)2Rb6, NR"S(0)2R", NR"S(0)2NR"R", and S(0)2NR"R", or any RC3 and Rd3 together with the N atom to which they are attached form a 4-, 5-, 6—, or 7—membered heterocycloalkyl group optionally substituted with l, 2, or 3 substituents independently selected from C1_6 alkyl, C3_7 cycloalkyl, 4—7 membered heterocycloalkyl, C640 aryl, 5-6 membered heteroaryl, C1_6 haloalkyl, halo, CN, ORa6, SRa6, C(O)Rb6, C(O)NRC6Rd6, C(0)0R", OC(O)R", OC(O)NR"R", NR"R", NR"C(0)R", NR"C(0)NR"R", NR"C(0)0R", C(=NR")NR"R", NR"C(=NR")NR"R", S(0)R", S(0)NR"R", S(O)2Rb6, NR"S(0)2R", NR"S(0)2NR"R", and S(0)2NR"R", wherein said 01.6 alkyl, 03.7 cycloalkyl, 4-7 membered heterocycloalkyl, C640 aryl, and 5-6 membered heteroaryl are optionally substituted by l, 2, or 3 substituents independently selected from halo, CN, ORa6, SR", C(0)R", "R", C(0)0R", ", OC(O)NR"R", NR"R", NR"C(0)R", NR"C(0)NR"R", NR"C(0)0R", )NR"R", NR"C(=NR")NR"R", S(0)R", S(0)NR"R", S(O)2Rb6, NR"S(0)2R", NR"S(0)2NR"R", and S(0)2NR"R", or any RC4 and Rd4 together with the N atom to which they are attached form a 4-, 5-, 6—, or 7—membered heterocycloalkyl group optionally substituted with l, 2, or 3 substituents independently selected from C1_6 alkyl, C3_7 cycloalkyl, 4-7 membered heterocycloalkyl, C640 aryl, 5-6 ed heteroaryl, C1_6 kyl, halo, CN, ORa6, SRa6, C(O)Rb6, C(O)NRC6Rd6, C(0)0R", OC(O)R", OC(O)NR"R", NR"R", )R", NR"C(0)NR"R", NR"C(0)0R", C(=NR")NR"R", NR"C(=NR")NR"R", , S(0)NR"R", S(O)2Rb6, NR"S(0)2R", NR"S(0)2NR"R", and R"R", wherein said 01.6 alkyl, 03.7 cycloalkyl, 4-7 membered heterocycloalkyl, C640 aryl, and 5-6 membered heteroaryl are optionally tuted by l, 2, or 3 tuents independently selected from halo, CN, ORa6, SR", C(0)R", C(0)NR"R", C(0)0R", OC(O)R", OC(O)NR"R", NR"R", NR"C(0)R", NR"C(0)NR"R", NR"C(0)0R", C(=NR")NR"R", NR"C(=NR")NR"R", , S(0)NR"R", S(O)2Rb6, NR"S(0)2R", NR"S(0)2NR"R", and S(0)2NR"R", or any Rcs and Rds together with the N atom to which they are attached form a 4-, 5-, 6—, or 7—membered heterocycloalkyl group optionally substituted with l, 2, or 3 substituents independently selected from C1_6 alkyl, C3_7 cycloalkyl, 4-7 ed heterocycloalkyl, C640 aryl, 5—6 membered heteroaryl, C1_6haloalkyl, halo, CN, 0Ra6, SRa6, C(O)Rb6, C(O)NRC6Rd6, a6, OC(O)Rb6, OC(O)NRC6Rd6, NRC6Rd6, O)Rb6, O)NRC6Rd6, NRc6C(0)0Ra6, C(=NRC6)NRC6Rd6, NRc6C(=NRe6)NRc6Rd6, 6, S(O)NRC6Rd6, S(O)2Rb6, NRC6S(O)2Rb6, O)2NRC6Rd6, and S(O)2NRC6Rd6, wherein said 01.6 alkyl, 03.7 cycloalkyl, 4-7 membered heterocycloalkyl, C640 aryl, and 5-6 membered heteroaryl are optionally substituted by l, 2, or 3 substituents independently selected from halo, CN, ORa6, SRa6, C(O)Rb6, C(O)NRC6Rd6, C(O)ORa6, b6, OC(O)NRC6Rd6, NRC6Rd6, NRC6C(O)Rb6, NRC6C(O)NRC6Rd6, NRc6C(0)0Ra6, C(=NR€6)NRC6Rd6, =NRC6)NRC6Rd6, S(O)Rb6, S(O)NRC6Rd6, S(O)2Rb6, NRC6S(O)2Rb6, NRC6S(O)2NRC6Rd6, and S(O)2NRC6Rd6; each R6, Rel, R62, R63 and Res is independently selected from H, C1_4 alkyl, CN, , RC4, 0R", SRb6, S(O)2Rb6, C(O)Rb6, S(O)2NRC6Rd6, and C(O)NRC6Rd6; each R", Rb6, RC6, and Rd6 is ndently ed from H, C1_4 alkyl, C1_4 haloalkyl, C2_4 alkenyl, and C2_4 alkynyl, wherein said C1_4 alkyl, C2_4 alkenyl, and C2_4 alkynyl, is optionally substituted with l, 2, or 3 substituents independently selected from OH, CN, amino, halo, C1_4 alkyl, C1_4 alkoxy, C1_4 alkylthio, C1_4 alkylamino, di(C1_4 alkyl)amino, C1_4 haloalkyl, and C1_4 haloalkoxy; or any RC6 and Rd6 together with the N atom to which they are attached form a 4-, 5-, 6—, or 7—membered heterocycloalkyl group optionally substituted with l, 2, or 3 tuents independently selected from OH, CN, amino, halo, C1_6 alkyl, C1_4 alkoxy, C1_4 alkylthio, C1_4 alkylamino, di(C1_4 alkyl)amino, C1_4 haloalkyl, and C1_4 haloalkoxy; and each R66 is independently selected from H, C1_4 alkyl, and CN.
In some embodiments, W is NR9 or CRloR".
In some embodiments, W is NR9.
In some embodiments, R9 is C1_6 alkyl.
In some embodiments, R9 is methyl.
In some embodiments, R9 is €6-10 aryl, €3.10 cycloalkyl, 5—10 membered heteroaryl, 4— membered heterocycloalkyl, C640 aryl—C1_4 alkyl, C3_10 lkyl—C1_4 alkyl, (5— 10 membered heteroaryl)-C1_4 alkyl, or (4-10 membered cycloalkyl)-C1_4 alkyl, wherein said C6_10 aryl, C340 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C640 aryl-C1_4 alkyl, C340 cycloalkyl-C1_4 alkyl, (5- 10 membered heteroaryl)-C1_4 alkyl, and 2014/034662 (4-10 membered heterocycloalkyl)-C1_4 alkyl are each optionally substituted with l, 2, 3, 4, or tuents independently selected from Rga.
In some embodiments, R9 is €6-10 aryl, €3.10 cycloalkyl, 5—10 membered heteroaryl, C640 aryl-C1_4 alkyl, C340 lkyl-C14 alkyl, or (5- 10 membered aryl)-C1_4 alkyl, wherein said C640 aryl, C3_10cycloalkyl, 5-10 membered heteroaryl, C640 aryl-C1_4 alkyl, C3_10 cycloalkyl-C14 alkyl, and (5-10 membered heteroaryl)-C1_4 alkyl are each optionally substituted with l or 2 substituents independently selected from halo and C1_4 alkyl.
In some embodiments, R9 is , 2H-tetrazolyl, benzyl, lH-pyrazolylmethyl, cyclopentyl, or cyclopropylmethyl each optionally substituted with l or 2 substituents independently selected from F and methyl.
In some embodiments, W is CRloR".
In some embodiments, R10 and R11 are each C1_6 alkyl.
In some embodiments, R10 and R11 are each methyl.
In some embodiments, R10 and R11 together with the carbon atom to which they are attached form a 3—, 4-, 5-, 6—, or ered cycloalkyl group or a 4—, 5—, 6—, or 7—membered heterocycloalkyl group, each optionally substituted with l, 2, or 3 substituents independently selected from Cy3, C1_6 alkyl, C1_6haloalkyl, halo, CN, 0R", SR", C(O)Rb4, C(O)NR°4Rd4, C(O)ORa4, b4, OC(O)NRC4Rd4, NRC4Rd4, NRC4C(O)Rb4, NRC4C(O)NRC4Rd4, NRC4C(O)ORa4, C(=NRC4)NRC4Rd4, NR°4C(=NRC4)NRC4Rd4, S(O)Rb4, S(O)NRC4Rd4, S(O)2Rb4, NRC4S(O)2Rb4, NR°4S(0)2NRc4Rd4, and S(O)2NRC4Rd4, wherein said C1_6 alkyl is optionally substituted by l, 2, or 3 substituents independently selected from Cy3, halo, CN, ORa4, SRa4, C(O)Rb4, C(0)NRc4Rd4, a4, OC(O)Rb4, R°4Rd4, NR°4Rd4, NRC4C(O)Rb4, NRC4C(O)NR°4Rd4, NRC4C(O)OR34, C(=NRC4)NRC4Rd4, =NR64)NRC4Rd4, S(O)Rb4, S(O)NR°4Rd4, S(O)2Rb4, NR°4S(O)2Rb4, NR°48(O)2NR°4Rd4, and S(O)2NRC4Rd4.
In some ments, R10 and R11 together with the carbon atom to which they are attached form a 3-, 4—, 5—, 6-, or 7—membered cycloalkyl group.
In some embodiments, R10 and R11 together with the carbon atom to which they are attached form a cyclopropyl group.
In some embodiments, R1 is methyl.
In some embodiments, R2 is halo.
In some embodiments, R2 is fluoro.
In some embodiments, R3 is H.
In some embodiments, R4 is OR".
In some embodiments, R4 is methoxy.
In some embodiments, R5 is halo.
In some embodiments, R5 is fluoro.
In some embodiments, R6 is H.
In some embodiments, R6 is H and W is CRloR".
In some embodiments, R6 is H, halo, C1_6 alkyl, C2_6 alkenyl, C640 aryl, 5-10 membered heteroaryl, 4—10 membered heterocycloalkyl, CN, or ORaZ; n said C1_6 alkyl, CM alkenyl, €6.10 aryl, 5—10 membered heteroaryl, and 4—10 membered heterocycloalkyl are each optionally substituted with l, 2, 3, 4, or 5 tuents independently selected from R6a.
In some embodiments, R6 is halo, C1_6 alkyl, C2_6 alkenyl, C640 aryl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, or ORaZ; wherein said C1_6 alkyl, C2_6 alkenyl, C640 aryl, 5-10 membered heteroaryl, and 4-10 ed heterocycloalkyl are each optionally substituted with l, 2, 3, 4, or 5 substituents independently ed from R6a.
In some embodiments, R6 is C1_6 alkyl, C2_6 l, C2_6 alkynyl, C640 aryl, C340 cycloalkyl, 5—10 membered heteroaryl, 4—10 membered heterocycloalkyl, CN, or ORaZ; wherein said C1_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C640 aryl, C340 lkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl are each optionally tuted with l, 2, 3, 4, or 5 substituents independently ed from R6a.
In some embodiments, R6 is halo, C1_6 alkyl, C2_6 alkenyl, phenyl, 5-6 membered heteroaryl, 6—membered heterocycloalkyl, CN, or ORaZ; wherein said C1_6 alkyl, C26 alkenyl, phenyl, 5—6 membered heteroaryl, and 6—membered heterocycloalkyl are each optionally tuted with l, 2, 3, 4, or 5 substituents independently selected from R6a.
In some embodiments, R6 is C1_6 alkyl, C2_6 alkenyl, phenyl, 5-6 membered heteroaryl, ered heterocycloalkyl, CN, or ORaZ; wherein said C1_6 alkyl, CM alkenyl, phenyl, 5—6 membered heteroaryl, and 6—membered heterocycloalkyl are each optionally substituted with l, 2, 3, 4, or 5 tuents independently selected from R6a.
In some embodiments, R6 is chloro, methyl, ethyl, CN, ethoxy, methoxyethoxy, phenoxy, 2-(4-methylpiperazin-l-yl)ethoxy, phenyl, 4-fluorophenyl, benzyl, ethyl, 2- phenylVinyl, 3,6-dihydro-2H-pyranyl, 3-pyridyl, 4-pyridyl, lH-pyrazolyl, l-methyl-lH- pyrazolyl, l-methyl-lH-pyrazolyl, l-ethyl-lH-pyrazolyl, l-(2-hydroxyethyl)-lH- pyrazolyl, or l-(piperidinyl)-lH-pyrazolyl. 2014/034662 In some embodiments, R6 is methyl, ethyl, CN, ethoxy, methoxyethoxy, phenoxy, 2- (4-methylpiperazin-l-yl)ethoxy, phenyl, 4-fluorophenyl, benzyl, hyl, 2-phenylVinyl, 3,6-dihydro-2H-pyranyl, 3-pyridyl, 4-pyridyl, lH-pyrazolyl, l-methyl-lH-pyrazol-S-yl, l-methyl- lH-pyrazolyl, l-ethyl-lH-pyrazolyl, ydroxyethyl)- azolyl, or l-(piperidinyl)- lH-pyrazolyl.
In some embodiments, R6 is methyl.
In some embodiments, R6 is pyrazolyl optionally substituted with l or 2 tuents independently selected from R6a.
In some embodiments, R7 and R8 are each independently selected from H, C1_6 alkyl, —C(O)RA, C640 aryl, C3_10cycloalkyl, 5—10 membered aryl, 4—10 membered heterocycloalkyl, C640 aryl-C1_4 alkyl, (5-10 membered heteroaryl)-C1_4 alkyl, or (4-10 membered heterocycloalkyl)-C1_4 alkyl, wherein said C1_6 alkyl, C640 aryl, C340 cycloalkyl, 5- membered heteroaryl, 4—10 ed heterocycloalkyl, (5—10 membered heteroaryl)—C1_4 alkyl, and (4-10 membered heterocycloalkyl)-C1_4 alkyl are each optionally substituted with l, 2, 3, 4, or 5 substituents independently selected from R".
In some embodiments, R7 and R8 are each independently selected from H, 2- hydroxypropyl, —C(O)OCH3, 3—fluorophenyl, cyclopropyl, utyl, 3,3— difluorocyclobutyl, cyclopentyl, cyclohexyl, 4-hydroxycyclohexyl, methyl, l-methyl-lH- pyrazolyl, pyridinyl, N—methylpiperidinyl, tetrahydro-2H-pyranyl, tetrahydrofuranyl, l-phenylethyl, (l-methyl-lH-pyrazolyl)methyl, 2-morpholino ylethyl, pyridinylmethyl, N-methylpiperazin- l -ylethyl, and tetrahydrofuran-Z-ylmethyl.
In some embodiments, one of R7 and R8 is H.
In some embodiments, R7 and R8 are each H.
In some embodiments, the nds of the invention have Formula IIa: OCH3 H3CO N NR9 R2 R6 \ R7 N ITI/ R8 11a. 2014/034662 In some embodiments, wherein the compound has Formula IIa, R2 is halo.
In some embodiments, wherein the compound has Formula IIa, R2 is fluoro.
In some embodiments, wherein the compound has Formula IIa, R5 is halo.
In some embodiments, wherein the compound has Formula IIa, R5 is fluoro.
In some ments, wherein the compound has Formula IIa, R6 is halo, C1_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C6_10 aryl, C3_10cycloalkyl, 5-10 membered heteroaryl, 4—10 membered heterocycloalkyl, CN, or ORaZ; wherein said C1_6 alkyl, CM l, CM alkynyl, C640 aryl, C3_10 cycloalkyl, 5-10 ed heteroaryl, and 4-10 membered heterocycloalkyl are each optionally substituted with l, 2, 3, 4, or 5 substituents independently selected from R63.
In some embodiments, wherein the nd has a IIa, R6 is C1_6 alkyl, CM alkenyl, C26 alkynyl, €6.10 aryl, €3-10 lkyl, 5—10 membered heteroaryl, 4—10 membered heterocycloalkyl, CN, or ORaz; wherein said C1_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C640 aryl, C340 cycloalkyl, 5—10 membered heteroaryl, and 4—10 membered heterocycloalkyl are each optionally substituted with l, 2, 3, 4, or 5 substituents independently ed from R6a.
In some embodiments, wherein the compound has Formula IIa, R6 is halo, C1_6 alkyl, CM alkenyl, , 5—6 membered heteroaryl, 6—membered heterocycloalkyl, CN, or ORaZ; wherein said C1_6 alkyl, CM alkenyl, phenyl, 5—6 membered heteroaryl, and 6—membered heterocycloalkyl are each optionally substituted with l, 2, 3, 4, or 5 tuents independently selected from R6a.
In some embodiments, wherein the nd has Formula IIa, R6 is C1_6 alkyl, C2_6 alkenyl, phenyl, 5-6 membered heteroaryl, 6—membered heterocycloalkyl, CN, or ORaZ; n said C1_6 alkyl, CM alkenyl, phenyl, 5—6 membered heteroaryl, and 6—membered heterocycloalkyl are each ally substituted with l, 2, 3, 4, or 5 substituents independently selected from R6a.
In some embodiments, wherein the compound has Formula IIa, R6 is chloro, methyl, ethyl, CN, ethoxy, methoxyethoxy, phenoxy, 2-(4-methylpiperazin-l-yl)ethoxy, , 4- fluorophenyl, benzyl, phenylethyl, 2-phenylVinyl, 3,6-dihydro-2H-pyranyl, 3-pyridyl, 4- pyridyl, lH-pyrazolyl, l-methyl-lH-pyrazolyl, l-methyl-lH-pyrazolyl, l-ethyl-lH- pyrazolyl, l-(2-hydroxyethyl)-lH-pyrazolyl, or l-(piperidinyl)-lH-pyrazolyl.
In some embodiments, wherein the nd has Formula IIa, R6 is methyl, ethyl, CN, ethoxy, methoxyethoxy, phenoxy, 2-(4-methylpiperazin-l-yl)ethoxy, phenyl, 4- fluorophenyl, benzyl, phenethyl, 2-phenylVinyl, 3,6-dihydro-2H-pyranyl, 3-pyridyl, 4- 2014/034662 l, lH-pyrazolyl, l-methyl-lH-pyrazolyl, yl-lH-pyrazolyl, l-ethyl-lH- pyrazolyl, l-(2-hydroxyethyl)-lH-pyrazolyl, or l-(piperidinyl)-lH-pyrazolyl.
In some embodiments, wherein the compound has Formula IIa, R9 is C1_6 alkyl.
In some embodiments, wherein the compound has Formula IIa, R9 is methyl.
In some embodiments, the compounds of the invention have Formula IIb: OCH3 H300 N NR9 F R6 N NH2 IIb.
In some embodiments, wherein the nd has Formula IIb, R6 is halo, C1_6 alkyl, CM alkenyl, €6-10 aryl, €3.10 cycloalkyl, 5—10 membered heteroaryl, 4—10 membered heterocycloalkyl, CN, or ORaz; wherein said C1_6 alkyl, C2_6 alkenyl, C640 aryl, C340 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl are each optionally substituted with l, 2, 3, 4, or 5 substituents independently selected from R6a.
In some embodiments, wherein the compound has Formula IIb, R6 is C1_6 alkyl, C26 alkenyl, CM alkynyl, €6.10 aryl, €3-10 cycloalkyl, 5—10 membered heteroaryl, 4—10 membered heterocycloalkyl, CN, or ORaZ; wherein said C1_6 alkyl, CM alkenyl, CM l, €6-10 aryl, C340 cycloalkyl, 5—10 membered heteroaryl, and 4—10 membered heterocycloalkyl are each optionally substituted with l, 2, 3, 4, or 5 substituents independently selected from R6a.
In some embodiments, wherein the compound has Formula IIb, R6 is halo, C1_6 alkyl, CM alkenyl, phenyl, 5—6 membered heteroaryl, ered heterocycloalkyl, CN, or ORaZ; wherein said C1_6 alkyl, CM alkenyl, phenyl, 5—6 membered heteroaryl, and 6—membered heterocycloalkyl are each optionally substituted with l, 2, 3, 4, or 5 tuents independently selected from R6a.
In some ments, wherein the compound has Formula IIb, R6 is C1_6 alkyl, CM alkenyl, phenyl, 5-6 membered aryl, 6—membered heterocycloalkyl, CN, or ORaZ; wherein said C1_6 alkyl, CM alkenyl, phenyl, 5—6 membered heteroaryl, and 6—membered cycloalkyl are each optionally substituted with l, 2, 3, 4, or 5 tuents ndently selected from R6a.
In some embodiments, wherein the compound has Formula IIb, R6 is chloro, methyl, ethyl, CN, ethoxy, yethoxy, phenoxy, 2—(4-methylpiperazin-l-yl)ethoxy, phenyl, 4- fluorophenyl, benzyl, phenylethyl, 2-phenylVinyl, 3,6-dihydro-2H-pyranyl, 3-pyridyl, 4- pyridyl, lH-pyrazolyl, l-methyl-lH-pyrazolyl, l-methyl-lH-pyrazolyl, l-ethyl-lH- pyrazolyl, l-(2-hydroxyethyl)-lH-pyrazolyl, or l-(piperidinyl)-lH-pyrazolyl.
In some embodiments, wherein the nd has Formula IIb, R6 is methyl, ethyl, CN, , methoxyethoxy, phenoxy, 2—(4-methylpiperazin-l-yl)ethoxy, phenyl, 4- fluorophenyl, benzyl, phenethyl, 2—phenylVinyl, 3,6-dihydro-2H-pyranyl, 3-pyridyl, 4- pyridyl, lH-pyrazolyl, l-methyl-lH-pyrazolyl, l-methyl-lH-pyrazolyl, l-ethyl-lH- pyrazolyl, l-(2-hydroxyethyl)-lH-pyrazolyl, or l-(piperidinyl)-lH-pyrazolyl.
In some embodiments, wherein the nd has Formula IIb, R9 is C1_6 alkyl.
In some embodiments, wherein the compound has Formula IIb, R9 is methyl.
In some embodiments, the compounds of the invention have Formula IIIa: OCH3 H3CO IIIa.
In some embodiments, wherein the compound has Formula IIIa, R2 is halo.
In some embodiments, wherein the compound has Formula IIIa, R2 is fluoro.
In some embodiments, wherein the compound has Formula IIIa, R5 is halo.
In some ments, wherein the compound has Formula IIIa, R5 is fluoro.
In some embodiments, wherein the compound has Formula IIIa, R6 is H. some embodiments, wherein the compound has Formula IIIa, R10 and R11 are both C1. 6 alkyl.
In some embodiments, wherein the compound has a IIIa, R10 and R11 are both methyl.
In some embodiments, wherein the compound has Formula IIIa, R10 and R11 together with the carbon atom to which they are attached form a 3—, 4—, 5—, 6—, or ered cycloalkyl group or a 4—, 5—, 6—, or 7-membered heterocycloalkyl group, each optionally substituted with l, 2, or 3 substituents independently selected from Cy3, C1_6 alkyl, C1_6 haloalkyl, halo, CN, 0R", SR", C(O)Rb4, C(O)NR°4Rd4, "4, OC(O)Rb4, OC(O)NR°4Rd4, NRC4Rd4, NRC4C(O)Rb4, NR°4C(O)NR°4Rd4, NRC4C(O)OR34, C(=NR64)NRC4Rd4, NRC4C(=NRC4)NRC4Rd4, S(O)Rb4, S(O)NRC4Rd4, S(O)2Rb4, NR°48(O)2Rb4, O)2NRC4Rd4, and S(O)2NRC4Rd4, n said 01.6 alkyl is optionally substituted by 1, 2, or 3 substituents independently selected from Cy3, halo, CN, ORa4, SRa4, C(O)Rb4, C(O)NR°4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NR°4Rd4, NR°4Rd4, NR°4C(O)Rb4, NRc4C(0)NRc4Rd4, NRC4C(O)ORa4, C(=NR€4)NRC4Rd4, NRC4C(=NR64)NRC4Rd4, S(O)Rb4, S(O)NR°4Rd4, S(O)2Rb4, NR°4S(O)2Rb4, NR°48(O)2NR°4Rd4, and S(O)2NRC4Rd4.
In some embodiments, wherein the compound has Formula Illa, R10 and R11 together with the carbon atom to which they are attached form a 3—, 4—, 5—, 6—, or 7—membered cycloalkyl group.
In some embodiments, wherein the compound has Formula IIIa, R10 and R11 together with the carbon atom to which they are attached form a ropyl group.
In some ments, wherein the compound has Formula IIIa, R7 and R8 are each independently selected from H, C1_6 alkyl, -C(O)RA, C6_10 aryl, C3_10cycloalkyl, 5-10 membered heteroaryl, 4—10 membered heterocycloalkyl, C640 aryl—C1_4 alkyl, (5—10 membered heteroaryl)-C1_4 alkyl, or (4-10 membered heterocycloalkyl)-C1_4 alkyl, wherein said C1_6 alkyl, €6-10 aryl, C3_10cycloalkyl, 5—10 membered heteroaryl, 4—10 membered cycloalkyl, (5-10 membered heteroaryl)-C1_4 alkyl, and (4-10 membered heterocycloalkyl)-C1_4 alkyl are each optionally substituted with l, 2, 3, 4, or 5 substituents independently selected from R".
In some embodiments, n the compound has Formula IIIa, R7 and R8 are each independently selected from H, 2—hydroxypropyl, CH3, 3—fluorophenyl, ropyl, cyclobutyl, 3,3—difluorocyclobutyl, entyl, cyclohexyl, 4-hydroxycyclohexyl, methyl, 1- methyl-lH-pyrazolyl, nyl, N—methylpiperidinyl, tetrahydro-2H-pyranyl, tetrahydrofuranyl, l-phenylethyl, (l-methyl-lH-pyrazolyl)methyl, 2-morpholino ylethyl, pyridinylmethyl, N-methylpiperazin- l -ylethyl, and tetrahydrofuranylmethyl.
In some embodiments, wherein the compound has Formula IIIa, one of R7 and R8 is In some ments, wherein the compound has Formula IIIa, R7 and R8 are each In some embodiments, the compounds of the invention have Formula IIIb: OCH3 H3CO IIIb.
In some embodiments, wherein the compound has Formula IIIb, R6 is H.
In some embodiments, wherein the compound has Formula IIIb, R10 and R11 are both C1_6 alkyl.
In some embodiments, wherein the compound has Formula IIIb, R10 and R11 are both methy.
In some embodiments, wherein the compound has Formula IIIb, R10 and R11 er with the carbon atom to which they are attached form a 3—, 4—, 5—, 6—, or 7—membered cycloalkyl group or a 4—, 5—, 6—, or 7-membered cycloalkyl group, each optionally substituted with l, 2, or 3 substituents ndently selected from Cy3, C1_6 alkyl, C1_6 kyl, halo, CN, 0R", SR", C(O)Rb4, C(0)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NR°4Rd4, NRC4Rd4, NRC4C(O)Rb4, NR°4C(O)NR°4Rd4, NRC4C(O)OR34, C(=NR64)NRC4Rd4, NRC4C(=NRC4)NRC4Rd4, S(O)Rb4, S(O)NRC4Rd4, S(O)2Rb4, NR°48(O)2Rb4, NRC4S(O)2NRC4Rd4, and S(O)2NRC4Rd4, wherein said 01.6 alkyl is ally substituted by 1, 2, or 3 substituents independently selected from Cy3, halo, CN, ORa4, SRa4, C(O)Rb4, C(0)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NR°4Rd4, NR°4Rd4, O)Rb4, NRC4C(O)NR°4Rd4, NRC4C(O)OR34, C(=NRC4)NRC4Rd4, =NR64)NRC4Rd4, S(O)Rb4, S(O)NR°4Rd4, S(O)2Rb4, NR°4S(O)2Rb4, NR°48(O)2NR°4Rd4, and S(O)2NRC4Rd4.
In some embodiments, wherein the compound has Formula IIIb, R10 and R11 together with the carbon atom to which they are attached form a 3—, 4—, 5—, 6—, or 7—membered cycloalkyl group.
In some embodiments, wherein the compound has Formula IIIb, R10 and R11 together with the carbon atom to which they are attached form a cyclopropyl group.
It is further appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, can also be provided in combination in a single embodiment. Conversely, various features of the invention which are, for brevity, bed in the context of a single embodiment, can also be ed separately or in any suitable subcombination.
At various places in the t specification, tuents of compounds of the invention are disclosed in groups or in ranges. It is specifically intended that the invention e each and every individual subcombination of the members of such groups and ranges.
For example, the term "C1_6 alkyl" is specifically intended to individually disclose methyl, ethyl, C3 alkyl, C4 alkyl, C5 alkyl, and C6 alkyl.
At various places in the present specification various aryl, heteroaryl, cycloalkyl, and heterocycloalkyl rings are bed. Unless otherwise specified, these rings can be attached to the rest of the le at any ring member as permitted by valency. For example, the term "a ne ring" or "pyridinyl" may refer to a pyridinyl, pyridin-3 -yl, or pyridinyl ring.
The term "n-membered" where n is an integer typically describes the number of ring- g atoms in a moiety where the number of ring-forming atoms is n. For example, piperidinyl is an example of a 6-membered heterocycloalkyl ring, pyrazolyl is an example of a 5-membered heteroaryl ring, l is an example of a 6-membered heteroaryl ring, and l,2,3,4-tetrahydro-naphthalene is an example of a lO-membered cycloalkyl group.
For compounds of the invention in which a variable appears more than once, each variable can be a different moiety independently selected from the group defining the variable. For example, where a structure is described having two R groups that are simultaneously present on the same nd, the two R groups can represent different moieties independently selected from the group defined for R.
As used herein, the phrase "optionally substituted" means unsubstituted or tuted.
As used herein, the term "substituted" means that a hydrogen atom is replaced by a drogen group. It is to be understood that substitution at a given atom is limited by valency.
As used herein, the term "Ci-j ", where i and j are integers, employed in combination with a chemical group, designates a range of the number of carbon atoms in the chemical group with i-j defining the range. For example, C1_6 alkyl refers to an alkyl group having 1, 2, 3, 4, 5, or 6 carbon atoms.
As used herein, the term "alkyl", employed alone or in combination with other terms, refers to a saturated hydrocarbon group that may be straight-chain or branched. In some ments, the alkyl group contains 1 to 6, l to 4, or 1 to 3 carbon atoms. Examples of alkyl moieties include, but are not limited to, chemical groups such as methyl, ethyl, npropyl , isopropyl, n—butyl, isobutyl, sec-butyl, tert—butyl, n—pentyl, 2—methyl—l—butyl, 3— , n-hexyl, l,2,2-trimethylpropyl, and the like. In some embodiments, the alkyl group is methyl, ethyl, or propyl.
As used herein, "alkenyl", employed alone or in combination with other terms, refers to an alkyl group having one or more carbon—carbon double bonds. In some embodiments, the alkenyl moiety ns 2 to 6 or 2 to 4 carbon atoms. Example alkenyl groups include, but are not limited to, ethenyl, n-propenyl, isopropenyl, n-butenyl, sec-butenyl, and the like.
As used , "alkynyl", employed alone or in combination with other terms, refers to an alkyl group haVing one or more carbon-carbon triple bonds. Example alkynyl groups include, but are not limited to, ethynyl, -l-yl, propynyl, and the like. In some ments, the alkynyl moiety contains 2 to 6 or 2 to 4 carbon atoms.
As used herein, "halo" or "halogen", employed alone or in combination with other terms, es fluoro, chloro, bromo, and iodo. In some embodiments, halo is F or Cl. In some embodiments, halo is F.
As used herein, the term "haloalkyl", ed alone or in ation with other terms, refers to an alkyl group haVing up to the full valency of halogen atom substituents, which may either be the same or different. In some embodiments, the halogen atoms are fluoro atoms. In some embodiments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms.
Example haloalkyl groups include CF3, C2F5, CHFZ, CCl3, CHClz, CzCls, and the like.
As used herein, the term "alkoxy", employed alone or in combination with other terms, refers to a group of formula -O-alkyl. Example alkoxy groups include methoxy, , propoxy (e. g., n-propoxy and isopropoxy), t-butoxy, and the like. In some embodiments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms.
As used herein, "haloalkoxy", employed alone or in combination with other terms, refers to a group of formula -O-(haloalkyl). In some embodiments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms. An example haloalkoxy group is -OCF3.
As used , "amino", employed alone or in combination with other terms, refers to NHz.
As used , the term "alkylamino", employed alone or in combination with other terms, refers to a group of formula -NH(alkyl). In some embodiments, the alkylamino group has 1 to 6 or 1 to 4 carbon atoms. Example alkylamino groups include methylamino, mino, propylamino (e.g., n-propylamino and isopropylamino), and the like.
As used herein, the term "dialkylamino", employed alone or in combination with other terms, refers to a group of formula -N(alkyl)2. Example lamino groups include dimethylamino, diethylamino, ylamino (e.g., di(n-propyl)amino and di(isopropyl)amino), and the like. In some embodiments, each alkyl group independently has 1 to 6 or 1 to 4 carbon atoms.
As used herein, the term "alkylthio", employed alone or in combination with other terms, refers to a group of formula -S-alkyl. In some ments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms.
As used herein, the term "cycloalkyl", employed alone or in combination with other terms, refers to a non-aromatic cyclic hydrocarbon including cyclized alkyl and alkenyl groups. Cycloalkyl groups can include mono— or polycyclic (e. g., having 2, 3, or 4 fused, bridged, or spiro rings) ring systems. Also included in the definition of cycloalkyl are moieties that have one or more aromatic rings (e. g., aryl or heteroaryl rings) fused (i.e., having a bond in common with) to the cycloalkyl ring, for example, benzo derivatives of cyclopentane, cyclohexene, cyclohexane, and the like, or pyrido derivatives of entane or exane. Ring-forming carbon atoms of a cycloalkyl group can be optionally substituted by oxo. Cycloalkyl groups also include cycloalkylidenes. The term "cycloalkyl" also includes bridgehead cycloalkyl groups (e. g., non—aromatic cyclic hydrocarbon moieties containing at least one bridgehead carbon, such as admantan-l-yl) and ycloalkyl groups (e. g., non-aromatic hydrocarbon moieties containing at least two rings fused at a single carbon atom, such as 2.5]octane and the like). In some embodiments, the cycloalkyl group has 3 to 10 ring members, or 3 to 7 ring members, or 3 to 6 ring members. In some embodiments, the cycloalkyl group is monocyclic or bicyclic. In some embodiments, the cycloalkyl group is monocyclic. In some embodiments, the cycloalkyl group is a C3_7 monocyclic cycloalkyl group. e cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, eptyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptatrienyl, norbornyl, norpinyl, yl, tetrahydronaphthalenyl, octahydronaphthalenyl, indanyl, and the like. In some embodiments, the cycloalkyl group is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
As used herein, the term "cycloalkylalkyl", employed alone or in combination with other terms, refers to a group of formula cycloalkyl-alkyl-. In some embodiments, the alkyl n has 1 to 4, l to 3, l to 2, or 1 carbon ). In some embodiments, the alkyl portion is methylene. In some ments, the cycloalkyl n has 3 to 10 ring members or 3 to 7 ring members. In some embodiments, the cycloalkyl group is monocyclic or bicyclic. In some embodiments, the cycloalkyl portion is clic. In some embodiments, the cycloalkyl n is a C3_7 monocyclic cycloalkyl group.
As used herein, the term "heterocycloalkyl", ed alone or in ation with other terms, refers to a non-aromatic ring or ring system, which may optionally contain one or more lene or alkynylene groups as part of the ring structure, which has at least one heteroatom ring member independently selected from nitrogen, , oxygen, and phosphorus. cycloalkyl groups can include mono— or polycyclic (e. g., having 2, 3 or 4 fused, bridged, or spiro rings) ring systems. In some embodiments, the heterocycloalkyl group is a monocyclic or bicyclic group having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, sulfur and oxygen. Also included in the definition of heterocycloalkyl are es that have one or more aromatic rings (e.g., aryl or heteroaryl rings) fused (i.e., haVing a bond in common with) to the non-aromatic heterocycloalkyl ring, for example, l,2,3,4-tetrahydro-quinoline and the like. Heterocycloalkyl groups can also include head heterocycloalkyl groups (e.g., a heterocycloalkyl moiety containing at least one bridgehead atom, such as azaadmantan-l-yl and the like) and spiroheterocycloalkyl groups (e. g., a heterocycloalkyl moiety containing at least two rings fused at a single atom, such as [l,4-dioxaaza-spiro[4.5]decan-N—yl] and the like). In some embodiments, the heterocycloalkyl group has 3 to 10 ring-forming atoms, 4 to 10 ring-forming atoms, or 3 to 8 ring forming atoms. In some embodiments, the heterocycloalkyl group has 1 to 5 heteroatoms, l to 4 heteroatoms, l to 3 heteroatoms, or 1 to 2 heteroatoms. The carbon atoms or heteroatoms in the ring(s) of the heterocycloalkyl group can be oxidized to form a carbonyl, an N—oxide, or a sulfonyl group (or other oxidized linkage) or a nitrogen atom can be quaternized. In some embodiments, the heterocycloalkyl portion is a C24 monocyclic heterocycloalkyl group. In some embodiments, the heterocycloalkyl group is a morpholine ring, idine ring, piperazine ring, piperidine ring, dihydropyran ring, tetrahydropyran ring, tetrahyropyridine, azetidine ring, or tetrahydrofuran ring.
As used herein, the term "heterocycloalkylalkyl", employed alone or in combination with other terms, refers to a group of formula heterocycloalkyl-alkyl-. In some embodiments, the alkyl portion has 1 to 4, l to 3, l to 2, or 1 carbon atom(s). In some embodiments, the alkyl n is methylene. In some embodiments, the heterocycloalkyl portion has 3 to 10 ring members, 4 to 10 ring members, or 3 to 7 ring members. In some embodiments, the heterocycloalkyl group is monocyclic or bicyclic. In some embodiments, the heterocycloalkyl portion is monocyclic. In some embodiments, the heterocycloalkyl portion is a C24 monocyclic heterocycloalkyl group.
As used herein, the term "aryl", employed alone or in combination with other terms, refers to a monocyclic or polycyclic (e. g., having 2 fused rings) aromatic hydrocarbon moiety, such as, but not limited to, phenyl, l-naphthyl, 2-naphthyl, and the like. In some embodiments, aryl groups have from 6 to 10 carbon atoms or 6 carbon atoms. In some embodiments, the aryl group is a monocyclic or bicyclic group. In some embodiments, the aryl group is phenyl or naphthyl.
As used herein, the term "arylalkyl", employed alone or in combination with other terms, refers to a group of formula aryl-alkyl-. In some embodiments, the alkyl portion has 1 to 4, l to 3, l to 2, or 1 carbon atom(s). In some embodiments, the alkyl portion is methylene. In some embodiments, the aryl portion is phenyl. In some embodiments, the aryl group is a monocyclic or bicyclic group. In some embodiments, the arylalkyl group is benzyl.
As used herein, the term "heteroaryl", employed alone or in combination with other terms, refers to a clic or polycyclic (e. g., having 2 or 3 fused rings) aromatic arbon moiety, having one or more heteroatom ring s independently selected from nitrogen, sulfur and oxygen. In some embodiments, the heteroaryl group is a monocyclic or bicyclic group having 1, 2, 3, or 4 heteroatoms independently selected from en, sulfur and . Example aryl groups include, but are not limited to, pyridyl, dinyl, pyrazinyl, pyridazinyl, triazinyl, furyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrryl, oxazolyl, benzofuryl, benzothienyl, benzthiazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, indazolyl, l,2,4-thiadiazolyl, isothiazolyl, l, olyl, benzimidazolyl, indolinyl, pyrrolyl, azolyl, quinolinyl, isoquinolinyl, oxazolyl, imidazo[l,2-b]thiazolyl or the like. The carbon atoms or heteroatoms in the ring(s) of the heteroaryl group can be oxidized to form a carbonyl, an N—oxide, or a sulfonyl group (or other ed linkage) or a nitrogen atom can be quaternized, ed the aromatic nature of the ring is preserved. In one embodiment the heteroaryl group is a 3 to 10 membered heteroaryl group. In another embodiment the heteroaryl group is a 4 to 10 membered heteroaryl group. In another embodiment the heteroaryl group is a 3 to 7 membered heteroaryl group. In another embodiment the aryl group is a 5 to 6 ed heteroaryl group.
As used herein, the term "heteroarylalkyl", employed alone or in combination with other terms, refers to a group of formula heteroaryl-alkyl-. In some embodiments, the alkyl portion has 1 to 4, l to 3, l to 2, or 1 carbon ). In some embodiments, the alkyl portion is methylene. In some embodiments, the heteroaryl portion is a monocyclic or bicyclic group having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, sulfur and oxygen.
The compounds described herein can be asymmetric (e.g., having one or more stereocenters). All stereoisomers, such as enantiomers and diastereomers, are intended unless ise indicated. Compounds of the present invention that contain asymmetrically tuted carbon atoms can be isolated in optically active or racemic forms. Methods on how to prepare optically active forms from lly inactive starting materials are known in the art, such as by resolution of racemic es or by stereoselective synthesis. Many geometric isomers of s, C=N double bonds, and the like can also be present in the compounds described herein, and all such stable isomers are contemplated in the present invention. Cis and trans geometric isomers of the compounds of the present invention are described and may be isolated as a e of isomers or as ted isomeric forms.
Resolution of racemic mixtures of compounds can be carried out by any of numerous methods known in the art. An example method includes fractional recrystallizaion using a chiral resolving acid which is an optically active, salt-forming organic acid. Suitable resolving agents for onal recrystallization methods are, for example, optically active acids, such as the D and L forms of tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid or the various optically active camphorsulfonic acids.
Other resolving agents suitable for fractional crystallization methods include stereoisomerically pure forms of methylbenzylamine (e.g., S and R forms, or diastereomerically pure forms), 2-phenylglycinol, norephedrine, ephedrine, N- methylephedrine, cyclohexylethylamine, l,2-diaminocyclohexane, and the like.
Resolution of racemic es can also be carried out by elution on a column packed with an optically active ing agent (e. g., dinitrobenzoylphenylglycine). Suitable elution solvent composition can be determined by one skilled in the art.
Compounds of the invention also include tautomeric forms. Tautomeric forms result from the swapping of a single bond with an adjacent double bond together with the concomitant migration of a proton. Tautomeric forms include prototropic tautomers which are isomeric protonation states having the same cal formula and total . Example prototropic tautomers include ketone — enol pairs, amide - imidic acid pairs, lactam — lactim pairs, enamine — imine pairs, and annular forms where a proton can occupy two or more positions of a cyclic system, for example, 1H- and 3H-imidazole, lH-, 2H- and 4H- l,2,4-triazole, 1H- and 2H- isoindole, and 1H- and 2H-pyrazole. eric forms can be in equilibrium or ally locked into one form by riate substitution.
Compounds of the invention also include all isotopes of atoms occurring in the intermediates or final compounds. es include those atoms having the same atomic number but different mass numbers. For e, es of hydrogen include tritium and deuterium.
The term, "compound," as used herein is meant to include all stereoisomers, ric iosomers, tautomers, and isotopes of the structures depicted.
All compounds, and pharmaceutically acceptable salts f, can be found together with other substances such as water and solvents (e. g., in the form of es and solvates) or can be isolated.
In some embodiments, the compounds of the invention, or salts thereof, are substantially isolated. By "substantially isolated" is meant that the compound is at least partially or substantially separated from the environment in which it was formed or detected.
Partial tion can include, for example, a composition enriched in the compounds of the invention. Substantial separation can include compositions containing at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% by weight of the compounds of the invention, or salt thereof Methods for isolating compounds and their salts are routine in the art.
The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and s without excessive toxicity, irritation, allergic response, or other problem or cation, commensurate with a reasonable benefit/risk ratio.
The present invention also includes pharmaceutically acceptable salts of the compounds bed herein. As used herein, "pharmaceutically acceptable salts" refers to tives of the disclosed compounds wherein the parent compound is modified by ting an existing acid or base moiety to its salt form. Examples of pharmaceutically acceptable salts include, but are not limited to, l or c acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts of the present invention include the non-toxic salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods.
Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a iometric amount of the appropriate base or acid in water or in an WO 72644 organic solvent, or in a mixture of the two; generally, non-aqueous media like ether, ethyl acetate, alcohols (e.g., methanol, ethanol, iso-propanol, or butanol) or acetonitrile (ACN) are preferred. Lists of suitable salts are found in Remington ’s ceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418 and Journal ofPharmaceutical Science, 66, 2 (1977), each of which is incorporated herein by reference in its ty.
The following abbreviations may be used herein: AcOH (acetic acid); ACZO (acetic ide); aq. us); atm. phere(s)); Boc (t—butoxycarbonyl); br (broad); Cbz (carboxybenzyl); calc. (calculated); d (doublet); dd (doublet of doublets); DCM (dichloromethane); DEAD (diethyl azodicarboxylate); DIAD (N,N’-diisopropyl azidodicarboxylate); DIPEA (N,N—diisopropylethylamine); DMF (N,N—dimethylformamide); Et ); EtOAc (ethyl acetate); g (gram(s)); h (hour(s)); HATU (N,N,N’,N’-tetramethyl-O- (7-azabenzotriazolyl)uronium hexafluorophosphate); HCl (hydrochloric acid); HPLC (high performance liquid chromatography); Hz ); J (coupling constant); LCMS d chromatography — mass spectrometry); m (multiplet); M (molar); mCPBA (3- chloroperoxybenzoic acid); MgSO4 (magnesium sulfate); MS (Mass spectrometry); Me (methyl); MeCN (acetonitrile); MeOH (methanol); mg (milligram(s)); min. (minutes(s)); mL (milliliter(s)); mmol (millimole(s)); N (normal); NaHCO3 (sodium bicarbonate); NaOH (sodium hydroxide); NazSO4 (sodium sulfate); NH4C1 (ammonium chloride); NH4OH (ammonium hydroxide); nM (nanomolar); NMR (nuclear magnetic resonance spectroscopy); OTf (trifluoromethanesulfonate); Pd (palladium); Ph (phenyl); pM (picomolar); PMB (para- methoxybenzyl), POCl3 (phosphoryl chloride); RP-HPLC (reverse phase high performance liquid tography); s (singlet); t (triplet or tertiary); TBS (tert-butyldimethylsilyl); tert (tertiary); tt (triplet of triplets); t—Bu (tert-butyl); TFA (trifluoroacetic acid); THF hydrofuran); ug gram(s)); uL liter(s)); uM (micromolar); wt% (weight percent).
Synthesis Compounds of the invention, including salts thereof, can be prepared using known organic synthesis techniques and can be synthesized according to any of numerous possible synthetic .
The reactions for preparing compounds of the invention can be d out in suitable solvents which can be readily selected by one of skill in the art of organic synthesis. Suitable solvents can be substantially nonreactive with the starting materials (reactants), the intermediates, or products at the temperatures at which the reactions are carried out, e. g., 2014/034662 temperatures which can range from the solvent's ng temperature to the solvent's boiling temperature. A given reaction can be carried out in one solvent or a e of more than one solvent. Depending on the particular reaction step, suitable solvents for a particular reaction step can be selected by the skilled artisan.
Preparation of nds of the invention can involve the protection and deprotection of various chemical groups. The need for tion and deprotection, and the selection of appropriate protecting groups, can be readily determined by one skilled in the art.
The chemistry of protecting groups can be found, for example, in T.W. Greene and P.G.M.
Wuts, Protective Groups in Organic Synthesis, 3rd. Ed., Wiley & Sons, Inc., New York (1999), which is incorporated herein by reference in its ty.
Reactions can be monitored according to any suitable method known in the art. For example, product formation can be monitored by spectroscopic means, such as nuclear ic resonance spectroscopy (e.g., 1H or 13C), infrared spectroscopy, spectrophotometry (e.g., UV—visible), or mass spectrometry, or by chromatography such as high performance liquid chromatography (HPLC) or thin layer chromatography.
The expressions, "ambient temperature,3’ EC room temperature," and "r.t.", as used herein, are understood in the art, and refer generally to a temperature, e. g. a reaction temperature, that is about the temperature of the room in which the reaction is carried out, for example, a temperature from about 20 0C to about 30 0C.
Compounds of the invention can be prepared according to numerous preparatory routes known in the literature. Example synthetic methods for ing nds of the invention are provided in the Schemes below.
A series of bicyclic urea derivatives of formula 10 can be prepared by the methods outlined in Scheme 1. Amino ester 2 can be prepared by ng suitable amines R9NH2 with ester 1. The resulting ester 2 is subjected to a reduction—oxidation sequence to afford aldehyde 3. e reducing reagents e DIBAL-H (diisobutylaluminium hydride), LAH (lithium aluminium hydride), Super-H (lithium triethylborohydride), etc; and example oxidants e Dess-Martin Periodinane, MnOz, Swern Oxidation, etc. The aniline compound 5 is synthesized by coupling aldehyde 3 and aniline 4 through reductive amination. Then cyclization of diamino compound 5 can be carried out with sgene or the equivalent such as carbonyldiimidazole (CD1), phosgene, diphosgene, etc. affording the bicyclic urea derivatives of formula 6. cement of the chloride with 4- methoxybenzylamine (PMB-NHZ) with the aid of a palladium catalyst and then deprotection of PMB hoxybenzyl) group with Trifluoroacetic acid (TFA) can provide the aminopyridine compound 8. Halogenation of the pyridine ring with an appropriate halogenation reagent such as, for example, NBS (N—bromosuccinimide), NCS (N— chlorosuccinimide)NIS (N—iodosuccinimide), etc., can introduce a halogen for further elaboration. A variety of groups can be attached h palladium catalyzed coupling including, but not d to, Suzuki coupling, Stille coupling, Neigishi coupling, Sonogashira ng, ect. and copper catalyzed Ullmann coupling to afford compound 10.
Schemel 0 HN’ R9NH2 DIBAL-H H / J A artin I Oxidation N CI 1 R4 R3 R5 Reductive R10 NHg Amination R4 R4 R3 R5 R3 R5 R3 R50 Tri 9 PMBNHZ phos ene9 ,R JL R9 R10 NHHN 1 JL [R9 R10 N N’ ‘— R O N N R2 2 R2 / / / I I \ | N CI 7 \N N’PMB \N CI 5 H 6 R4 R4 R4 R3 R5 R3 R5 R3 R5 r o pd c r 9 9 H.aogena Iont- 9 or U N N’R —> R10 NJLNR —. R10 N N R2 R2 x R2 R6 / / / | | \ I \ 3 \ N NH2 9 N NH2 N NH2 X=C|,Br,| A series of aniline derivatives of formula 13 can be prepared by the methods outlined in Scheme 2. Displacement of the chloride 6 with RS-NHZ in the presence of palladium catalyst can provide the aminopyridine compound 11. Halogenation of the pyridine ring with an appropriate halogenating t such as NBS, NCS, NIS, etc. can provide compound 12 for further elaboration. Palladium catalyzed coupling of compound 12 by, for example, Suzuki coupling, Stille coupling, Neigishi ng, Sonogashira coupling, etc. or copper catalyzed Ullmann coupling can afford nd 13.
Scheme 2 R4 R4 R3 R5 R3 R5 EL (R9 2 i IR9 1 1 R o N N <— R o N N R2 Pd R2 / / | | \ \ N NHR8 N CI R3 R5 R3 R50 /U\ Pd or Cu /U\ R9 1 , R9 R10 —> N N' R O N N R2 R6 R2 Br / N NHR8 12 13 A series of aniline derivatives 14 can be prepared according to the procedures outlined in Scheme 3. Displacement of fluorine in compound 15 with benzylamine ) provides the aniline 16 which can be converted to bis-ether by ng with a suitable sodium alkoxide (NaOR where R is alkyl) followed by saponification to provide acid 17.
Compound 18 can be obtained by decarboxylation of benzoic acid 17, followed by hydrogenation to remove the protecting group to afford aniline 14.
Scheme 3 BnHN F 1) NaOR, ROH F 2) 50% aq. NaOH F O BnHN OR BnHN OR Pd ()OH)2/o H2 H2N OR OR O OR 17 18 14 An alternative synthesis of compound 8 is outlined in Scheme 4. Ester 1 is reduced and oxidized to the corresponding aldehyde 19. The reductive amination on this aldehyde with aniline 4 affords aniline 20, which can be subjected to palladium zed amination to provide ediate aniline 5. The synthesis of nd 8 from aniline 5 follows the same procedure described in Scheme 1.
Scheme4 CI CI DIBAL—H R3 R5 / + 0 / —> H 2 I \ Doss-Martin \ R10 NH2 N CI ion N CI R2 Reductive 19 4 Amination R4 R4 R3 R5 R3 R5 R3 R5 Triphosgene RQNHZ 9 ‘— 1 / R z R R10 N N R10 R0 NH NH HN Pd R2 R2 R2 / / / I I I \ \ \N CI N CI N CI 6 21 PMBNH2 R4 R4 R3 R5 o R3 R50 R3 R5 9 TFA 1)NBS R10 NJJWR —> Jk .R9 —> R9 R10 N N R10 N N / 2 2) Pd or Cu I R / R2 R6 \ ,PMB l | N I2 \ N NH2 N NH2 7 8 10 Compounds of formula 26 can be prepared by the methods outlined in Scheme 5.
Lactam 24 can be prepared from compounds 22 and 23 using Palladium-catalyzed Buchwald—Hartwig-type reactions or copper-mediated Ullmann-type and am-type N- arylation reactions. (x-Substituted lactam 25 can be obtained by treating nd 24 with a base such as, for example, K2CO3 or CszCO3 in DMF or acetonitrile, and followed by the addition of halides RloX and/or RHX (X is halo such as C1 or Br). Chloride 25 can be converted to the corresponding aminopyridine 26 under Buchwald—Hartwig amination conditions using reagents such as, for example, )2/Xantphos/Cs2CO3 or Pd2(dba)3/BINAP/NaOtBu, etc.
Schemes R3 R5 R4 R3 R5 R10 Hal/B(OR)2 0 HN R2 23 R10 N / R2 I / Cu or Pd \ l N CI \ 24 N CI R1OXand/orR11X Base R4 R4 R3 R5 R3 R5 NH2R8 R10 <— R10 R10 N R10 R11 N Pd R11 R2 R2 / / | l \ \ N NHR8 26 25 N CI Compounds of formula 34 can be prepared by the methods outlined in Scheme 6.
Ester 27 can be ed by selective displacement of chloride with sodium allyloxide. The resulting ester 27 is subjected to a reduction—oxidation ce to afford de 28.
Example reducing reagents include DIBAL-H (diisobutylaluminium hydride), LAH (lithium aluminium hydride), Super-H (lithium triethylborohydride), etc; and example ts include Dess-Martin Periodinane, MnOz, Swern Oxidation, etc. The aniline compound 29 is sized by coupling aldehyde 28 and e 4 through reductive amination. After the removal of allyl group by palladium dichloride, then cyclization of amino hydroxyl intermediate can be carried outwith triphosgene or the equivalent such as carbonyldiimidazole (CD1), phosgene, diphosgene, etc. ing the bicyclic carbamate derivatives of formula 30. The synthesis of compound 34 from carbamate 30 follows the same procedure as described in Scheme 1.
PCT/USZOl4/034662 Scheme 6 / / 0 CI 0 o/\/ WOH 0 ON DIBAL-H O / O / —> H / J J I I \ N \ Doss-Martin \ N CI N CI Oxidation N CI Reductive R10 Amination R4 R4 R3 R3 R5 R3 R5 PMBNH2 1) Pdc'z i JL R10 :Hof R10 ‘— R1O N o N O Pd 2) Tri hos one 2 R2 P g / / /NC| 31 \Nl N’P'V'B \Nl CI R4 R4 R4 R3 R50 R3 R50 R3 R50 Halo enation Pd or Cu NJJ\O —>g R10 NJJ\O —> R10 NAG 2 6 | | \ 32 \N NH2 33 \N N NH2 An alternative sis of compound 26 is outlined in Scheme 7. Ester 1 is reduced to the corresponding aldehyde 19. Then reductive amination of aldehyde 19 with aniline 4 affords compound 20, which can be treated with ethyl 3-chlorooxopropanoate in the presence ofNaH in THF to provide intermediate aniline 35. Lactam 24 can be prepared by ent of compound 35 with a strong base such as, but not limited to, NaH or CszCO3 in DMF, then followed by an acid, for example, HCl mediated decarboxylation. (II—Substituted lactam 25 can be obtained by ng compound 24 with a suitable base such as, NaH or CsZCO3 in DMF and followed by the on of halides RloX and/or RHX (X is halo such as C1 or Br). Chloride 25 can be converted to the corresponding aminopyridine 26 under Buchwald—Hartwig amination conditions using reagents such as, but not limited to, )2/Xantphos/Cs2CO3 or Pd(OAc)2/BrettPhos/NaOtBu.
Scheme7 ) Reductive Amination 19 4 O O CIMOA R R3 R5 O O NW R10 NH Cl Base, DMF R2 R2 / / | I then acid \ \ mediated N CI N 20 oxylation R3 R50 R1°x and/or R11X 1 R10 NH2R8 R O N R11 —, Base R2 Pd N Cl R3 R5 RRH10 R10 N N NHR8 Methods of Use Compounds of the invention can inhibit ty of one or more FGFR enzymes. For example, the compounds of the invention can be used to inhibit activity of an FGFR enzyme in a cell or in an individual or patient in need of inhibition of the enzyme by administering an inhibiting amount of a nd of the invention to the cell, individual, or patient.
In some embodiments, the compounds of the invention are inhibitors of one or more of FGFRl, FGFRZ, FGFR3, and FGFR4. In some embodiments, the compounds of the invention inhibit each of FGFRl, FGFRZ, and FGFR3. In some embodiments, the nds of the invention are selective for one or more FGFR enzymes. In some embodiments, the compounds of the invention are selective for one or more FGFR s over VEGFRZ. In some embodiments, the selectivity is 2—fold or more, 3—fold or more, 5— fold or more, 10—fold or more, 50—fold or more, or lOO—fold or more.
As FGFR inhibitors, the nds of the invention are useful in the treatment of various diseases associated with abnormal expression or activity of FGFR s or FGFR ligands.
For example, the compounds of the invention are useful in the treatment of cancer.
Example cancers e bladder cancer, breast cancer, cervical cancer, colorectal cancer, cancer of the small intestine, colon cancer, rectal , cacncer of the anus, endometrial cancer, gastric cancer, head and neck cancer (e.g., cancers of the larynx, hypopharynx, nasopharynx, oropharynx, lips, and mouth), kidney cancer, liver cancer (e.g., hepatocellular carcinoma, cholangiocellular carcinoma), lung cancer (e.g., adenocarcinoma, small cell lung cancer and non-small cell lung carcinomas, parvicellular and non-parvicellular carcinoma, bronchial oma, bronchial adenoma, pulmonary blastoma), ovarian , prostate cancer, testicular cancer, uterine cancer, geal cancer, gall bladder cancer, pancreatic cancer (e.g. exocrine pancreatic carcinoma), stomach cancer, d cancer, parathyroid , skin cancer (e.g., squamous cell carcinoma, Kaposi sarcoma, Merkel cell skin cancer), and brain cancer (e. g., astrocytoma, medulloblastoma, ependymoma, neuro— ectodermal tumors, pineal tumors).
Further example cancers include hematopoietic malignancies such as leukemia or lymphoma, multiple myeloma, chronic lymphocytic lymphoma, adult T cell leukemia, B-cell lymphoma, cutaneous T-cell lymphoma, acute myelogenous leukemia, n’s or non— Hodgkin’s lymphoma, myeloproliferative neoplasms (e.g., polycythemia vera, essential thrombocythemia, and primary myelof1brosis), Waldenstrom's Macroglubulinemia, hairy cell lymphoma, chronic myelogenic lymphoma, acute blastic lymphoma, AIDS-related lymphomas, and Burkitt's lymphoma.
Other cancers treatable with the compounds of the invention include tumors of the eye, glioblastoma, melanoma, rhabdosarcoma, lymphosarcoma, and osteosarcoma.
In addition to oncogenic neoplasms, the compounds of the invention can be useful in the treatment of skeletal and chondrocyte disorders ing, but not limited to, achrondroplasia, ondroplasia, dwarfism, thanatophoric sia (TD) (clinical forms TD I and TD II), Apert syndrome, Crouzon syndrome, Jackson—Weiss syndrome, Beare— Stevenson cutis gyrate syndrome, Pfeiffer syndrome, and craniosynostosis syndromes.
The compounds of the invention can also be useful in the treatment of hypophosphatemia disorders including, for example, X-linked hypophosphatemic rickets, autosomal recessive hypophosphatemic rickets, autosomal dominant hypophosphatemic rickets, and tumor-induced osteromalacia.
The compounds of the invention may further be useful in the treatment of f1brotic diseases, such as where a disease symptom or disorder is characterized by fibrosis. Example fibrotic diseases include liver cirrhosis, glomerulonephritis, pulmonary fibrosis, systemic fibrosis, rheumatoid arthritis, and wound healing.
The nds of the invention can also be useful in the treatment of psoriasis, keloids, bullous skin disorders, atherosclerosis, restenosis, ial cell proliferative disorders, glomerulopathy, diabetic nephropathy, kidney diseases, and benign prostate hyperplasia.
The compounds of the invention can also be useful in the treatment of various eye diseases including, for example, lated r degeneration, dry macular degeneration, ischemic l vein occlusion, diabetic macula edema, diebetic retinopathy, and retinopathy of prematurity.
The nds of the invention can also be useful in the inhibition of tumor isis.
As used herein, the term "cell" is meant to refer to a cell that is in vitro, ex vivo or in vivo. In some embodiments, an ex vivo cell can be part of a tissue sample excised from an organism such as a mammal. In some embodiments, an in vitro cell can be a cell in a cell culture. In some embodiments, an in vivo cell is a cell living in an organism such as a mammal.
As used herein, the term "contacting" refers to the ng together of indicated moieties in an in vitro system or an in vivo . For example, "contacting" the FGFR enzyme with a compound of the invention es the administration of a compound of the present invention to an individual or patient, such as a human, having FGFR, as well as, for example, introducing a compound of the invention into a sample containing a cellular or purified preparation containing the FGFR enzyme.
As used herein, the term "individual" or nt," used interchangeably, refers to any animal, including mammals, ably mice, rats, other s, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates, and most preferably .
As used herein, the phrase "therapeutically effective amount" refers to the amount of active compound or pharmaceutical agent that elicits the biological or nal response in a tissue, system, animal, dual or human that is being sought by a researcher, veterinarian, medical doctor or other clinician.
As used herein the term ing" or ment" refers to l) preventing the disease; for example, preventing a disease, ion or disorder in an individual who may be predisposed to the disease, condition or disorder but does not yet ence or display the pathology or symptomatology of the disease; 2) inhibiting the disease; for example, ting a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., arresting further development of the pathology and/or symptomatology), or 3) ameliorating the disease; for example, ameliorating a disease, condition or er in an dual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., reversing the pathology and/or symptomatology).
Combination Therapy One or more additional pharmaceutical agents or treatment methods such as, for e, anti-viral agents, herapeutics or other anti-cancer agents, immune ers, immunosuppressants, radiation, anti-tumor and anti-viral vaccines, cytokine therapy (e.g., 1L2, GM-CSF, eta), and/or tyrosine kinase inhibitors can be used in combination with the compounds of the present invention for treatment of FGFR—associated es, disorders or conditions. The agents can be combined with the present compounds in a single dosage form, or the agents can be administered simultaneously or sequentially as separate dosage forms.
Suitable antiviral agents contemplated for use in combination with the compounds of the present invention can comprise nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs), non—nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors and other antiviral drugs.
Example suitable NRTIs include zidovudine (AZT); sine (ddl); zalcitabine (ddC); stavudine (d4T); lamivudine (3TC); abacavir (1592U89); adefovir dipivoxil [bis(POM)-PMEA]; lobucavir (BMS-180194); BCH-10652; emitricitabine [(-)-FTC]; beta-L- FD4 (also called beta-L-D4C and named beta-L-2', 3'-dicleoxyfluoro-cytidene); DAPD, ((— )-beta-D-2,6,-diamino-purine dioxolane); and lodenosine (FddA). Typical suitable NNRTIs e nevirapine (BI-RG-S 87); radine (BHAP, U-90152); enz (DMP-266); PNU- l 4272 1; AG- 1549; MKC—442 (l-(ethoxy-methyl)-5 -( l -methylethyl)(phenylmethyl)- (2,4(lH,3H)-pyrimidinedione); and (+)-calanolide A (NSC—67545 l) and B. Typical suitable protease inhibitors include saquinavir (Ro 9); ritonavir (ABT-53 8); indinavir (MK- 63 9); vir (AG-1343); amprenavir (141W94); lasinavir (BMS-234475); DMP-450; BMS-2322623; ABT-3 78; and AG-l 549. Other antiviral agents include hydroxyurea, ribavirin, IL—2, IL-12, uside and Yissum Project No. l 1607.
Suitable agents for use in ation with the compounds of the present invention for the treatment of cancer e chemotherapeutic agents, targeted cancer ies, immunotherapies or radiation therapy. Compounds of this invention may be effective in combination with anti-hormonal agents for treatment of breast cancer and other tumors.
Suitable examples are anti-estrogen agents including but not d to tamoxifen and toremifene, aromatase inhibitors ing but not limited to letrozole, anastrozole, and exemestane, adrenocorticosteroids (e.g. prednisone), progestins (e. g. megastrol acetate), and estrogen receptor antagonists (e.g. trant). Suitable ormone agents used for treatment of prostate and other s may also be combined with compounds of the present invention. These include ndrogens including but not limited to flutamide, bicalutamide, and mide, luteinizing hormone-releasing hormone (LHRH) analogs including leuprolide, goserelin, triptorelin, and histrelin, LHRH antagonists (e. g. degarelix), androgen receptor blockers (e. g. enzalutamide) and agents that inhibit androgen production (e. g. abiraterone).
Compounds of the t invention may be combined with or in sequence with other agents against membrane receptor kinases especially for patients who have developed primary or acquired resistance to the targeted therapy. These therapeutic agents include inhibitors or antibodies against EGFR, Her2, VEGFR, c-Met, Ret, IGFRl, or Flt-3 and against cancer-associated fusion protein kinases such as l and EML4-Alk. Inhibitors against EGFR include gefitinib and erlotinib, and inhibitors against EGFlUHerZ include but are not limited to dacomitinib, afatinib, lapitinib and neratinib. Antibodies against the EGFR include but are not limited to cetuximab, panitumumab and necitumumab. Inhibitors of c- Met may be used in combination with FGFR inhibitors. These include onartumzumab, tivantnib, and INC-280. Agents against Abl (or Bcr-Abl) include imatinib, dasatinib, nilotinib, and nib and those against Alk (or EML4-ALK) include crizotinib.
Angiogenesis inhibitors may be efficacious in some tumors in combination with FGFR tors. These include antibodies against VEGF or VEGFR or kinase inhibitors of VEGFR. Antibodies or other therapeutic proteins against VEGF include bevacizumab and aflibercept. Inhibitors ofVEGFR kinases and other anti-angiogenesis tors include but are not limited to sunitinib, sorafenib, axitinib, cediranib, pazopanib, fenib, brivanib, and vandetanib Activation of intracellular signaling pathways is frequent in cancer, and agents targeting components of these pathways have been combined with receptor targeting agents to enhance efficacy and reduce resistance. Examples of agents that may be combined with compounds of the present invention include inhibitors of the PI3K—AKT—mTOR y, inhibitors of the Raf-MAPK pathway, inhibitors of JAK-STAT pathway, and inhibitors of n chaperones and cell cycle progression.
Agents t the PI3 kinase include but are not limited topilaralisib, idelalisib, buparlisib. Inhibitors of mTOR such as cin, sirolimus, temsirolimus, and everolimus may be combined with FGFR tors. Other suitable examples include but are not limited to vemurafenib and dabrafenib (Raf inhibitors) and trametinib, selumetinib and GDC-0973 (MEK inhibitors). Inhibitors of one or more JAKs (e. g., ruxolitinib, baricitinib, tofacitinib), Hsp90 (e.g., tanespimycin), cyclin dependent kinases (e.g., palbociclib), HDACs (e.g., panobinostat), PARP (e. g., ib), and proteasomes (e. g., bortezomib, carfilzomib) can also be combined with compounds of the present invention. In some embodiments, the JAK inhibitor is selective for JAKl over JAKZ and JAK3.
Other suitable agents for use in combination with the compounds of the present invention include chemotherapy combinations such as platinum—based doublets used in lung cancer and other solid tumors (cisplatin or carboplatin plus gemcitabine; cisplatin or latin plus docetaxel; cisplatin or carboplatin plus axel; cisplatin or carboplatin plus pemetrexed) or gemcitabine plus paclitaxel bound particles ane®).
Suitable chemotherapeutic or other ancer agents include, for example, alkylating agents ding, without limitation, en mustards, ethylenimine derivatives, alkyl sulfonates, nitrosoureas and triazenes) such as uracil mustard, chlormethine, cyclophosphamide (CytoxanTM), mide, melphalan, chlorambucil, pipobroman, ylene-melamine, triethylenethiophosphoramine, busulfan, carmustine, lomustine, streptozocin, dacarbazine, and temozolomide.
Other suitable agents for use in combination with the compounds of the present ion include: dacarbazine (DTIC), optionally, along with other chemotherapy drugs such as carmustine (BCNU) and cisplatin; the "Dartmouth regimen," which consists of DTIC, BCNU, cisplatin and tamoxifen; a combination of cisplatin, vinblastine, and DTIC, or temozolomide. Compounds according to the invention may also be combined with immunotherapy drugs, including cytokines such as interferon alpha, eukin 2, and tumor necrosis factor (TNF) in.
Suitable chemotherapeutic or other anti-cancer agents include, for example, antimetabolites (including, without tion, folic acid antagonists, dine analogs, purine analogs and adenosine deaminase tors) such as methotrexate, 5-fluorouracil, floxuridine, cytarabine, 6-mercaptopurine, 6-thioguanine, fludarabine phosphate, tatine, and gemcitabine. le chemotherapeutic or other anti-cancer agents further include, for example, certain natural products and their derivatives (for e, vinca alkaloids, antitumor otics, s, lymphokines and epipodophyllotoxins) such as vinblastine, vincristine, vindesine, bleomycin, dactinomycin, daunorubicin, doxorubicin, epirubicin, idarubicin, ara— C, paclitaxel (TAXOLTM), mithramycin, deoxycoformycin, mitomycin-C, L-asparaginase, interferons (especially IFN—a), etoposide, and teniposide.
Other cytotoxic agents include navelbene, CPT-l l, anastrazole, letrazole, capecitabine, fine, cyclophosphamide, ifosamide, and droloxafine.
Also suitable are cytotoxic agents such as hyllotoxin; an antineoplastic enzyme; a topoisomerase inhibitor; procarbazine; mitoxantrone; platinum coordination complexes such as cis-platin and carboplatin; biological response modifiers; growth inhibitors; antihormonal eutic agents; leucovorin; r; and haematopoietic growth factors.
Other anti-cancer agent(s) e antibody therapeutics such as trastuzumab (Herceptin), antibodies to costimulatory molecules such as CTLA-4, 4-lBB and PD-l, or antibodies to cytokines (IL—10, TGF—B, etc.).
Other anti-cancer agents also include those that block immune cell ion such as antagonists to chemokine receptors, including CCR2 and CCR4.
Other anti-cancer agents also include those that augment the immune system such as adjuvants or adoptive T cell transfer.
Anti—cancer vaccines include dendritic cells, synthetic peptides, DNA vaccines and recombinant viruses.
Methods for the safe and effective administration of most of these chemotherapeutic agents are known to those skilled in the art. In addition, their administration is described in the standard literature. For example, the administration of many of the chemotherapeutic agents is described in the "Physicians' Desk Reference" (PDR, e. g., 1996 edition, Medical ics Company, Montvale, NJ), the disclosure of which is orated herein by reference as if set forth in its entirety.
Pharmaceutical ations and Dosage Forms When employed as pharmaceuticals, the compounds of the invention can be administered in the form of pharmaceutical compositions which refers to a combination of a compound of the invention, or its pharmaceutically acceptable salt, and at least one pharmaceutically acceptable carrier. These compositions can be prepared in a manner well known in the pharmaceutical art, and can be administered by a variety of routes, depending upon whether local or systemic treatment is desired and upon the area to be treated.
Administration may be topical (including ophthalmic and to mucous membranes including intranasal, vaginal and rectal delivery), pulmonary (e. g., by inhalation or insufflation of powders or ls, including by nebulizer; intratracheal, intranasal, epidermal and transdermal), ocular, oral or parenteral. Methods for ocular delivery can include topical administration (eye drops), subconjunctival, periocular or intravitreal injection or uction by balloon catheter or lmic inserts surgically placed in the conjunctival sac. eral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal, or uscular injection or on; or intracranial, e. g., intrathecal or intraventricular, administration. Parenteral stration can be in the form of a single bolus dose, or may be, for example, by a continuous perfusion pump. Pharmaceutical compositions and ations for l administration may include transdermal patches, ointments, s, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, s, powder or oily bases, thickeners and the like may be necessary or desirable.
This invention also includes pharmaceutical compositions which n, as the active ingredient, one or more of the compounds of the invention above in combination with one or more ceutically acceptable rs. In making the compositions of the invention, the active ingredient is typically mixed with an excipient, diluted by an excipient or enclosed within such a carrier in the form of, for example, a capsule, sachet, paper, or other container.
When the excipient serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ient. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10 % by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders.
In preparing a formulation, the active compound can be milled to provide the appropriate particle size prior to combining with the other ingredients. If the active compound is substantially insoluble, it can be milled to a particle size of less than 200 mesh. If the active compound is substantially water soluble, the particle size can be adjusted by milling to provide a substantially uniform distribution in the formulation, e. g. about 40 mesh.
Some examples of suitable excipients e lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, n, m silicate, microcrystalline cellulose, polyvinylpyrrolidone, ose, water, syrup, and methyl cellulose. The formulations can additionally include: lubricating agents such as talc, ium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxy-benzoates; sweetening agents; and flavoring . The compositions of the invention can be formulated so as to e quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art.
The itions can be formulated in a unit dosage form, each dosage containing from about 5 to about 100 mg, more usually about 10 to about 30 mg, of the active ingredient. The term "unit dosage forms" refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient.
The active compound can be effective over a wide dosage range and is lly administered in a pharmaceutically effective amount. It will be understood, however, that the amount of the compound actually administered will usually be determined by a physician, according to the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and se of the individual patient, the severity of the patient's symptoms, and the like.
For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical excipient to form a solid pre-formulation composition containing a homogeneous mixture of a nd of the present ion. When referring to these pre-formulation compositions as homogeneous, the active ingredient is typically dispersed evenly throughout the composition so that the composition can be readily subdivided into equally ive unit dosage forms such as s, pills and capsules. This solid pre—formulation is then subdivided into unit dosage forms of the type described above containing from, for example, 0.1 to about 500 mg of the active ient of the present invention.
The tablets or pills of the present invention can be coated or otherwise compounded to provide a dosage form ing the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage ent, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.
The liquid forms in which the compounds and compositions of the present invention can be incorporated for stration orally or by injection include aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as seed oil, sesame oil, coconut oil, or peanut oil, as well as elixirs and similar pharmaceutical vehicles.
Compositions for inhalation or insufflation include solutions and sions in pharmaceutically acceptable, s or organic solvents, or mixtures thereof, and powders.
The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra. In some embodiments, the compositions are administered by the oral or nasal respiratory route for local or systemic . itions in can be nebulized by use of inert gases. Nebulized solutions may be breathed directly from the nebulizing device or the nebulizing device can be attached to a face masks tent, or intermittent positive pressure breathing machine. Solution, sion, or powder compositions can be stered orally or nasally from devices which deliver the formulation in an appropriate manner.
The amount of compound or composition administered to a patient will vary ing upon what is being administered, the purpose of the administration, such as prophylaxis or therapy, the state of the t, the manner of administration, and the like. In therapeutic applications, compositions can be administered to a patient already suffering from a e in an amount sufficient to cure or at least partially arrest the symptoms of the e and its complications. Effective doses will depend on the disease condition being treated as well as by the judgment of the attending clinician depending upon factors such as the severity of the disease, the age, weight and general condition of the patient, and the like.
The compositions administered to a patient can be in the form of pharmaceutical compositions described above. These compositions can be sterilized by conventional sterilization techniques, or may be sterile filtered. Aqueous solutions can be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous carrier prior to administration. The pH of the compound preparations typically will be between 3 and 11, more preferably from 5 to 9 and most ably from 7 to 8. It will be understood that use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of pharmaceutical salts.
The therapeutic dosage of the compounds of the t ion can vary according to, for example, the particular use for which the treatment is made, the manner of administration of the compound, the health and condition of the patient, and the nt of the prescribing ian. The proportion or concentration of a compound of the invention in a pharmaceutical composition can vary depending upon a number of factors including , chemical characteristics (e. g., hydrophobicity), and the route of administration. For example, the compounds of the invention can be provided in an aqueous physiological buffer solution containing about 0.1 to about 10% w/v of the compound for eral administration. Some typical dose ranges are from about 1 ug/kg to about 1 g/kg of body weight per day. In some embodiments, the dose range is from about 0.01 mg/kg to about 100 mg/kg of body weight per day. The dosage is likely to depend on such variables as the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological cy of the nd ed, formulation of the excipient, and its route of administration. Effective doses can be extrapolated from dose— se curves derived from in vitro or animal model test systems.
The compounds of the ion can also be formulated in ation with one or more additional active ingredients which can include any pharmaceutical agent such as anti- viral agents, vaccines, antibodies, immune enhancers, immune suppressants, anti- inflammatory agents and the like.
Labeled Compounds and Assay Methods Another aspect of the present invention relates to fluorescent dye, spin label, heavy metal or radio-labeled compounds of the invention that would be useful not only in imaging but also in assays, both in vitro and in vivo, for localizing and quantitating the FGFR enzyme in tissue samples, including human, and for identifying FGFR enzyme ligands by inhibition binding of a labeled compound. Accordingly, the t invention includes FGFR enzyme assays that contain such labeled compounds.
The present ion further includes isotopically—labeled compounds of the invention. An "isotopically" or "radio-labeled" compound is a compound of the invention where one or more atoms are ed or substituted by an atom having an atomic mass or mass number different from the atomic mass or mass number typically found in nature (i.e., naturally occurring). le radionuclides that may be incorporated in compounds of the present invention include but are not limited to 2H (also n as D for ium), 3H (also n as T for tritium), 11C, 13C, 14C, 13N, 15N, 15O, 17O, 18O, 18F, 35S, 36Cl, 82Br, 75Br, 76Br, 77Br, 123I, 1241, 1251 and 131I. The radionuclide that is incorporated in the instant radio-labeled compounds will depend on the specific ation of that radio—labeled compound. For e, for in vitro FGFR enzyme labeling and competition assays, compounds that incorporate 3H, 14C, 82Br, 1251 or 35S will generally be most useful. For radio-imaging , 131I, ations 11C, 18F, 1251, 123I, 1241, 1311, 75Br, 76Br or 77Br will generally be most useful.
It is understood that a "radio-labeled " or "labeled compound" is a compound that has incorporated at least one radionuclide. In some embodiments the radionuclide is selected from the group consisting of 3H, 14C, 1251 35S and 82Br.
Synthetic methods for incorporating radio-isotopes into organic compounds are applicable to compounds of the invention and are well known in the art.
A radio—labeled compound of the invention can be used in a screening assay to identify/evaluate nds. In general terms, a newly synthesized or identifled compound (i.e., test compound) can be evaluated for its ability to reduce binding of the radio—labeled compound of the invention to the FGFR enzyme. Accordingly, the ability of a test compound to compete with the radio-labeled compound for binding to the FGFR enzyme directly correlates to its binding affinity.
Kits The present ion also includes pharmaceutical kits , for example, in the treatment or prevention of FGFR-associated diseases or disorders, obesity, diabetes and other diseases referred to herein which include one or more containers containing a pharmaceutical composition comprising a therapeutically effective amount of a compound of the ion.
Such kits can further include, if desired, one or more of various conventional pharmaceutical kit components, such as, for example, containers with one or more pharmaceutically acceptable carriers, additional containers, etc., as will be readily apparent to those skilled in the art. Instructions, either as inserts or as labels, indicating quantities of the components to be administered, guidelines for administration, and/or ines for mixing the components, can also be included in the kit.
The invention will be described in greater detail by way of specific examples. The following examples are offered for illustrative purposes, and are not intended to limit the invention in any manner. Those of skill in the art will readily recognize a y of non- al parameters which can be changed or modified to yield essentially the same results.
The compounds of the Examples were found to be inhibitors of one or more FGFR’s as described below.
EXAMPLES Experimental procedures for compounds of the invention are provided below. atory LC—MS purifications of some of the nds prepared were performed on Waters mass directed fractionation systems. The basic equipment setup, protocols, and control software for the operation of these systems have been described in detail in the literature. See e. g. "Two-Pump At Column Dilution Configuration for Preparative LC-MS", K. Blom, J. Combi. Chem, 4, 295 (2002); izing Preparative LC-MS Configurations and Methods for Parallel sis Purification", K. Blom, R. Sparks, J. Doughty, G. Everlof, T. Haque, A. Combs, J. Combi. Chem, 5, 670 (2003); and "Preparative LC—MS Purification: Improved Compound Speciflc Method zation", K. Blom, B. Glass, R. Sparks, A.
Combs, J. Combi. Chem, 6, 874—883 (2004). The compounds separated were typically subjected to analytical liquid chromatography mass spectrometry (LCMS) for purity check under the following conditions: Instrument; Agilent 1100 , , : Waters SunflreTM C18 5 pm, 2.1 x 5.0 mm, Buffers: mobile phase A: 0.025% TFA in water and mobile phase B: 0.025% TFA in itrile; gradient 2% to 80% of B in 3 minutes with flow rate 1.5 mL/minute.
Some of the compounds prepared were also separated on a preparative scale by reverse-phase high performance liquid chromatography (RP-HPLC) with MS detector or flash chromatography (silica gel) as indicated in the Examples. Typical preparative reverse- phase high performance liquid chromatography (RP-HPLC) column conditions are as follows: pH = 2 purifications: Waters SunfireTM C18 5 pm, 19 x 100 mm column, eluting with mobile phase A: 0.1% TFA (trifluoroacetic acid) in water and mobile phase B: 0.1% TFA in acetonitrile; the flow rate was 30 mL/minute, the separating gradient was optimized for each compound using the Compound c Method Optimization protocol as described in the ture [see "Preparative LCMS Purification: ed Compound Specific Method Optimization", K. Blom, B. Glass, R. Sparks, A. Combs, J. Comb. Chem., 6, 874—883 (2004)]. Typically, the flow rate used with the 30 x 100 mm column was 60 mL/minute. pH = 10 purifications: Waters XBridge C18 5 um, 19 x 100 mm column, eluting with mobile phase A: 0.15% NH4OH in water and mobile phase B: 0.15% NH4OH in acetonitrile; the flow rate was 30 mL/minute, the separating gradient was optimized for each compound using the Compound c Method Optimization protocol as described in the ture [See "Preparative LCMS Purification: Improved Compound Specific Method Optimization", K. Blom, B. Glass, R. Sparks, A. Combs, J. Comb. Chem., 6, 874—883 (2004)]. Typically, the flow rate used with 30 x 100 mm column was 60 mL/minute. 7-amin0(2,6-diflu0r0-3,5-dimethoxyphenyl)-1,8-dimethyl-3,4-dihydropyrid0 [4,3- d]pyrimidin-2(1H)-0ne \0iii N N/ PW\| N NH2 Step I: ethyl 6-chlor0(methylamin0)nicotinate To a solution of 2, 4—dichloro—5—carbethoxypyridine (10.0 g, 45.4 mmol, purchased from Ark, catalog No. AK-25933 ) in acetonitrile (40 mL) was added methylamine (8.52 mL, 8.0 M in EtOH, 68.2 mmol) dropwise at 0 0C. The resulting solution was stirred at room temperature for 6 h before it was concentrated in vacuo. The crude residue was taken to the next step directly without further ation. LC-MS calculated for C9H12ClN202 [M+H]+ m/z: 215.1; found 215.1.
Step 2: 6-chZora(methylamin0)nicotinaldehyde o/ ’/ N a To a solution of ethyl 6-chloro(methylamino)nicotinate (11.0 g, 50.2 mmol) in methylene chloride (400 mL) was added 1.0 M diisobutylaluminum hydride in THF (150 mL, 150 mmol). The resulting mixture was stirred at room temperature for 6 h before it was quenched by a solution of Rochelle's salt. After stirring for 12 h, the aqueous solution was extracted with EtOAc (3><150 mL) and the organic layer was dried over NaZSO4 and trated in vacuo to afford the crude l. LC—MS calculated for C7H10C1N20 [M+H]+ m/z: 173.0; found 173.0.
To the solution of crude alcohol in methylene chloride (300 mL) were added sodium bicarbonate (42 g, 500 mmol) and Dess-Martin periodinane (42 g, 100 mmol). The resulting mixture was stirred for 1 h before it was quenched with Na2S203 (sat. aq, 100 mL) and NaHC03 (sat. aq, 100 mL). The aqueous phase was extracted with EtOAc (3><100 mL) and the organic layer was dried over NaZSO4 and concentrated in vacuo. Purifled by flash column chromatography to afford the the aldehyde (6.2 g, 80% yield over two . LC—MS ated for C7HgClN20 [M+H]+ m/z: 171.0; found 171.0.
Step 3 .‘ 2-ch10r0{[(2, 6-diflu0r0-3, 5-dimeth0xyphenyl)amin0]methyl}-N-methylpyridin amine \o NHHN/ N CI To a mixture of 2,6-difluoro-3,5-dimethoxyaniline (CAS 42, LakeStar Tech, LSP-210C, Lot: 132—110—05: 1.07 g, 5.68 mmol) in trifluoroacetic acid (7.9 mL, 0.1 mol) was added sodium triacetoxyborohydride ( 3.6 g, 17.0 mmol). The mixture was stirred at 0 0C for 2 s before a solution of 6-chloro(methylamino)-nicotinaldehyde (0.97 g, .7 mmol) in methylene chloride (8.0 mL) was added dropwise. The reaction mixture was stirred at room temperature overnight before it was concentrated in vacuo to remove the excess trifluoroacetic acid. The residue was neutralized by NaHCO3 solution. The aqueous phase was extracted with EtOAc (3>< 10 mL) and the organic layer was dried over NaZSO4 and concentrated in vacuo. The crude product was purified by flash column chromatography to afford the aniline (1.36 g, 68%). LC—MS calculated for C15H17C1F2N302 [M+H]+ m/z: 344.1; found 344.1.
Step 4: 7-chlor0(2,6-diflu0r0-3,5-dimeth0xypheny0-I—methyl—S,4-dihydr0pyrid0[4,3- d]pyrimidin-2(IH)-0ne \ i/ To a mixture of dianiline (206 mg, 0.60 mmol) in THF (6.0 mL) were added triethylamine (0.41 mL, 2.9 mmol) and triphosgene (70.0 mg, 0.23 mmol) at 0 0C. The resulting mixture was stirred for l h at 0 0C before it was quenched with sodium ate.
The aqueous phase was extracted with EtOAc (3>< 10 mL) and the organic layer was dried over Na2804 and concentrated in vacuo. The crude product was purified by flash column chromatography to afford the urea (190 mg, 90%). LC—MS calculated for C16H15C1F2N303 [M+H]+ m/z: 370.1; found 370.1.
Step 5 .‘ 3-(2, 6-diflu0r0-3, 5-dimeth0xyphenyD[(4-meth0xybenzy0amin0]-I-methyl—3,4- opyrid0[4,3-d]pyrimidin-2(IH)-0ne FJOL \o N N/ \ [PMB N N To a e of 4-methoxybenzylamine (2.65 mL, 20.3 mmol), ro—3—(2,6— difluoro-3,5-dimethoxyphenyl)- l -methyl-3,4-dihydropyrido[4,3-d]pyrimidin-2( l H)-one (1.5 g, 4.0 mmol), palladium acetate (90 mg, 0.4 mmol), (R)-(+)-2,2'-bis(diphenylphosphino)— l,l'-binaphthyl (200 mg, 0.4 mmol) and cesium carbonate (2.6 g, 8.1 mmol) in l,4-dioxane (30 mL, 400 mmol) was heated at 100 0C for 12 h. The mixture was filtered and concentrated in vacuo. The crude product was ed by flash column chromatography to afford the aniline. LC—MS calculated for C24H25F2N4O4 [M+H]+ m/z: 471.2; found 471.2.
Step 6: 7-amin0(2,6-diflu0r0-3,5-dimeth0xyphenyl)-I—methyl—S,4-dihydr0pyrid0[4,3- d]pyrimidin-2(IH)-0ne \ JL/ o NN N NH2 A solution of 3—(2,6—difluoro-3,5-dimethoxyphenyl)[(4-methoxybenzyl)amino] methyl-3,4-dihydropyrido[4,3-d]pyrimidin-2(1H)-one (1.1 g, 2.3 mmol) in TFA (10.0 mL) was heated to 85 °C for 3 h before it was concentrated in vacuo and neutralized with sodium bicarbonate solution. The aqueous phase was extracted with EtOAc (3 ><20 mL) and the organic layer was dried over NaZSO4 and concentrated in vacuo. The crude product was purified by flash column chromatography to afford the aniline (0.55 g, 67%). LC—MS ated for C16H17F2N403 [M+H]+ m/z: 351.1; found 351.1.
Step 7: 7-amin0-8—br0m0(2, 6-difluor0-3, 5-dimeth0xypheny0-I—methyl—S, 4- dihydropyrid0[4,3-d]pyrimidin-2(IH)-0ne \ Jk/ o NN N NH2 To a solution of 7-amino(2,6-difluoro-3,5-dimethoxyphenyl)methyl-3,4- dihydropyrido[4,3-d]pyrimidin-2(1H)-one (37 mg, 0.106 mmol) in acetonitrile (2.0 mL) was added NBS (23 mg, 0.13 mmol). The resulting mixture was stirred for 1 h before it was concentrated in vacuo. The crude product was purified by flash column chromatography to afford the bromide. LC—MS ated for C16H16BrF2N4O3 [M+H]+ m/z: 429.1; found 429.1.
Step 8: 7-amin0(2,6-diflu0r0-3,5-dimeth0xyphenyD-I,8-dimethyl—3,4-dihydr0pyrid0[4,3- d]pyrimidin-2(IH)-0ne To a on of o—8-bromo(2,6—difluoro—3,5—dimethoxyphenyl)—1—methyl— 3,4-dihydropyrido[4,3-d]pyrimidin-2(1H)-one (34.0 mg, 0.080 mmol) in 1,4—dioxane (0.8 mL) were added Pd(dppf)Clz (8.0 mg, 0.01 mmol) and ZnMez (2.0 M solution in toluene, 0.11 mL, 0.22 mmol). The resulting e was stirred for l h at 110 0C before it was diluted with MeOH (4 mL) and purified by RP-HPLC (pH 2) to afford the product as its TFA salt. LC—MS calculated for C17H19F2N403 [M+H]+ m/z: 365.1; found 365.1. 1H NMR (500 MHz, DMSO) 5 7.73 (s, 3H), 7.04 (t, J= 7.5 Hz, 1H), 4.59 (s, 2H), 3.88 (s, 6H), 3.39 (s, 3H), 2.80 ppm (s, 3H).
Example 2 7-amino(2,6-difluoro-3,5-dimethoxyphenyl)ethyl—1-methyl—3,4-dihydropyrido[4,3- d]pyrimidin-2(1H)-one \0 N N/ N NH2 This compound was synthesized by the same method bed in Example 1 by using diethylzinc (purchased from Sigma-Aldrich, catalog No. ) instead of dimethylzinc. LC—MS calculated for C18H21F2N403 [M+H]+ m/z: 379.1; found 379.1.
Example 3 7-amin0(2,6-difluoro-3,5-dimethoxyphenyl)—1-methyl—2-oxo-l,2,3,4- tetrahydropyrido-[4,3-d]pyrimidinecarbonitrile \ JL/ 0 N N F /|/ N NH2 To a solution of 7—amino—8-bromo(2,6—difluoro—3,5—dimethoxyphenyl)—l—methyl— 3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one (10.0 mg, 0.0233 mmol) in DMF (1.0 mL) was added Pd(dppf)Clz (4.0 mg, 0.005 mmol) and zinc cyanide (8.2 mg, 0.070 mmol). The ing mixture was stirred for l h at 180 0C before it was diluted with MeOH (4 mL) and purified by RP—HPLC (pH 2) to afford the product. LC—MS calculated for C17H16F2N503 [M+H]+ m/z: 376.1; found 376.1. 1H NMR (500 MHz, DMSO) 5 7.90 (s, 1H), 7.15 (s, 2H), 7.05 (t, J= 7.5 Hz, 1H), 4.55 (s, 2H), 3.89 (s, 6H), 3.53 ppm (s, 3H).
Example 4 7-amin0(2,6-difluor0-3,5-dimethoxyphenyl)—8-ethoxy-l-methyl—3,4- dihydropyrido[4,3-d]pyrimidin-2(1H)-one \ NJLN/ / O\/ \N NH2 To a solution of o—8-bromo(2,6—difluoro—3,5—dimethoxyphenyl)—l—methyl— 3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one (10.0 mg, 0.0233 mmol) in ethanol (1.0 mL) were added copper (10.0 mg, 0.157 mmol) and ium hydroxide (10.0 mg, 0.178 mmol). The resulting mixture was heated to 150 0C for 3 h and then diluted with MeOH (4 mL) and purified by RP-HPLC (pH 2). LC—MS calculated for C18H21F2N4O4 [M+H]+ m/z: 395.1; found 395.1. 1H NMR (500 MHz, DMSO) 5 7.57 (s, 1H), 7.03 (t, J= 7.5 Hz, 1H), 6.48 (s, 2H), 4.58 (s, 2H), 3.88 (s, 6H), 3.82 (q, J= 7.5 Hz, 2H), 3.42 (s, 3H), 1.34 ppm (t, J: 7.5 Hz, 3H).
Example 5 0(2,6-difluoro—3,5-dimethoxyphenyl)—8-(2-methoxyethoxy)—1-methyl—3,4— dihydro-pyrido [4,3-d]pyrimidin-2(1H)-one \ it / O N N / O\/\O/ N NH2 This compound was synthesized by the same method described in Example 4 by using 2-methoxyethanol instead of ethanol. LC—MS calculated for C19H23F2N405 [M+H]+ m/z: 424.2; found 424.1. 2014/034662 Example 6 7-amin0(2,6-difluoro-3,5-dimeth0xyphenyl)—1-methyl—8—[2-(4-methylpiperazin yl)eth0xy]-3,4-dihydropyrid0 [4,3-d]pyrimidin-2(1H)-one \o N N/ F O\/\ N NH2 This nd was synthesized by the same method described in Example 4 by using 2-(4-methy1piperaziny1)ethanol (purchased from Oakwood, catalog No. 021290) instead of ethanol. LC-MS calculated for C23H31F2N6O4 [M+H]+ m/z: 493.2; found 493.2.
Example 7 7-amin0(2,6-diflu0r0-3,5-dimethoxyphenyl)—1-methyl—8—phen0xy-3,4— dihydropyrido[4,3-d]pyrimidin-2(1H)-one This compound was synthesized by the same method described in Example 4 by using phenol instead of ethanol. LC-MS calculated for C22H21F2N4O4 [M+H]+ m/z: 443.1; found 443.1.
Example 8 7-amin0(2,6-difluoro-3,5-dimeth0xyphenyl)—1-methyl—8—(1-methyl—1H-pyraz01—4—yl)- 3,4—dihydropyrid0[4,3-d]pyrimidin-2(1H)-one i / \o N N/ I NtN F / N NH2 To a solution of 7—aminobromo(2,6-difluoro-3,5-dimethoxyphenyl)—1-methyl- 3,4-dihydropyrido[4,3-d]pyrimidin-2(1H)-one (Example I, Step 7: 9.0 mg, 0.021 mmol) and 1-methyl(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)-4,5-dihydro-1H-pyrazole (6.5 mg, 0.031 mmol, purchased from Sigma-Aldrich, catalog No. 595314) in 1, 4- dioxane (0.6 mL) /water (0.15 mL) were added potassium carbonate (8.6 mg, 0.062 mmol) and tetrakis(triphenylphosphine)palladium(0) (3.6 mg, 0.0031 mmol). The resulting mixture was stirred for 2 h at 110 0C before it was diluted with MeOH (4 mL) and purified by RP- HPLC (pH 2) to give the product as its TFA salt. LC—MS calculated for C20H21F2N603 [M+H]+ m/z: 431.2; found 431.1. 1H NMR (500 MHz, DMSO) 5 7.87 (s, 1H), 7.81 (s, 1H), 7.49 (s, 1H), 7.20 (s, 2H), 7.04 (t, J: 7.5 Hz, 1H), 4.61 (s, 2H), 3.90 (s, 3H), 3.88 (s, 6H), 2.67 ppm (s, 3H).
Example 9 7-amin0(2,6-difluoro-3,5-dimeth0xyphenyl)—1-methyl—8—(1-ethyl—1H-pyrazol—4—yl)—3,4- opyrido[4,3-d]pyrimidin-2(1H)-one F / N NH2 This compound was synthesized by the same method described in e 8 by using 1-ethyl(4,4,5 ,5-tetramethyl- 1,3 ,2-dioxaborolanyl)-4,5-dihydro-1H-pyrazole (purchased from Combi—Blocks, catalog No. BB-8817) d of 1—methyl—4—(4,4,5,5— tetramethyl-l,3,2-dioxaborolanyl)—4,5-dihydro-1H-pyrazole. LC-MS ated for C21H23F2N6O3 [M+H]+ m/z: 443.2; found 443.1.
Example 10 7-amin0(2,6-diflu0ro—3,5-dimethoxyphenyl)—8-[1-(2-hydroxyethyl)—1H-pyrazol—4—yl]- 1-methyl—3,4—dihydropyrido[4,3-d]pyrimidin-2(1H)-one \0 N N/ /N\N\/\0H F \ N NH2 This compound was synthesized by the same method described in Example 8 by using 4,4,5,5-tetramethyl-1,3 ,2-dioxaborolan-2—yl)-4,5-dihydro- l H-pyrazol- l - yl]ethanol instead of l-methyl(4,4,5,5-tetramethyl-l,3,2—dioxaborolan-2—yl)-4,5-dihydrolH-pyrazole (purchased from Syntech Solution, catalog No. BH—3012)N. LC—MS calculated for C21H23F2N6O3 [M+H]+ m/z: 461.2; found 461.2. e 11 7-amin0(2,6-difluor0-3,5-dimeth0xyphenyl)methyl—8—(1-piperidin-4—yl—1H-pyrazol— 4-yl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(1H)-0ne This compound was sized by the same method described in Example 8 by using {1-[1-(tert-butoxycarbonyl)piperidinyl]-4,5-dihydro-1H-pyrazolyl}boronic acid (purchased from Combi—Blocks, catalog No. 7) instead of 1—methyl—4—(4,4,5,5— tetramethyl-l,3,2-dioxaborolan-2—yl)-4,5-dihydro- lH-pyrazole. After the reaction was completed, it was diluted with TFA (4 mL) and purified by RP-HPLC to afford the product.LC—MS calculated for C24H28F2N7O3 [M+H]+ m/z: 500.2; found 500.1.
Example 12 7-amin0(2,6-difluoro-3,5-dimeth0xyphenyl)—1-methyl—8—(1H-pyrazol—4—yl)—3,4- dihydro-pyrido [4,3-d]pyrimidin-2(1H)-0ne \o N N/ IN‘HN F / N NH2 This compound was synthesized by the same method bed in Example 8 by using 4-(4,4,5,5-tetramethyl-1,3,2—dioxaborolan-2—yl)—lH-pyrazole (purchased from Sigma- Aldrich, catalog No. 525057) instead of 1-methyl(4,4,5,5-tetramethyl-1,3,2—dioxaborolan- 2—y1)-4,5-dihydro-1H-pyrazole.. LC—MS calculated for F2N6O3 [M+H]+ m/z: 417.1; found 417.1.
Example 13 7-amin0(2,6-difluoro-3,5-dimeth0xyphenyl)—1-methyl—8—(1-methyl—1H-pyrazol—5—yl)— 3,4-dihydropyrid0[4,3-d]pyrimidin-2(1H)-one N NH2 This compound was synthesized by the same method described in Example 8 by using 1-methyl(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)-lH-pyrazole (purchased from ChemBridge Corp., catalog No. 4003213) instead of 1—methyl—4—(4,4,5,5—tetramethyl—1,3,2- orolanyl)-4,5-dihydro-1H-pyrazole.. LC—MS calculated for F2N6O3 [M+H]+ m/z: 431.2; found 431.1.
Example 14 7-amin0(2,6-difluor0-3,5-dimeth0xyphenyl)—1-methyl—8—phenyl—3,4- dihydropyrido[4,3-d]pyrimidin-2(1H)-one \o N N/ N NH2 This compound was synthesized by the same method described in Example 8 by using boronic acid (purchased from Sigma-Aldrich, catalog No. 20009) instead of 1- methyl(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)-4,5-dihydro-1H-pyrazole.. LC—MS calculated for C22H21F2N4O3 [M+H]+ m/z: 427.2; found 427.1.
Example 15 7-amin0(2,6-difluoro-3,5-dimeth0xyphenyl)(4-flu0r0phenyl)methyl—3,4-dihydr0- pyrido[4,3-d]pyrimidin-2(1H)-0ne \ fix/ F o N N N NH2 This compound was synthesized by the same method described in Example 8 by using 4-fluorophenylboronic acid (purchased from Sigma-Aldrich, catalog No. 417556) instead of 1-methy1(4,4,5,5-tetramethyl- 1 ,3,2-dioxaborolanyl)-4,5-dihydro- 1H- pyrazole.. LC—MS calculated for C22H20F3N4O3 [M+H]+ m/z: 445.1; found 445.1.
Example 16 7-amin0(2,6-difluoro-3,5-dimeth0xyphenyl)—1-methyl—8-pyridinyl—3,4- dihydropyrido [4,3-d]pyrimidin-2(1H)-one \0 N N/ /N F \ N NH2 This compound was synthesized by the same method described in Example 8 by using 3-pyridylboronic acid ased from Aldrich, catalog No. 512125) instead of 1-methyl(4,4,5,5-tetramethyl-1,3,2-dioxaborolany1)-4,5-dihydro-1H-pyrazole.. LC-MS calculated for C21H20F2N503 [M+H]+ m/z: 428.1; found 428.1. e 17 7-amin0(2,6-difluoro-3,5-dimeth0xyphenyl)—1-methyl—8-pyridinyl—3,4- dihydropyrido [4,3-d]pyrimidin-2(1H)-one \o NN//'\l F /\ NNH2 This compound was synthesized by the same method described in Example 8 by using 4-pyridylboronic acid (purchased from Sigma-Aldrich, catalog No. 634492) instead of 1-methyl(4,4,5,5-tetramethyl-1,3,2-dioxaborolany1)-4,5-dihydro-1H-pyrazole.. LC-MS calculated for F2N503 [M+H]+ m/z: 428.1; found 428.1.
Example 18 7-amin0(2,6-difluoro-3,5—dimeth0xyphenyl)—1-methyl—8-[(E)phenylvinyl]-3,4— dihydropyrido[4,3-d]pyrimidin-2(1H)-one \0 N N/ F \ N NH2 This nd was synthesized from Suzuki coupling of the bromide (Example 1, Step 7) with (E)pheny1Vinyl boronic acid (purchased from Sigma-Aldrich, catalog No. 473790) by the same method described in Example 2. LC—MS calculated for C24H23F2N4O3 [M+H]+ m/z: 453.2; found 453.1.
Example 19 0(2,6-diflu0r0-3,5-dimeth0xyphenyl)—1-methylphenylethyl—3,4- dihydropyrido-[4,3-d]pyrimidin-2(1H)-0ne \o N N/ N NH2 To a solution of 7-amino(2,6-difluoro-3,5-dimethoxyphenyl)methyl[(E) phenylVinyl]-3,4-dihydropyrido[4,3-d]pyrimidin-2(1H)-one (10.0 mg) in MeOH (1 mL) was added palladium on charcoal (10.0 mg). The on was kept under H2 atmosphere for 2 h before it was filtered, and purified by RP-HPLC (pH 2). LC-MS calculated for C24H25F2N4O3 [M+H]+ m/z: 4552; found 455.1.
Example 20 7-amin0benzyl—3-(2,6-difluoro-3,5-dimeth0xyphenyl)methyl—3,4-dihydropyrido [4, 3-d]pyrimidin-2(1H)—one 0N1?F1N/ \N NH2 This compound was synthesized from Suzuki coupling of the bromide (Example 1, Step 7) with 2-benzyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (purchased from Ark, catalog No. AK—23881)by the same method described in Example 2. LC—MS calculated for F2N4O3 [M+H]+ m/z: 4411; found 441.1.
Example 21 7-amin0(2,6-diflu0ro-3,5-dimethoxyphenyl)(3,6-dihydro—2H-pyranyl)methyl- hydropyrid0[4,3-d]pyrimidin-2(1H)—one This compound was synthesized from Suzuki coupling of the bromide (Example 1, Step 7) with 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)-3,6-dihydro-2H-pyran ased from Sigma—Aldrich, catalog No. 721352) by the same method described in Example 2. LC—MS calculated for C21H23F2N4O4 [M+H]+ m/z: 433.2; found 433.1.
Example 22 6-amin0(2,6-difluor0-3,5-dimethoxyphenyl)-4,4-dimethyl-1,2-dihydro-2,7- naphthyridin-3(4H)—0ne \ ii 0 N N NH2 Step I. 6-ch10r0(3, 5-dimeth0xyphenyl)-I, 4-dihydr0-2, 7-naphthyridin-3 (2H)-0ne \ 00 o N To a d slurry of 6-chloro-l,4-dihydro-2,7-naphthyridin-3 (2H)—one (from Anichem, cat # NC1485, 250.0 mg, 1.37 mmol) in 1,4-dioxane (3.8 mL), potassium carbonate (568 mg, 4.11 mmol), (lR,2R)—N,N’-dimethylcyclohexane-l,2-diamine (77.9 mg, 0.548 mmol), copper(l) iodide (52.1 mg, 0.274 mmol), and 3,5-dimethoxybromobenzene(446 mg, 2.05 mmol) were added sequentially at room ature. The resulting mixture was then heated at 90 0C under the atmosphere of N2. After 15 h, the reaction was ed with saturated aq. NH4Cl, and extracted with methylene chloride. The combined organic layers were dried over MgSO4, and then concentrated. The residue was purified on silica gel ng with 0 to 0-40% EtOAc in DCM) to afford the desired product (120 mg). LC—MS calculated for C16H16C1N203 [M+H]+ m/z: 319.1; found 319.1.
Step 2. 6-chlor0(2, 6-diflu0r0-3, 5-dimeth0xyphenyD-4, 4-dimethyl—I, 4-dihydr0-2, 7- naphthyridin-3 (2H)-0ne \o/t\N N CI To a stirred solution of 6-chloro(3,5-dimethoxyphenyl)-1,4-dihydro-2,7- yridin-3(2H)-one (109.0 mg, 0.342 mmol) in N,N—dimethylformamide (3.6 mL), cesium carbonate (330 mg, 1.0 mmol) and methyl iodide (53 uL, 0.85 mmol) were added sequentially at room ature. After 5 hours, the reaction mixture was quenched with ted aq. NH4Cl, and extracted with methylene chloride. The combined organic layers were dried over MgSO4, and then concentrated to afford the crude product (110 mg), which was used directly in the next step without purification. LC-MS calculated for C18H20C1N203 [M+H]+ m/z: 347.1; found 347.1.
Step 3. tert—bulyl [7-(3,5-dimeth0xyphenyD-5, 5-dimethyl—6—0x0-5, 6, 7, 8-tetrahydr0-2, 7- naphthyridin-S-yUcarbamate N NH Boc A stirred mixture of 6-chloro(3,5-dimethoxyphenyl)-4,4-dimethyl-1,4-dihydro-2,7- naphthyridin-3(2H)-one (100.0 mg, 0.288 mmol), t—butyl carbamate (40.5 mg, 0.346 mmol), (9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphine) (33 mg, 0.058 mmol), palladium acetate (6.5 mg, 0.029 mmol), and cesium carbonate (93.9 mg, 0.288 mmol) in 1,4- dioxane (5 mL) was heated at 90 0C under the atmosphere of N2. After 12 h, the reaction was quenched with saturated aq. NH4Cl, and extracted with methylene chloride. The combined organic layers were dried over MgSO4, and then concentrated. The residue was purified on silica gel (eluting with 0 to 0-40% EtOAc in DCM) to afford the desired product (22 mg).
LC-MS calculated for C23H30N305 [M+H]+ m/z: 428.2; found 428.2.
Step 4. 6-amin0(2, 6-diflu0r0-3,5-dimeth0xyphenyD-4,4-dimethyl—I,4-dihydr0-2, 7- yridin-3 (2H)-0ne To a stirred on of tert—butyl [7—(3,5—dimethoxyphenyl)-5,5-dimethyloxo- ,6,7,8-tetrahydro-2,7-naphthyridin-3 -yl]carbamate (22.0 mg, 0.0515 mmol) in acetonitrile (1.5 mL), 1-(chloromethyl)fluoro-1,4-diazoniabicyclo[2.2.2]octane afluoroborate (54.7 mg, 0.154 mmol) was added at 0°C. The resulted mixture was then warmed up to room temperature. After 3 hours, the reaction was quenched with saturated aq. NaHC03, and extracted with methylene chloride. The combined organic layers were dried over MgSO4, concentrated to dryness, and then dissolved in trifluoroacetic acid (1.0 mL) / methylene chloride (1.0 mL, 16 mmol). After 1 hour, the volatiles was removed under reduced pressure and the residue was purified on RP-HPLC (XBridge C18 column, eluting with a nt of acetonitrile/water containing 0.05% TFA, at a flow rate of 30 ) to afford the desired product (2.0 mg) as its TFA salt. LC—MS calculated for C18H20F2N3O3 [M+H]+ m/z: 364.1; found 364.2.
Example 23 2'-(2,6-diflu0r0-3,5-dimethoxyphenyl)-6'-[(Z-morpholinylethyl)amino]-1',2'-dihydro- 3'H-spir0[cyclopropane-1,4'-[2,7]naphthyridin]-3'-0ne Step I .‘ 4, 6-dichZoronicotinaldehyde N CI To a d solution of 2,4-dichlorocarbethoxypyridine (Ark Pharm, cat# AK- 25933: 10.0 g, 45.4 mmol) in methylene chloride (100.0 mL) at —78°C was added a on of diisobutylaluminum hydride in methylene chloride (50.0 mL, 1.0 M, 50.0 mmol) dropwise. After 2 hours, the reaction was quenched with a saturated solution of Rochelle's salt. After stirring for 12 h, the aqueous solution was extracted with DCM (3>< 150 mL). The ed organic layers were dried over NaZSO4 and concentrated in vacuo to afford the crude de (7.51 g, 42.9 mmol), which was used in the next step without further purification. LC—MS calculated for C6H4C12NO [M+H]+ m/z: 176.0; found 176.0.
Step 2: N-[(4, 6-dichloropyridin-S-ybmethyl]-2, 6-diflu0r0-3, 5-dimeth0xyaniline ‘0 NH Cl F \ N CI To a stirred solution of 2,6-difluoro-3,5-dimethoxyaniline (CAS #6517342, LakeStar Tech, LSP—210C, Lot: 132—110—05: 9.03 g, 47.7 mmol) and sodium triacetoxyborohydride (38.0 g, 180 mmol) in methylene chloride (60 mL) / trifluoroacetic acid (30 mL) was added 4,6—dichloronicotinaldehyde (8.00 g, 45.5 mmol) in small portions at room temperature. After 1 hour, the volatiles were removed in vacuo and saturated aqueous NaHCO3 (200 mL) was added. The resulting mixture was extracted with DCM (3 X150 mL).
The organic layers were combined, dried over NaZSO4, and concentrated. The residue was purified on silica gel (eluting with 0 to 40% EtOAc in hexanes) to afford the desired product (15.0 g). LC—MS calculated for C14H13C12F2N202 [M+H]+ m/z: 349.0; found 349.1.
Step 3 .‘ ethyl 3-[[(4, Zoropyridin-S-ybmethyl] (2, 6-diflu0r0-3, 5- dimethoxyphenyl)amin0]0x0pr0pan0ate o o \o N Jk/Cufo" N’ CI To a stirred on of N—[(4,6-dichloropyridin-3 thyl]-2,6-difluoro—3,5— dimethoxyaniline (3.50 g, 10.0. mmol) in tetrahydrofuran (20 mL) was added NaH (60% w/w in mineral oil, 421 mg, 10.5 mmol) at room temperature. After 10 minutes, ethyl l chloride (1.92 mL, 15.0 mmol) was added se. After another 1 hour, the reaction was ed with saturated aqueous NH4Cl, and extracted with DCM (3 X 100 mL). The organic layers were combined, dried over NaZSO4, and concentrated. The residue was purified on silica gel (eluting with 0 to 35% EtOAc in hexanes) to afford the desired product (4.20 g, 9.1 mmol). LC-MS calculated for C19H19C12F2N205 [M+H]+ m/z: 463.1; found 463.1.
Step 4 .‘ 6-chlor0(2, 0r0-3,5-dimeth0xyphenyD0x0-1,2, 3,4-tetrahydr0-2, 7- naphthyridinecarb0xylate \ogrxfig‘f"F O O N/ CI To a stirred solution of ethyl 3-[[(4,6-dichloropyridinyl)methyl](2,6-difluoro-3,5— dimethoxyphenyl)amino]—3 -oxopropanoate (1.50 g, 3.24 mmol) in DMF (15. mL) was added NaH (60% w/w in l oil, 337 mg, 8.42 mmol) at room temperature. The resulting mixture was then warmed up to 110°C. After 5 hours, the reaction mixture was cooled to room temperature then saturated aqueous NH4Cl (50 mL) was added forming precipitate.
After filtration, the solid was dried in vacuo to give crude cyclized product (0.95 g, 2.23 mmol) which was used in the next step without further purification. LC—MS calculated for clnggclerzo5 [M+H]+ m/z: 427.1; found 427.0.
Step 5 .‘ 6-chlor0(2, 6-diflu0r0-3, 5-dimeth0xypheny0-1,2-dihydr0-2, 7-naphthyridin-3 (4H)- \0 N N CI To a stirred solution of ro(2,6-difluoro-3,5-dimethoxyphenyl)oxo-1,2,3,4- tetrahydro-2,7- naphthyridinecarboxylate(0.95 g, 2.23 mmol) in 1,4-dioxane (5 mL) was added hydrogen chloride (4.0 M in dioxane, 2 mL, 8 mmol) at room temperature. The resulting mixture was warmed up to 100 °C. After stirring at 100 0C for 4 hours, the reaction mixture was cooled to ambient temperature, quenched with saturated aqueous NaHCO3, and extracted with DCM (3>< 100 mL). The organic layers were combined, dried over NaZSO4, and trated. The residue was ed on silica gel (eluting with 0 to 30% EtOAc in DCM) to afford the desired product (0.75 g, 2.12 mmol). LC—MS ated for C16H14C1F2N203 [M+H]+ m/z: 3551; found 355.1.
Step 6: 6’-ch10r0-2’-(2,6-diflu0r0-3,5-dimeth0xyphenyD-I ’,2’-dihydr0-3 ’H- cyclopr0pane-I,4 ’-[2, 7]naphthyridin]-3 ’-0ne \o N N CI To a stirred solution of ro(2,6-difluoro-3,5-dimethoxyphenyl)-1,4-dihydro- 2,7-naphthyridin-3(2H)-one (1.50 g, 4.23 mmol) in DMF (10 mL) was added tially cesium carbonate (3.03 g, 9.30 mmol) and o—2-chloro—ethane (701 uL, 8.46 mmol) at room temperature. After stirring at room temperature for 5 hours, the reaction mixture was quenched with saturated aqueous NH4Cl, and extracted with DCM (3 ><75 mL). The organic layers were combined, dried over NaZSO4, and concentrated. The residue was purified on silica gel (eluting with 0 to 50% EtOAc in hexanes) to afford the desired product (1.20 g, 3.15 mmol). LC—MS calculated for C1F2N203 [M+H]+ m/z: 381.1; found 381.1.
Step 7.‘ 2 ’-(2, 6—diflu0r0-3, 5-dimeth0xyphenyD-6 m0rph01inylethyl)amin0]-I ’,2’- dihydro-S H—Spir0[cyclopr0pane-I, 4 ’-[2, 7]naphthyridin]-3 ’-0ne To a stirred solution of 6'-chloro-2'-(2,6-difluoro-3,5-dimethoxyphenyl)-1',2'-dihydro- 3'H—spiro[cyclopropane-1,4'-[2,7]naphthyridin]—3'-one (250 mg, 0.657 mmol) and 2- morpholinoethanamine (214 mg, 1.64 mmol) in 1,4-dioxane (6.0 mL) were added sequentially dicyclohexyl(2',4',6'-triisopropyl-3,6-dimethoxybiphenylyl)phosphine (BrettPhos, Aldrich, cat# 718742: 70.5 mg, 0.131 mmol), sodium tert—butoxide (126 mg, 1.31 mmol) and palladium acetate (29.5 mg, 0.131 mmol) at room temperature. The resulting mixture was purged with N2 then heated to 110 0C. After stirring at 110 0C for 45 minutes, the reaction mixture was cooled to ambient temperature and was purified on C (XBridge C18 column, eluting with a nt of acetonitrile/water containing 0.05% TFA, at flow rate of 60 mL/min) to give the desired product (150 mg) as its TFA salt. LC—MS calculated for C24H29F2N4O4 [M+H]+ m/z: 475.2; found 475.2. 1H NMR (500 MHz, DMSO— d6): 5 7.96 (s, 1 H), 7.06 (t, J: 10.0 Hz, 1 H), 6.22 (s, 1 H), 4.77 (s, 2 H), 3.88 (s, 6 H), 3.82 (br, 4 H), 3.65 (br, 2 H), 3.27—3.33 (m, 6 H), 1.71 (dd, J: 7.0 Hz, 4.0 Hz, 2 H), 1.43 (dd, J: 7.0 Hz, 4.0 Hz, 2 H) ppm.
Example 24 6'-amin0-2'-(2,6-difluoro—3,5-dimethoxyphenyl)-1 'H—spiro [cyclopropane-1,4'- [2,7]naphthyridin]-3'(2'H)—0ne N H2 To a stirred solution of oro-2'-(2,6-difluoro-3,5-dimethoxyphenyl)-1',2'-dihydro- 3'H—spiro[cyclopropane-1,4'-[2,7]naphthyridin]—3'—one (Example 23, Step 6: 248 mg, 0.651 mmol) and benzophenone imine (164 uL, 0.977 mmol) in e (5 mL) were added sequentially (R)-(+)-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (40.6 mg, 0.0651 mmol), sodium utoxide (125 mg, 1.30 mmol) and tris(dibenzylideneacetone)dipalladium(0) (23.9 mg, 0.0260 mmol) at room temperature. The resulting e was purged with N2 and heated to 90 0C. After stirring for 2 hours at 90 0C, the reaction mixture was cooled to ambient temperature and the volatiles were removed in vacuo. The residue was dissolved in tetrahydrofuran (5 mL) then a solution of hydrogen chloride in water (1.0 M, 650 uL, 0.65 mmol) was added. After ng at room temperature for 1 hour, the reaction mixture was concentrated and the residue was purified on RP—HPLC (XBridge C18 column, eluting with a gradient of acetonitrile/water containing 0.05% TFA, at flow rate of 60 mL/min) to give the desired product (202 mg) as its TFA salt. LC—MS calculated for C18H18F2N3O3 [M+H]+ m/z: 362.1; found 362.1. 1H NMR (500 MHz, DMSO—dg): 5 7.90 (s, 1 H),7.77 (br, 2H), 7.07 (t, J= .0 Hz, 1 H), 6.49 (s, 1 H), 4.79 (s, 2 H), 3.89 (s, 6 H), 1.82 (dd, J= 10.0 Hz, 5.0 Hz, 2 H), 1.51 (dd, J: 10.0 Hz, 5.0 Hz, 2 H) ppm.
Example 25 2'-(2,6-difluoro-3,S-dimethoxyphenyl)-6'-(methylamin0)—1',2'-dihydr0-3'H— Spiro[cyclopropane—1,4'-[2,7]naphthyridin]-3'-0ne To a stirred solution of 6'-chloro-2'-(2,6-difluoro-3,5-dimethoxyphenyl)-1',2'-dihydro- 3'H—spiro[cyclopropane—1,4'—[2,7]naphthyridin]—3'—one le 23, Step 6: 90.0 mg, 0.236 mmol) and tert-butyl methylcarbamate (89.5 mg, 0.682 mmol) in 1,4-dioxane (3 mL) were added sequentially dicyclohexyl(2',4',6'-triisopropyl-3,6-dimethoxybiphenylyl)phosphine (BrettPhos, Aldrich, cat# 718742: 24.4 mg, 0.0455 mmol), sodium tert—butoxide (52.4 mg, 0.546 mmol), and ium e (10.2 mg, 0.0455 mmol) at room ature. The resulting mixture was purged with N2 and heated to 90 °C. After stirring for 45 minutes at 90 0C, the reaction mixture was cooled to ambient temperature and the volatiles were d in vacuo. The e was dissolved in DCM (1 mL) then TFA (1 mL) was added. After stirring at room temperature for 1 hour, the reaction mixture was concentrated and the crude was purified on RP-HPLC (XBridge C18 column, eluting with a nt of acetonitrile/water containing 0.05% TFA, at flow rate of 60 mL/min) to give the desired product (32 mg) as its TFA salt. LC—MS calculated for C19H20F2N303 [M+H]+ m/z: 376.1; found 376.2. 1H NMR (500 MHz, DMSO—dg): 5 7.90 (s, 1 H), 7.07 (t, J= 10.0 Hz, 1 H), 6.46 (s, 1 H), 4.80 (s, 2 H), 3.89 (s, 6 H), ), 2.90 (s, 3 H) 1.79 (dd, J=10.0 Hz, 5.0 Hz, 2 H), 1.56 (dd, J=10.0 Hz, 5.0 Hz, 2 H) ppm.
Example 26 2'-(2,6-diflu0ro-3,5-dimeth0xyphenyl)-6'-(tetrahydr0-2H-pyranylamin0)—1',2'- dihydro—3'H—spir0 [cyclopropane—1,4'-[2,7] naphthyridin]-3'-0ne This compound was prepared using procedures analogous to those for Example 23, Step 7 with tetrahydro-2H—pyranamine replacing 2-morpholinoethanamine. LCMS calculated for C23H26F2N304 (M+H)+i l’l’l/Z = 446.2, Found: 446..2 Example 27 (S)—2'-(2,6-diflu0ro-3,5-dimeth0xyphenyl)—6'-(2-hydroxypropylamino)—1'H— spiro[cyclopropane—1,4'-[2,7]naphthyridin]-3'(2'H)—one 2014/034662 This compound was prepared using procedures analogous to those for Example 23, Step 7, with (S)-l-aminopropanol ing 2-morpholinoethanamine. LCMS calculated for C21H24F2N304 (M+H)+: m/z = 420.2; Found: 420.2.
Example 28 2'-(2,6-diflu0ro-3,5-dimethoxyphenyl)-6'-(pyridinylmethylamin0)-1'H- spiro[cyclopropane—1,4'-[2,7]naphthyridin]-3'(2'H)—one This compound was prepared using procedures analogous to those for Example 23, Step 7, with nylmethanamine replacing 2-morpholinoethanamine. LCMS calculated for C24H23F2N403 (M+H)+i l’l’l/Z = 453.2, Found: 453.2 Example 29 (S)—2'-(2,6-diflu0ro-3,5-dimethoxyphenyl)-6'-(tetrahydrofuranylamino)—1 'H- spiro[cyclopropane—1,4'-[2,7]naphthyridin]-3'(2'H)—one \o N / o \ pi) N N This compound was prepared using procedures analogous to those for Example 23, Step 7, with (S)-tetrahydrofuranamine replacing 2-morpholinoethanamine. LCMS calculated for F2N304 (M+H)+i l’l’l/Z = 432.2, Found: 432..2 Example 30 2'-(2,6-diflu0r0-3,5-dimeth0xyphenyl)-6'-(2-(4-methylpiperazinyl)ethylamin0)—1'H- spiro[cyclopropane—1,4'-[2,7]naphthyridin]-3'(2'H)—one \0 N F / / N /\/NC This compound was prepared using procedures analogous to those for Example 23, Step 7, with ethylpiperazin-l-yl)ethanamine replacing 2-morpholinoethanamine.
LCMS calculated fOI' C25H32F2N504 (Md—HY: l’l’l/Z = 488.2; Found: 488.2 Example 31 methyl 2'-(2,6-difluor0-3,5-dimeth0xyphenyl)—3'-0X0-2',3'-dihydro-1'H- spiro[cyclopropane— 1,4'-[2,7]naphthyridine]-6'-ylcarbamate F rs /| it This compound was prepared using procedures analogous to those for Example 23, Step 7, with methyl carbamate replacing holinoethanamine. LCMS calculated for C20H20F2N305 (M+H)+2 l’l’l/Z = 420.1, Found: 420.1 Example 32 2v-(2,6-diflu0r0-3,5-dimethoxypheny1)-6'-(pyridin_3_ylamin0)_1.H_Spim[cyclopmpane_ 1,4'-[2,7]naphthyridin]-3'(2'H)-0ne This compound was prepared using procedures analogous to those for Example 23, Step 7, with namine replacing 2-morpholinoethanamine. LCMS calculated for F2N403 (M+H)+i l’l’l/Z = 439.2, Found: 439..2 Example 33 2'-(2,6-diflu0r0-3,5-dimethoxyphenyl)-6'-(3-flu0r0phenylamino)—1'H- spiro[cyclopropane—1,4'-[2,7]naphthyridin]-3'(2'H)—one N F This compound was prepared using procedures analogous to those for Example 23, Step 7, with 3-fluoroaniline replacing 2—morpholinoethanamine. LCMS calculated for C24H21F3N3O3 : m/z = 456.2; Found: 456.2. e 34 6v-(cy010pentylamin0)'2'-(2,6-diflu0ro—3,5-dimethoxyphenyl)-1'H-spiro[cyclopropane- 1,4'-[2,7]naphthyridin]-3'(2'H)-0ne This compound was prepared using procedures analogous to those for Example 23, Step 7, with cyclopentanamine replacing 2-morpholinoethanamine. LCMS calculated for C23H26F2N3O3 (M+H)+: m/z = 430.2; Found: 430.2.
Example 35 (S)—2'-(2,6-diflu0r0-3,5-dimethoxyphenyl)—6'-((tetrahydrofuranyl)methylamin0)—1'H- spiro[cyclopropane-1,4'-[2,7] yridin]-3'(2'H)—one This compound was prepared using procedures analogous to those for Example 23, Step 7, with (S)-(tetrahydrofuranyl)methanamine replacing 2-morpholinoethanamine.
LCMS calculated for C23H26F2N3O4 (M+H)+: m/z = 446.2; Found: 446.2.
Example 36 2'-(2,6-diflu0ro-3,5-dimeth0xyphenyl)—6'-(1-methyl—1H-pyrazol—4-ylamin0)—1'H- spiro[cyclopropane-1,4'-[2,7]naphthyridin]-3'(2'H)-one \0 N / N\ \I LN N N This nd was prepared using procedures analogous to those for Example 23, Step 7, with l-methyl-lH-pyrazolamine replacing 2-morpholinoethanamine. LCMS ated for C22H22F2N503 (M+H)+; m/z = 4422; Found: 442.2.
Example 37 2'-(2,6-diflu0r0-3,5-dimethoxyphenyl)—6'-((1-methyl—1H-pyrazol—4—yl)methylamino)—1'H— spiro[cyclopropane-1,4'-[2,7]naphthyridin]-3'(2'H)-one N / H \ IN\ This compound was prepared using procedures analogous to those for Example 23, Step 7, with (l-methyl-lH-pyrazolyl)methanamine replacing 2-morpholinoethanamine.
LCMS calculated for C23H24F2N503 : m/z = 456.2; Found: 456.2.
Example 38 (R)-2'-(2,6-difluoro-3,5-dimeth0xyphenyl)—6'-(1-phenylethylamino)—1'H- spiro[cyclopropane-1,4'-[2,7] naphthyridin]-3'(2'H)-one This compound was prepared using procedures analogous to those for Example 23, Step 7, with (R)-l-phenylethanamine replacing 2-morpholinoethanamine. LCMS ated for C26H26F2N303 (M+H)+i Z = 466.2, Found: 466.2 Example 39 6'-(cyclohexylamin0)—2'-(2,6-diflu0r0-3,5—dimethoxyphenyl)-1'H-spir0[cyclopropane- 1,4'-[2,7]naphthyridin]-3'(2'H)-one This compound was prepared using procedures analogous to those for Example 23, Step 7, with cyclohexanamine replacing 2-morpholinoethanamine. LCMS calculated for C24H28F2N3O3 (M+H)+; m/z = 4442; Found: 444.2.
Example 40 2'-(2,6-diflu0r0-3,5-dimethoxyphenyl)-6'-(trans—4—hydroxycyclohexylamino)—1 'H— spiro[cyclopropane-1,4'-[2,7] naphthyridin]-3'(2'H)-one This compound was prepared using procedures analogous to those for e 23, Step 7, with transaminocyclohexanol replacing 2-morpholinoethanamine. LCMS calculated for C24H28F2N3O4 : m/z = 460.2; Found: 460.2. e 41 6'-(cyclopropylamino)—2'-(2,6-difluoro-3,5-dimeth0xyphenyl)—1'H—spiro[cyclopropane- 1,4'-[2,7]naphthyridin]-3'(2'H)-one \0 N N N This compound was prepared using procedures analogous to those for Example 23, Step 7, with cyclopropanamine replacing 2-morpholinoethanamine. LCMS calculated for C21H22F2N3O3 (M+H)+: m/z = 4022; Found: 402.2.
Example 42 6'-(cyclobutylamin0)—2'-(2,6-diflu0r0-3,5-dimethoxyphenyl)—1'H—spir0[cyclopr0pane- 1,4'-[2,7]naphthyridin]-3'(2'H)-one \o N \l D N N This compound was prepared using procedures ous to those for Example 23, Step 7, with cyclobutylamine replacing 2-morpholinoethanamine. LCMS calculated for F2N303 (M+H)+2 l’l’l/Z = 416.2, Found: 416.2 Example 43 2'-(2,6-diflu0r0-3,5-dimeth0xyphenyl)—6'-(3,3-difluorocyclobutylamino)—1'H- spiro[cyclopropane-1,4'-[2,7]naphthyridin]-3'(2'H)-one \o N / F I HF N N This compound was prepared using procedures analogous to those for e 23, Step 7, with 3,3—difluorocyclobutanamine replacing 2-morpholinoethanamine. LCMS calculated for C22H22F4N3O3 (M+H)+: m/z = 452.2; Found: 452.2.
Example 44 2'-(2,6-diflu0r0-3,5-dimethoxyphenyl)-6'-(1-methylpiperidinylamin0)—1 'H— spiro[cyclopropane-1,4'-[2,7]naphthyridin]-3'(2'H)-one This nd was prepared using procedures analogous to those for Example 23, Step 7, with l-methylpiperidinamine replacing 2-morpholinoethanamine. LCMS calculated for C24H29F2N4O3 (M+H)+: m/z = 459.2; Found: 459.2.
Example 45 7-amin0(2,6-difluoro-3,5-dimeth0xyphenyl)—1-(2-flu0r0phenyl)methyl—3,4- dihydropyrido[4,3-d]pyrimidin-2(1H)-one \ 130 Step I.‘ (4, 6-dichloromethylpyridin-S-ybmethanOZ OH CI K61\l To a stirred on of ethyl 4,6-dichloromethylnicotinate (1.75 g, 7.48 mmol, Ark Pharm, cat# AK121795) in methylene chloride (30 mL) at —78 °C was added diisobutylaluminum hydride (1.0 M in toluene, 18.0 mL, 18.0 mmol) dropwise. The resulting mixture was stirred at —78 °C for 2 h then quenched with saturated aqueous NH4C1. The mixture was warmed to room temperature then extracted with DCM (3 x 20 mL). The combined organic layers were washed with brine, dried over , filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column eluting with MeOH in DCM (0—5%) to afford the d product (0.80 g, 56 %). LCMS calculated for C7H8C12NO : m/z = 192.0; Found: 192.0.
Step 2 .‘ N-[(4, 6-dichloromethylpyridinyl)methyl]-2, 0r0-3, 5-dimeth0xyaniline \0 NH Cl N CI To a stirred solution of (4,6-dichloromethylpyridin-3 -yl)methanol (0.80 g, 4.2 mmol) in methylene chloride (20 mL) at 0 0C was added N,N—diisopropylethylamine (1.45 mL, 8.33 mmol), followed by methanesulfonyl chloride (0.42 mL, 5.4 mmol). The resulting e was warmed to room temperature and stirred for 2 h then quenched with saturated s NaHCO3. The mixture was extracted with DCM (3x 50 mL). The combined organic layers were washed with brine, dried over NaZSO4, ed and concentrated under reduced pressure. The residue was dissolved in N,N—diisopropylethylamine (3.5 mL) then 2,6- difluoro-3,5- dimethoxyaniline (0.79 g, 4.2 mmol) was added. The mixture was stirred at 100 °C overnight. The reaction mixture was cooled to room ature then quenched with saturated aqueous NaHCO3, and extracted with ethyl acetate (3 x 20 mL). The combined organic layers were washed with brine, dried over NaZSO4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column g with ethyl acetate in hexanes (0-25%) to afford the desired product (1.5 g, 99%). LCMS calculated for C15H15Clz F2N202 (M+H)+: m/z = 363.0; Found: 363.0.
Step 3 .‘ 4-chlor0{[(2, 6-diflu0r0-3, 5-dimeth0xypheny0amin0]methyl}-N-(4-meth0xybenzyl) methylpyridinamine ,PMB H A e of N—[(4,6-dichloromethylpyridin-3 -yl)methyl]-2,6-difluoro—3,5— dimethoxyaniline (1.5 g, 4.1 mmol), benzenemethanamine, 4-methoxy- (1.1 mL, 8.3 mmol), (R)—(+)—2,2'-bis(diphenylphosphino)—l,l'-binaphthyl (0.26 g, 0.42 mmol), palladium acetate (0.093 g, 0.41 mmol) and cesium carbonate (2.7 g, 8.3 mmol) in oxane (10 mL) was purged with nitrogen then heated to 150 0C and stirred overnight. After cooling to room temperature, the reaction mixture was diluted with ethyl acetate, filtered and concentrated under d pressure. The residue was purified by flash chromatography on a silica gel column eluting with ethyl acetate in hexanes ) to afford the desired product (1.0 g, 52 %). LCMS calculated for C23H25C1F2N3O3 (M+H)+: m/z = 464.2; Found: 464.1.
Step 4: 5-{[(2, 6-diflu0r0-3, 5-dimeth0xypheny0amin0]methyZ}-N4-(Z-fluorophenyD-NZ- (4- methoxybenzyD-S-methylpyridin6-2, 4-diamine F F: : \0 NH HN \ ,PMB N N To a mixture of 4-chloro {[(2,6-difluoro-3,5-dimethoxyphenyl)amino]methyl}-N- (4-methoxybenzyl)methylpyridinamine (32 mg, 0.070 mmol), palladium acetate (1.6 mg, 0.0070 mmol), (R)—(+)—2,2'—bis(diphenylphosphino)—1,1'—binaphthyl (4.4 mg, 0.0070 mmol), and cesium carbonate (69 mg, 0.21 mmol) in 1,4-dioxane (1.0 mL) was added 2— fluoroaniline (11 mg, 0.098 mmol). The resulting mixture was purged with nitrogen then heated to 150 0C and stirred overnight. After cooling to room temperature, the reaction mixture was diluted with ethyl acetate, filtered and concentrated under reduced pressure. The residue was used in the next step without further purification. LCMS calculated for C29H30 F3N403 (M+H)+: m/z = 539.2; Found: 539.2.
Step 5 .‘ 3-(2, 6-diflu0r0-3, th0xyphenyl)-I-(2-flu0r0phenyl)-7—[(4- methoxybenzyDamino] methyl-3, 4-dihydr0pyrid0[4, 3-d]pyrimidin-2(1H)-0ne O 13 \ NJLN K61\ ,PMB sgene (21 mg, 0.070 mmol) was added to a on of the crude product from Step 4 and N,N—diisopropylethylamine (73 uL, 0.42 mmol) in tetrahydrofuran (2.0 mL). The resulting mixture was stirred at room temperature for 30 min then 2N NaOH (2 mL) was added. The mixture was stirred at 30 0C for 1 h then cooled to room temperature and extracted with ethyl acetate (3 x 20 mL). The combined organic layers were washed with brine, dried over NaZSO4, filtered and trated under reduced re. The residue was used in the next step t further purification. LCMS calculated for C30H28 F3N4O4 (M+H)+: m/z = 565.2; Found: 565.2.
Step 6: 7-amin0(2,6-diflu0r0-3,5-dimeth0xypheny0-I-(Z-fluorophenyl)methyl—3,4- dihydropyrido[4, 3-d]pyrimidin-2(IH)-0ne The crude product from Step 5 was dissolved in 1 mL of TFA and the reaction mixture was d at 85 0C for 3 h. The mixture was cooled to room temperature and concentrated in vacuo. The residue was dissolved in acetonitrile then purified by RP—HPLC (pH = 2) to afford the desired t as TFA salt. LCMS calculated for szHzo F3N4O3 (M+H)+: m/z = 445.1; Found: 445.2.
Example 46 7-amin0(2,6-difluoro-3,5-dimethoxyphenyl)methyl(2-methyl—2H-tetrazol—S-yl)— 3,4—dihydropyrid0[4,3-d]pyrimidin-2(1H)-one \0 N N N N NH2 This compound was prepared using procedures analogous to those as described for Example 45 with 2-methyl-2H-tetrazolamine -Blocks, cat#OR-5103) replacing 2- fluoroaniline in Step 4. LCMS calculated for C18H19 F2NgO3 (M+H)+: m/z = 433.2; Found: 433.2.
Example 47 7-amin0(2,6-difluoro-3,5-dimeth0xyphenyl)methyl—1-[(1-methyl—1H-pyrazol—4- yl)methyl]-3,4-dihydr0pyrido[4,3-d]pyrimidin-2(1H)-0ne \o N—N \ i OKiF ?N N F YT N NH2 This compound was prepared using procedures ous to those as described for Example 45 with 1-(1-methyl-1H-pyrazolyl)methanamine hydrochloride (J&W PharmLab, Cat#68R0166) replacing 2-fluoroaniline in Step 4. LCMS ated for C21H23 F2N603 (M+H)+; m/z = 445.2; Found: 445.1.
Example 48 methyl [3-(2,6-difluoro-3,5-dimethoxyphenyl)—1,8-dimethyl0xo-1,2,3,4- tetrahydropyrido [4,3-d]pyrimidinyl]carbamate o NJkN/ \N "JKO/ Step I: [(4, 6-dichloromethylpyridinyl)methyl] (2, 0r0-3, 5-dimeth0xyphenyl) carbamic chloride FitCI \0 N CI N CI To a solution of N-[(4,6-dichloromethylpyridinyl)methyl]-2,6-difluoro-3,5- dimethoxyaniline (Example 45, Step 2: 1.25 g, 3.44 mmol) in methylene chloride (30 mL) at 0 °C was added triphosgene (0.61 g, 2.1 mmol), followed by pyridine (840 uL, 10. mmol).
The reaction mixture was stirred at 0 0C for 1 hour then diluted with methylene chloride and washed with 1N HCl solution. Then the s solution was ted with methylene chloride. The combined organic layers were washed with water, brine, dried over NaZSO4, then concentrated to give the desired product (1.45 g, 99 %) which was used in the next step without further ation. LCMS calculated for C16H14C13F2N203 (M+H)+: m/z = 425.0; Found: 425.0.
Step 2 .‘ N-[(4, 6-dichIoromethylpyridinyl)methyl]-N-(2, 6-diflu0r0-3, 5-dimeth0xypheny0- N’-methylurea Fj’lNH \0 N CI F Y5K\l N CI 2014/034662 To a solution of [(4,6-dichloromethylpyridinyl)methyl](2,6-difluoro-3,5- dimethoxyphenyl)carbamic chloride (1.45 g, 3.41 mmol) in methylene chloride (6 mL) was added methylamine (2M in THF, 3.4 mL, 6.8 mmol) and N,N—diisopropylethylamine (3.0 mL, 17 mmol). The resulting mixture was stirred at room temperature for 30 min then concentrated. The e was purified on a silica gel column to give the desired product (1.35 g, 94 %). LCMS calculated for C17H18C12F2N303 (M+H)+2 l’l’l/Z = 420.1, Found: 420.0 Step 3 .‘ 7-chlor0(2, 6-diflu0r0-3,5-dimeth0xypheny0-1,8-dimethyl-3,4-dihydr0pyrid0[4,3- d] pyrimidin-2(II-I)-0ne \o N N/ N CI A mixture of N—[(4,6-dichloromethylpyridin-3 -yl)methyl]—N—(2,6—difluoro—3,5— dimethoxyphenyl)-N'-methylurea (0.80 g, 1.9 mmol), cesium carbonate (1.9 g, 5.7 mmol) in N,N—dimethylformamide (7 mL) in a reaction vial was stirred at 110 OC overnight. After cooling to room temperature, the mixture was quenched with sat'd NH4Cl solution, and extracted with ethyl acetate. The combined extracts were washed with water and brine then dried over NaZSO4 and concentrated. The residue was purified on a silica gel column to give the desired product (0.58 g, 79 %). LCMS calculated for C1F2N3O3 (M+H)+: m/z = 384.1; Found: 384.1.
Step 4: 7-amin0(2,6-diflu0r0-3,5-dimeth0xyphenyD-I,8-dimethyl—3,4-dihydr0pyrid0 [4,3- d]pyrimidin-2(IH)-0ne \ Jk/ O NN PW\| NNH2 A e of 7-chloro(2,6-difluoro-3,5-dimethoxyphenyl)—1,8-dimethyl-3,4- dihydropyrido[4,3-d]pyrimidin-2(1H)-one (200 mg, 0.5 mmol), henone imine (110 uL, 0.68 mmol), 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (32 mg, 0.052 mmol) and tris(dibenzylideneacetone)dipalladium(0) (20 mg, 0.02 mmol) in toluene (4 mL) was purged with nitrogen for 5 min. The mixture was stirred at 90 °C for 2 hours then cooled to room temperature and concentrated. The residue was purified on a silica gel column to give the intermediate (210 mg). The intermediate was dissolved in tetrahydrofuran (3 mL) then hydrogen chloride (1 M in water, 0.3 mL, 0.3 mmol) was added. The mixture was stirred at room temperature for 3 hours then concentrated and the e was purified on a silica gel column to give the desired product (150 mg). LCMS ated for C17H19F2N4O3 (M+H)+: m/z = 365.1; Found: 365.1.
Step 5: methyl [3-(2,6-diflu0r0-3,5-dimeth0xypheny0-I,8-dimethyl—2-0x0-I,2,3,4 - tetrahydropyrido [4, 3-d]pyrimidin- 7-yl]carbamate To a on of 7-amino(2,6-difluoro-3,5-dimethoxyphenyl)-1,8-dimethyl-3,4- dihydropyrido[4,3-d]pyrimidin-2(1H)—one (120 mg, 0.33 mmol) in methylene chloride (5 mL) was added methyl chloroformate (38 uL, 0.49 mmol) and triethylamine (230 uL, 1.6 mmol). The resulting e was stirred at room temperature overnight then concentrated.
The residue was purified by reverse phase HPLC (pH = 2, acetonitrile/water+TFA) to give the d product as the TFA salt. LCMS calculated for C19H21F2N405 (M+H)+: m/z = 423.1; Found: 423.1. 1H NMR (500 MHz, DMSO-dg) 5 9.80 (s, 1H), 8.03 (s, 1H), 7.02 (t, J: 8.2 Hz, 1H), 4.67 (s, 2H), 3.88 (s, 6H), 3.68 (s, 3H), 3.34 (s, 3H), 2.21 (s, 3H) ppm.
Example 49 7-amino(cyclopropylmethyl)—3-(2,6-difluor0-3,5-dimethoxyphenyl)—2-ox0-1,2,3,4— ydropyrido[4,3-d]pyrimidine-8—carbonitrile <1 ELYF \o N N N NH2 Step I : 2, 4-dichlorof0rmylnicotinonitrile OI CI N CI A mixture of malononitrile (2.0 g, 30. mmol) and trimethylorthoacetate (4.0 g, 33 mmol) was heated at reflux for 3 hours then it was cooled to room temperature and concentrated to give (1-methoxyethylidene)malononitrile (3.7 g) which was used in the next step without further purification. A solution of (1-methoxyethylidene)malononitrile (2.0 g, 16 mmol) in N,N—dimethylformamide (4.8 g, 66 mmol) was added dropwise to phosphoryl chloride (10 g, 66 mmol) at 95 0C. The resulting mixture was d at 95 0C for 3 days then cooled to room temperature and diluted with methylene chloride (50 mL). The mixture was stirred at room temperature for 1 h then water (50 mL) was added and the e was stirred at room temperature for an additional 1 h. The mixture was ted with methylene de. The combined organic layers were washed with water and brine then dried over NaZSO4 and concentrated. The residue was purified on a silica gel column to give the desired product (1.46 g, 44 %). 1H NMR (400 MHz, CDCl3): 5 10.44 (s, 1 H), 8.99 (s, 1 H) ppm.
Step 2: 2, 4-dichlor0{[(2, 6-diflu0r0-3, 5-dimeth0xyphenyl)amin0]methyl}nicotinonitrile \0 NH Cl F ON N CI To a mixture of sodium triacetoxyborohydride (1.0 g, 5.0 mmol) in trifluoroacetic acid (2 mL, 20 mmol) at room temperature was added a solution of fluoro—3,5— dimethoxyaniline (0.52 g, 2.7 mmol) in methylene chloride (20 mL). The resulting mixture was stirred for 5 min at room temperature then a solution of 2,4-dichloro formylnicotinonitrile (0.50 g, 2.5 mmol) in ene chloride (20 mL) was added.
The mixture was d at room temperature for 1 h then neutralized with sat'd NaHCO3 solution and extracted with methylene chloride. The combined organic layers were washed with water and brine then dried over NaZSO4 and concentrated. The residue was purified on a silica gel column to give the desired product (0.87 g, 93 %). LCMS calculated for C15H12C12F2N302 (M+H)+: m/z = 374.0; Found: 373.9.
Step 3 .‘ [(4, 6-dichIorocyan0pyridinyl)methyl] (2, 6-diflu0r0-3,5- dimethoxyphenybcarbamic chloride \ J—CI O N CI F ON N CI To a solution of 2,4-dichloro {[(2,6-difluoro-3,5-dimethoxyphenyl)amino]methyl}- nicotinonitrile (810 mg, 2.2 mmol) in methylene chloride (30 mL) at 0 0C was added triphosgene (0.38 g, 1.3 mmol), ed by pyridine (520 uL, 6.5 mmol). The mixture was stirred at 0 0C for 1 hour then diluted with methylene de and washed with 1 N HCl solution. The mixture was then ted with methylene chloride. The combined organic layers were washed with water and brine then dried over NaZSO4 and concentrated to yield the desired product (0.84 g, 89 %) which was used in the next step without further purification. LCMS calculated for C13F2N303 (M+H)+: m/z = 436.0; Found: 435.8.
Step 4: N’-(cyclopr0pylmethyl)-N—[(4, 6—dichlor0cyan0pyridinyl)methyl]-N— (2, 6- diflu0r0-3, 5-dimeth0xyphenyl) urea N CI To a solution of [(4,6-dichlorocyanopyridinyl)methyl](2,6-difluoro—3,5- dimethoxyphenyl)carbamic chloride (35 mg, 0.080 mmol) in methylene chloride (1 mL) was added cyclopropylmethylamine (8.9 uL, 0.10 mmol) and N,N—diisopropylethylamine (70 uL, 0.40 mmol). The resulting solution was stirred at room temperature for 30 min then diluted with DCM and washed with 1 N HCl aqueous solution. The organic layer was washed with brine then dried over NaZSO4 and trated. The residue was used in the next step without further purification. LCMS calculated for C20H19C12F2N4O3 (M+H)+: m/z = 471.1; Found: 471. 1.
Step 5: r0-I—(cyclopropylmethyD-S-(Z, 6—diflu0r0-3, 5-dimeth0xyphenyD0x0-I, 2, 3, 4- tetrahydropyrido[4, 3-d]pyrimidinecarb0nitrile WO 72644 A mixture of the crude product from Step 4 and potassium carbonate (22 mg, 0.16 mmol) in itrile (3 mL) was heated to reflux and stirred overnight. The reaction mixture was cooled to room ature then diluted with DCM and washed with water and brine.
The organic layer was dried over NaZSO4 then concentrated. The residue was used in the next step without further purification. LCMS calculated for C20H18C1F2N4O3 (M+H)+: m/z = 435.1; Found: 434.7.
Step 6: I-(cyclopr0pylmethyl)(2,6-diflu0r0-3,5-dimeth0xypheny0[(dzphenylmethylene) - amino]0x0-I,2, 3, 4-tetrahydr0pyrid0[4 3-61]pyrimidinecarb0nitrile N/xPh A mixture of the crude product from Step 5, bis(dibenzylideneacetone)palladium(0) (5 mg, 0.008 mmol), (R)—(+)—2,2'—bis(diphenylphosphino)—l,l'—binaphthyl (5 mg, 0.008 mmol), sodium tert—butoxide (15 mg, 0.16 mmol) and benzophenone imine (20. uL, 0.12 mmol) in toluene (5 mL) was evacuated then filled with nitrogen. The resulting mixture was heated to 90 0C and stirred for 3 h. The reaction mixture was cooled to room temperature then diluted with water and extracted with DCM. The combined ts were dried over NaZSO4 then concentrated. The residue was d on a silica gel column eluting with 0 to 100 % EtOAc/Hexanes to give the desired product (13 mg) as a yellow solid. LCMS calculated for CBHzgerso3 (M+H)+: m/z = 580.2; Found: 580.0.
Step 7.‘ 7-amin0-I—(cyclopropylmethyD-S-(Z, 6-diflu0r0-3, 5-dimeth0xyphenyD0x0-1,2, 3,4 - tetrahydropyrido[4, 3-d]pyrimidinecarb0nitrile The product from Step 6 was dissolved in tetrahydrofuran (3 mL) then 1.0 M hydrogen chloride in water (0.16 mL, 0.16 mmol) was added. The resulting mixture was 2014/034662 d at room temperature for 2 h then diluted with acetonitrile and purified by prep HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LCMS calculated for C20H20F2N503 (M+H)+i l’l’l/Z = 416.2, Found: 416.2 e 50 7-aminocyclopentyl(2,6-difluoro-3,5-dimeth0xyphenyl)ox0-1,2,3,4— tetrahydropyrido [4,3-d]pyrimidinecarbonitrile ii J3 \o N N F CN N NH2 This compound was prepared using procedures analogous to those as described for Example 49 With cyclopentanamine replacing cyclopropylmethylamine in Step 4. LCMS calculated for C21H22F2N503 (M+H)+: m/z = 430.2; Found: 430.2.
Example 51 7-amin0(2,6-diflu0ro-3,5-dimethoxyphenyl)—1-[(l-methyl-lH-pyrazol—4—yl)methyl] ox0-1,2,3,4-tetrahydropyrido[4,3-d]pyrimidine-8—carbonitrile \o N—N F / AOL 5) \o N N F CN N NH2 This compound was prepared using procedures analogous to those as described for Example 49 with l-(l-methyl-lH-pyrazolyl)methanamine (AstaTech, cat#BL0093 l3) replacing cyclopropylmethylamine in Step 4. LCMS calculated for C21H20F2N703 (M+H)+: m/z = 456.2; Found: 456.0. e 52 7-amin0(3,5-diflu0r0benzyl)(2,6-difluoro-3,5—dimethoxyphenyl)oxo-1,2,3,4— tetrahydropyrido [4,3-d]pyrimidinecarbonitrile 2014/034662 \ F F \o N N F CN N NH2 This compound was prepared using procedures analogous to those as described for e 49 with l—(3,5—difluorophenyl)methanamine replacing cyclopropylmethylamine in Step 4. LCMS calculated for C23H18F4N503 (M+H)+: m/z = 488.1; Found: 488.1. e 53 7-amin0(2,6-diflu0ro—3,5-dimethoxyphenyl)(2-flu0r0phenyl)—2-0xo—1,2,3,4— tetrahydropyrido [4,3-d]pyrimidinecarbonitrile Fj\F \o N N: F CN N NH2 Step I .‘ 7-chlor0(2, 6-diflu0r0-3,5-dimeth0xypheny0-I—(2-flu0r0phenyD0x0-1,2,3,4- tetrahydropyrido[4, 3-d]pyrimidinecarb0nitrile F F \O NAN KEICN\N I A e of [(4,6-dichlorocyanopyridin-3 -yl)methyl](2,6—difluoro—3,5— oxyphenyl)carbamic chloride (35 mg, 0.080 mmol), 2—fluoro—benzenamine (9.8 mg, 0.088 mmol) and N,N—diisopropylethylamine (42 uL, 0.24 mmol) in 1,2-dichloroethane (0.4 mL) was stirred at 90 OC overnight. The reaction mixture was cooled to room temperature then potassium carbonate (25 mg, 0.18 mmol) and acetonitrile (1 mL) were added. The mixture was stirred at 90 0C for 4 hours. After cooling to room temperature, the mixture was concentrated and the residue was purified on a silica gel column to give the desired product (30 mg, 80 %). LCMS calculated for C22H15C1F3N4O3 (M+H)+: m/z = 475.1; Found: 474.9.
Step 2: 7-amin0(2,6-diflu0r0-3,5-dimeth0xypheny0-I—(2-flu0r0phenyD0x0-1,2,3,4- tetrahydropyrido[4, 3-d]pyrimidinecarb0nitrile This compound was prepared from 7—chloro—3-(2,6-difluoro—3,5—dimethoxyphenyl)—l— (2-fluorophenyl)—2-oxo- l ,2,3 rahydropyrido [4,3 -d]pyrimidinecarbonitrile using similar conditions as described for Example 49, Step 6- 7. LCMS calculated for F3N503 (M+H)+; m/z = 456.1; Found: 455.9.
Example 54 7-amin0chlor0(2,6-difluoro—3,5-dimethoxyphenyl)methyl-3,4- dihydropyrido[4,3-d]pyrimidin-2(1H)-one \ i/ F CI N NH2 To a solution of 7-amino(2,6-difluoro-3,5-dimethoxyphenyl)-l-methyl-3,4- dihydropyrido[4,3-d]pyrimidin-2(lH)-one (Example I, Step 6: 15 mg, 0.043 mmol) in DMF (1.0 mL) was added N—chlorosuccinimide (17 mg, 0.13 mmol). The resulting mixture was stirred at room temperature for l h then it was purified by prep-HPLC (pH 2, acetonitrile/water+TFA) to afford the desired product as the TFA salt. LC—MS calculated for C16H16C1F2N4O3 [M+H]+ m/z: 385.1; found 385.1. 1H NMR (500 MHz, DMSO) 5 7.75 (s, 1H), 7.15 (s, 2H), 7.02 (t, J: 7.5 Hz, 1H), 4.57 (s, 2H), 3.88 (s, 6H), 3.45 (s, 3H) ppm.
Example A FGFR tic Assay The inhibitor potency of the exemplified compounds was ed in an enzyme assay that measures peptide phosphorylation using FRET measurements to detect product ion. Inhibitors were serially diluted in DMSO and a volume of 0.5 uL was erred to the wells of a 384-well plate. For FGFR3, a 10 uL volume of FGFR3 enzyme (Millipore) diluted in assay buffer (50 mM HEPES, 10 mM MgC12, 1 mM EGTA, 0.01% Tween-20, 5 mM DTT, pH 7.5) was added to the plate and pre-incubated for 5-10 minutes. Appropriate controls (enzyme blank and enzyme with no inhibitor) were included on the plate. The assay was initiated by the addition of a 10 uL solution containing biotinylated EQEDEPEGDYFEWLE peptide substrate (SEQ ID NO: 1) and ATP (final concentrations of 500 nM and 140 HM respectively) in assay buffer to the wells. The plate was incubated at 25 °C for 1 hr. The reactions were ended with the addition of 10 uL/well of quench solution (50 mM Tris, 150 mM NaCl, 0.5 mg/mL BSA, pH 7.8; 30 mM EDTA with Perkin Elmer Lance ts at 3.75 nM Eu-antibody PY20 and 180 nM APC—Streptavidin). The plate was allowed to equilibrate for ~1 hr before scanning the wells on a PheraStar plate reader (BMG Labtech).
FGFRl and FGFR2 were measured under equivalent conditions with the following changes in enzyme and ATP concentrations: FGFRl, 0.02 nM and 210 HM, respectively and FGFR2, 0.01 nM and 100 HM, respectively. The enzymes were purchased from Millipore or Invitrogen.
GraphPad prism3 was used to analyze the data. The IC50 values were d by fitting the data to the on for a sigmoidal dose-response with a variable slope.
Y=Bottom + (Top-Bottom)/(1+10A((LogIC50-X)*HillSlope)) where X is the logarithm of concentration and Y is the response. Compounds having an IC50 of 1 HM or less are ered active.
The compounds of the invention were found to be inhibitors of one or more of FGFRl, FGFR2, and FGFR3 according to the above—described assay. IC50 data is provided below in Table 1. The symbol "+" indicates an IC50 less than 100 nM.
Table 1 e No. FGFRI FGFR2 FGFR3 IC50 nM IC50 nM IC50 nM fi—‘fi—‘fi—‘fi—‘fi—‘fi—‘fi—‘Hfiam$mNHOKOOOfl0UIJ>UJNH \O O\ 2014/034662 Example B FGFR Cell Proliferation/Survival Assays The ability of the example compounds to inhibit the growth of cells dependent on FGFR signaling for survival can be measured using viability assays. A inant cell line over—expressing human FGFR3 was developed by stable transfection of the mouse pro—B Ba/F3 cells (obtained from the Deutsche Sammlung von Mikroorganismen und Zellkulturen) with a plasmid encoding the full length human FGFR3. Cells were sequentially selected for puromycin resistance and proliferation in the presence of heparin and FGFl. A single cell clone was isolated and characterized for functional expression of FGFR3. This Ba/F3-FGFR3 clone is used in cell proliferation assays, and compounds are screened for their ability to inhibit cell proliferation/survival. The Ba/F3—FGFR3 cells are seeded into 96 well, black cell culture plates at 3500 cells/well in 40 media containing 2 % PBS, 20 ug/mL Heparin and 5 ng/mL FGFl. The cells were treated with 10 uL of 10X concentrations of serially diluted compounds ed with medium lacking serum from 5 mM DSMO dots) to a final volume of 100 uL/well. After 72 hour incubation, 100 uL of Cell Titer Glo® reagent (Promega Corporation) that measures cellular ATP levels is added to each well. After 20 minute incubation with shaking, the luminescence is read on a plate reader. The luminescent readings are converted to t inhibition relative to DMSO treated control wells, and the IC50 values are calculated using GraphPad Prism software by fitting the data to the equation for a sigmoidal dose—response with a le slope. Compounds having an IC50 of 10 uM or less are ered active. Cell lines representing a variety of tumor types including KMS—ll (multiple myeloma, FGFR3 ocation), RT112 (bladder cancer, FGFR3 overexpression), KatoHI (gastric cancer, FGFR2 gene amplification), and H-1581 (lung, FGFRl gene amplification) are used in similar proliferation assays. In some experiments, MTS reagent, Cell Titer 96® AQueous One Solution Reagent (Promega Corporation) is added to a final concentration of 333 ug/mL in place Cell Titer G10 and read at 490/650 nm on a plate reader.
Compounds having an IC50 of 5 HM or less are considered active.
Example C ased FGFR Phosphorylation Assays The inhibitory effect of compounds on FGFR phosphorylation in nt cell lines (Ba/F3-FGFR3, KMS-l 1, RT112, KatoIH, H-1581 cancer cell lines and HUVEC cell line) can be assessed using immunoassays specific for FGFR phosphorylation. Cells are starved in media with reduced serum (0.5%) and no FGFl for 4 to 18 h depending upon the cell line then treated with various trations of individual tors for 1-4 hours. For some cell lines, such as Ba/F3-FGFR3 and KMS-l 1, cells are stimulated with Heparin (20 ug/mL) and FGFl (10 ng/mL) for 10 min. Whole cell protein extracts are prepared by incubation in lysis buffer with protease and atase inhibitors [50 mM HEPES (pH 7.5), 150 mM NaCl, 1.5 mM MgC12, 10% Glycerol, 1% Triton X-100, 1 mM sodium orthovanadate, 1 mM sodium fluoride, aprotinin (2 ug/mL), tin (2 ug/mL), tin A (2 ug/mL), and phenylmethylsulfonyl fluoride (1 mM)] at 4°C. n extracts are cleared of cellular debris by centrifugation at 14,000 x g for 10 minutes and quantified using the BCA (bicinchoninic acid) late assay reagent (Thermo Scientific).
Phosphorylation of FGFR receptor in protein ts was determined using immunoassays including western blotting, enzyme-linked immunoassay ) or bead- based immunoassays (Luminex). For ion of phosphorylated FGFR2, a commercial ELISA kit DuoSet IC Human Phospho-FGF R20t ELISA assay (R&D s, Minneapolis, MN) can be used. For the assay KatoIII cells are plated in 0.2% FBS supplemented ’s medium (50,000 cells / well/ per 100 uL) into 96—well flat—bottom tissue culture treated plates (Corning, Corning, NY), in the presence or absence of a concentration range of test compounds and incubated for 4 hours at 37 OC, 5% C02. The assay is stopped with addition of 200 uL of cold PBS and centrifugation. The washed cells are lysed in Cell Lysis Buffer (Cell Signaling, #9803 ) with Protease Inhibitor (Calbiochem, #535140) and PMSF (Sigma, ) for 30 min on wet ice. Cell lysates were frozen at —80 0C before testing an aliquot with the DuoSet IC Human Phospho-FGF R20t ELISA assay kit. GraphPad prism3 was used to analyze the data. The IC50 values were derived by g the data to the equation for a sigmoidal dose—response with a le slope.
For detection of phosphorylated FGFR3, a bead based immunoassay was ped.
An anti-human FGFR3 mouse mAb (R&D Systems, cat#MAB7661) was conjugated to Luminex MAGplex microspheres, bead region 20 and used as the capture antibody. RT-112 cells were seeded into multi—well tissue culture plates and cultured until 70% confluence.
Cells were washed with PBS and starved in RPMI + 0.5% FBS for 18 hr. The cells were treated with 10 uL of 10X concentrations of serially diluted nds for 1 hr at 37 OC, 5% C02 prior to stimulation with 10 ng/mL human FGFl and 20 ug/mL Heparin for 10 min.
Cells were washed with cold PBS and lysed with Cell Extraction Buffer (Invitrogen) and centrifuged. Clarified supernatants were frozen at -80 0C until analysis.
For the assay, cell lysates are diluted 1:10 in Assay Diluent and incubated with capture antibody—bound beads in a 96-well filter plate for 2 hours at room temperature on a plate shaker. Plates are washed three times using a vacuum manifold and ted with anti-phospho-FGF R1-4 (Y653/Y654) rabbit polyclonal antibody (R&D Systems cat# AF3285) for 1 hour at RT with shaking. Plates are washed three times. The diluted reporter antibody, goat anti-rabbit-RPE conjugated antibody (Invitrogen Cat. # LHB0002) is added and incubated for 30 minutes with shaking. Plates are washed three times. The beads are suspended in wash buffer with shaking at room temperature for 5 s and then read on a Luminex 200 instrument set to count 50 events per sample, gate settings 7500—13500. Data is expressed as mean fluorescence intensity (MFI). MFI from compound treated samples are divided by MFI values from DMSO controls to determine the percent inhibition, and the IC50 values are calculated using the GraphPad Prism software. Compounds having an IC50 of 1 uM or less are considered active.
Example D FGFR Cell-Based Signaling Assays Activation of FGFR leads to phosphorylation of Erk proteins. Detection of pErk is monitored using the Cellu’Erk HTRF eneous Time Resolved Flurorescence) Assay (CisBio) according to the cturer’s ol. KMS—ll cells are seeded into 96—well plates at 40,000 cells/well in RPMI medium with 0.25% FBS and starved for 2 days. The medium is aspirated and cells are treated with 30 uL of IX concentrations of serially diluted compounds ed with medium g serum from 5 mM DSMO dots) to a final volume of 30 uL/well and incubated for 45 min at room temperature. Cells are stimulated by addition of 10 uL of Heparin (100 ug/mL) and FGFl (50 ng/mL) to each well and incubated for 10 min at room ature. After lysis, an aliquot of cell extract is transferred into 384- well low volume , and 4 HL of ion reagents are added followed by incubation for 3 hr at room ature. The plates are read on a PheraStar instrument with settings for HTRF. The normalized cence readings are converted to percent inhibition relative to DMSO treated control wells, and the IC50 values are calculated using the GraphPad Prism software. Compounds having an IC50 of 1 uM or less are considered active.
Example E VEGFRZ Kinase Assay 40 uL Enzyme reactions are run in black 384 well polystyrene plates for 1 hour at 25 °C. Wells are dotted with 0.8 uL of test compound in DMSO. The assay buffer contains 50 mM Tris, pH 7.5, 0.01% Tween—20, 10 mM MgC12, 1 mM EGTA, 5 mM DTT, 0.5 uM Biotin-labeled EQEDEPEGDYFEWLE peptide substrate (SEQ ID NO: 1), 1 mM ATP, and 0.1 nM enzyme (Millipore catalogue number 14—630). Reactions are stopped by addition of uL Stop Buffer (50 mM Tris, pH= 7.8, 150 mM NaCl, 0.5 mg/mL BSA, 45 mM EDTA) with 225 nM LANCE Streptavidin Surelight® APC (PerkinElmer catalogue number CRl30— 100) and 4.5 nM LANCE Eu-W1024 anti phosphotyrosine (PY20) antibody (PerkinElmer catalogue number AD0067). After 20 minutes of incubation at room temperature, the plates are read on a PheraStar FS plate reader (BMG Labtech). IC50 values can be ated using GraphPad Prism by fitting the data to the equation for a sigmoidal dose—response With a variable slope. Compounds having an IC50 of 1 HM or less are considered active.
Various modifications of the ion, in addition to those bed herein, Will be apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims. Each reference, including all patent, patent applications, and ations, cited in the present application is incorporated herein by reference in its entirety.

Claims (26)

The claims defining the ion are as follows:
1. A compound of Formula IIIa: IIIa or a pharmaceutically acceptable salt thereof, wherein: R2 and R5 are each independently selected from H, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, cyclopropyl, CN, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)ORa, OC(O)Rb, OC(O)NRcRd, NRcRd, NRcC(O)Rb, NRcC(O)ORa, NRcC(O)NRcRd, C(=NRe)Rb, C(=NRe)NRcRd, NRcC(=NRe)NRcRd, NRcS(O)Rb, NRcS(O)2Rb, NRcS(O)2NRcRd, S(O)Rb, S(O)NRcRd, S(O)2Rb, and RcRd; R6 is H, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-10 lkyl, 5-10 membered heteroaryl, 4-10 membered cycloalkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, c2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, C(=NRe2)Rb2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, O)Rb2, O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, or S(O)2NRc2Rd2; wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5- 10 membered heteroaryl, and 4-10 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from R6a; each R6a is independently selected from Cy1, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 l, C1-6 haloalkyl, CN, NO2, ORa2, SRa2, 2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2, wherein said C1-6 alkyl, C2-6 alkenyl, and C2-6 l are each ally substituted with 1, 2, or 3 substituents independently selected from Cy 1, halo, CN, NO2, ORa2 , SRa2 , C(O)Rb2 , C(O)NRc2 Rd2 , C(O)ORa2 , OC(O)Rb2 , OC(O)NRc2 Rd2 , C(=NR e2 )NR c2 Rd2 , NRc2 C(=NR e2 )NR c2 Rd2 , NRc2 Rd2 , NRc2 C(O)R b2 , NRc2 C(O)OR a2 , NR c2 C(O)NR c2 Rd2 , NRc2 S(O)R b2 , NRc2 S(O) b2 , NRc2 S(O) c2 Rd2 , S(O)Rb2 , S(O)NRc2 Rd2 , 2R 2NR S(O) 2Rb2 , and S(O)2NR c2 Rd2 ; R7 and R8 are each independently selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, -C(O)R A, S(O)RA, S(O) A, C 2R 6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-10 cycloalkyl-C1-4 alkyl, (5-10 membered heteroaryl)-C1-4 alkyl, or (4-10 membered heterocycloalkyl)-C1-4 alkyl, wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 lkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-10 cycloalkyl-C1-4 alkyl, (5-10 membered heteroaryl)- C1-4 alkyl, and (4-10 membered heterocycloalkyl)-C1-4 alkyl are each optionally substituted with 1, 2, 3, 4, or 5 tuents independently ed from R7a ; each R7a is independently selected from Cy2, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, CN, NO2, ORa3 , SRa3 , 3 , C(O)NRc3 Rd3 , C(O)ORa3 , b3 , OC(O)NR c3 Rd3 , C(=NRe3 )NR c3 Rd3 , NRc3 C(=NR e3 )NR c3 Rd3 , NRc3 Rd3 , NRc3 C(O)R b3 , NR c3 C(O)OR a3 , NRc3 C(O)NR c3 Rd3 , NRc3 S(O)R b3 , NRc3 S(O) b3 , NRc3 S(O) c3 Rd3 , S(O)Rb3 , 2R 2NR S(O)NR c3 Rd3 , S(O) b3 , and S(O) c3 Rd3 , wherein said C 2R 2NR 1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally tuted with 1, 2, or 3 substituents independently selected from Cy 2, halo, CN, NO2, ORa3 , SRa3 , C(O)Rb3 , C(O)NRc3 Rd3 , C(O)ORa3 , OC(O)Rb3 , OC(O)NRc3 Rd3 , C(=NR e3 )NR c3 Rd3 , NRc3 C(=NR e3 )NR c3 Rd3 , NRc3 Rd3 , NRc3 C(O)R b3 , NRc3 C(O)OR a3 , NR c3 C(O)NR c3 Rd3 , NRc3 S(O)R b3 , NRc3 S(O) b3 , NRc3 S(O) c3 Rd3 , S(O)Rb3 , c3 Rd3 , 2R 2NR S(O) 2Rb3 , and S(O)2NR c3 Rd3 ; R10 and R11 together with the carbon atom to which they are attached form a 3-, 4-, 5-, 6-, or 7-membered cycloalkyl group or a 4-, 5-, 6-, or 7-membered heterocycloalkyl group, each optionally substituted with 1, 2, or 3 substituents independently selected from Cy3, C1-6 alkyl, C1- a4 , SRa4 , C(O)Rb4 , C(O)NRc4 Rd4 , C(O)ORa4 , OC(O)Rb4 , 6 haloalkyl, halo, CN, OR OC(O)NR c4 Rd4 , NRc4 Rd4 , NRc4 C(O)R b4 , NRc4 C(O)NR c4 Rd4 , NRc4 C(O)OR a4 , C(=NRe4 )NR c4 Rd4 , NR c4 C(=NR e4 )NR c4 Rd4 , S(O)Rb4 , S(O)NRc4 Rd4 , S(O) b4 , NRc4 S(O) b4 , NRc4 S(O) c4 Rd4 , 2R 2R 2NR and S(O)2NR c4 Rd4 , wherein said C 1-6 alkyl is optionally tuted by 1, 2, or 3 substituents independently selected from Cy3, halo, CN, ORa4 , SRa4 , C(O)Rb4 , C(O)NRc4 Rd4 , C(O)ORa4 , OC(O)R b4 , OC(O)NRc4 Rd4 , NRc4 Rd4 , NRc4 C(O)R b4 , NRc4 C(O)NR c4 Rd4 , NRc4 C(O)OR a4 , C(=NR e4 )NR c4 Rd4 , NRc4 C(=NR e4 )NR c4 Rd4 , S(O)Rb4 , S(O)NRc4 Rd4 , S(O) b4 , NRc4 S(O) b4 , 2R 2R NR c4 S(O) c4 Rd4 , and S(O) c4 Rd4 ; 2NR 2NR each RA is independently ed from H, C1-6 alkyl, C1-6 alkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered aryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-10 cycloalkyl-C1-4 alkyl, (5-10 membered heteroaryl)-C1-4 alkyl, and (4-10 membered heterocycloalkyl)-C1-4 alkyl, wherein said C1-6 alkyl, C1-6 alkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-10 ed heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-10 cycloalkyl- C1-4 alkyl, (5-10 membered heteroaryl)-C1-4 alkyl, and (4-10 ed heterocycloalkyl)-C1-4 alkyl are each optionally substituted with 1, 2, or 3 substituents independently selected from R7a ; Cy1, Cy2, and Cy3 are each independently selected from C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, each of which is optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered aryl, 3-10 membered heterocycloalkyl, CN, NO2, ORa5 , SRa5 , C(O)Rb5 , C(O)NRc5 Rd5 , C(O)ORa5 , OC(O)R b5 , OC(O)NRc5 Rd5 , NRc5 Rd5 , NRc5 C(O)R b5 , NRc5 C(O)OR a5 , NRc5 C(O)NR c5 Rd5 , C(=NR e5 )R b5 , C(=NRe5 )NR c5 Rd5 , NRc5 C(=NR e5 )NR c5 Rd5 , NRc5 S(O)R b5 , NRc5 S(O) b5 , NR c5 S(O) c5 Rd5 , S(O)Rb5 , S(O)NRc5 Rd5 , S(O) b5 , and S(O) c5 Rd5 ; wherein said C 2NR 2R 2NR 1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl are each ally substituted with 1, 2, 3, 4, or 5 tuents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, CN, NO2, OR a5 , SRa5 , C(O)Rb5 , C(O)NRc5 Rd5 , C(O)ORa5 , OC(O)Rb5 , OC(O)NRc5 Rd5 , C(=NRe5 )NR c5 Rd5 , NR c5 C(=NR e5 )NR c5 Rd5 , NRc5 Rd5 , NRc5 C(O)R b5 , NRc5 C(O)OR a5 , NRc5 C(O)NR c5 Rd5 , NR c5 S(O)R b5 , NRc5 S(O) b5 , NRc5 S(O) c5 Rd5 , S(O)Rb5 , S(O)NRc5 Rd5 , S(O) b5 , and 2R 2NR 2R S(O) 2NR c5 Rd5 ; each Ra, Rb, Rc, and Rd is independently selected from H, C1-6 alkyl, C1-4 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, and cyclopropyl, wherein said C1-6 alkyl, C2-6 l, C2-6 alkynyl, and cyclopropyl is ally substituted with 1, 2, or 3 substituents independently selected from C1-4 alkyl, C1-4 haloalkyl, halo, CN, ORa6 , SRa6 , C(O)Rb6 , C(O)NRc6 Rd6 , C(O)ORa6 , OC(O)Rb6 , OC(O)NR c6 Rd6 , NRc6 Rd6 , NRc6 C(O)R b6 , NRc6 C(O)NR c6 Rd6 , NRc6 C(O)OR a6 , C(=NRe6 )NR c6 Rd6 , NR c6 C(=NR e6 )NR c6 Rd6 , S(O)Rb6 , c6 Rd6 , S(O) b6 , NRc6 S(O) b6 , NRc6 S(O) c6 Rd6 , 2R 2R 2NR and S(O)2NR c6 Rd6 ; each Ra2 , Rb2 , Rc2 , Rd2 , Ra3 , Rb3 , Rc3 , Rd3 , Ra4 , Rb4 , Rc4 , Rd4 , Ra5 , Rb5 , Rc5 , and Rd5 is independently selected from H, C1-6 alkyl, C1-4 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 ed heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-10 cycloalkyl-C1-4 alkyl, (5-10 membered heteroaryl)-C1-4 alkyl, or (4-10 membered heterocycloalkyl)-C1-4 alkyl, wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered aryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-10 cycloalkyl-C1-4 alkyl, (5-10 ed aryl)-C1-4 alkyl, and (4-10 membered heterocycloalkyl)-C1-4 alkyl is ally substituted with 1, 2, 3, 4, or 5 substituents independently selected from C1-4 alkyl, C1-4 haloalkyl, halo, CN, ORa6 , SRa6 , C(O)Rb6 , C(O)NR c6 Rd6 , C(O)ORa6 , OC(O)Rb6 , OC(O)NRc6 Rd6 , NRc6 Rd6 , NRc6 C(O)R b6 , NR c6 C(O)NR c6 Rd6 , NRc6 C(O)OR a6 , C(=NRe6 )NR c6 Rd6 , NRc6 C(=NR e6 )NR c6 Rd6 , S(O)Rb6 , S(O)NR c6 Rd6 , S(O) b6 , NRc6 S(O) b6 , NRc6 S(O) c6 Rd6 , and S(O) c6 Rd6 ; 2R 2R 2NR 2NR or any Rc and Rd together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group ally substituted with 1, 2, or 3 substituents independently selected from C1-6 alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, C6-10 aryl, 5-6 membered heteroaryl, C1-6 haloalkyl, halo, CN, ORa6 , SRa6 , C(O)Rb6 , c6 Rd6 , C(O)OR a6 , OC(O)Rb6 , OC(O)NRc6 Rd6 , NRc6 Rd6 , NRc6 C(O)R b6 , NRc6 C(O)NR c6 Rd6 , NR c6 C(O)OR a6 , C(=NRe6 )NR c6 Rd6 , NRc6 C(=NR e6 )NR c6 Rd6 , S(O)Rb6 , S(O)NRc6 Rd6 , S(O) b6 , NR c6 S(O) b6 , NRc6 S(O) c6 Rd6 , and S(O) c6 Rd6 , wherein said C 2R 2NR 2NR 1-6 alkyl, C3-7 cycloalkyl, 4- 7 membered heterocycloalkyl, C6-10 aryl, and 5-6 membered heteroaryl are optionally substituted by 1, 2, or 3 tuents independently selected from halo, CN, ORa6 , SRa6 , C(O)Rb6 , C(O)NR c6 Rd6 , C(O)ORa6 , OC(O)Rb6 , OC(O)NRc6 Rd6 , NRc6 Rd6 , NRc6 C(O)R b6 , NR c6 C(O)NR c6 Rd6 , NRc6 C(O)OR a6 , C(=NRe6 )NR c6 Rd6 , NRc6 C(=NR e6 )NR c6 Rd6 , S(O)Rb6 , S(O)NR c6 Rd6 , S(O) b6 , NRc6 S(O) b6 , NRc6 S(O) c6 Rd6 , and S(O) c6 Rd6 ; 2R 2R 2NR 2NR or any Rc2 and Rd2 together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from C1-6 alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, C6-10 aryl, and 5-6 membered heteroaryl, C1-6 haloalkyl, halo, CN, ORa6 , SRa6 , C(O)Rb6 , C(O)NRc6 Rd6 , C(O)OR a6 , OC(O)Rb6 , OC(O)NRc6 Rd6 , NRc6 Rd6 , NRc6 C(O)R b6 , NRc6 C(O)NR c6 Rd6 , NR c6 C(O)OR a6 , C(=NRe6 )NR c6 Rd6 , NRc6 C(=NR e6 )NR c6 Rd6 , S(O)Rb6 , S(O)NRc6 Rd6 , S(O) b6 , NR c6 S(O) b6 , NRc6 S(O) c6 Rd6 , and S(O) c6 Rd6 , wherein said C 2R 2NR 2NR 1-6 alkyl, C3-7 cycloalkyl, 4- 7 membered cycloalkyl, C6-10 aryl, and 5-6 membered heteroaryl are optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, ORa6 , SRa6 , C(O)Rb6 , C(O)NR c6 Rd6 , C(O)ORa6 , b6 , OC(O)NRc6 Rd6 , NRc6 Rd6 , NRc6 C(O)R b6 , NR c6 C(O)NR c6 Rd6 , NRc6 C(O)OR a6 , C(=NRe6 )NR c6 Rd6 , NRc6 C(=NR e6 )NR c6 Rd6 , S(O)Rb6 , S(O)NR c6 Rd6 , S(O) b6 , NRc6 S(O) b6 , NRc6 S(O) c6 Rd6 , and S(O) c6 Rd6 ; 2R 2R 2NR 2NR or any Rc3 and Rd3 together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from C1-6 alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, C6-10 aryl, 5-6 membered heteroaryl, C1-6 haloalkyl, halo, CN, ORa6 , SRa6 , C(O)Rb6 , C(O)NRc6 Rd6 , C(O)OR a6 , OC(O)Rb6 , Rc6 Rd6 , NRc6 Rd6 , NRc6 C(O)R b6 , NRc6 C(O)NR c6 Rd6 , NR c6 C(O)OR a6 , 6 )NR c6 Rd6 , NRc6 C(=NR e6 )NR c6 Rd6 , S(O)Rb6 , S(O)NRc6 Rd6 , S(O) b6 , NR c6 S(O) b6 , NRc6 S(O) c6 Rd6 , and S(O) c6 Rd6 , wherein said C 2R 2NR 2NR 1-6 alkyl, C3-7 cycloalkyl, 4- 7 ed heterocycloalkyl, C6-10 aryl, and 5-6 membered heteroaryl are optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, ORa6 , SRa6 , C(O)Rb6 , C(O)NR c6 Rd6 , a6 , OC(O)Rb6 , OC(O)NRc6 Rd6 , NRc6Rd6 , NRc6 C(O)R b6 , NR c6 C(O)NR c6 Rd6 , NRc6 C(O)OR a6 , C(=NRe6 )NR c6 Rd6 , NRc6 C(=NR e6 )NR c6 Rd6 , S(O)Rb6 , S(O)NR c6 Rd6 , S(O) b6 , NRc6 S(O) b6 , NRc6 S(O) c6 Rd6 , and S(O) c6 Rd6 ; 2R 2R 2NR 2NR or any Rc4 and Rd4 together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from C1-6 alkyl, C3-7 cycloalkyl, 4-7 ed heterocycloalkyl, C6-10 aryl, 5-6 membered heteroaryl, C1-6 haloalkyl, halo, CN, ORa6 , SRa6 , C(O)Rb6 , C(O)NRc6 Rd6 , C(O)OR a6 , OC(O)Rb6 , OC(O)NRc6 Rd6 , NRc6 Rd6 , NRc6 C(O)R b6 , NRc6 C(O)NR c6 Rd6 , NR c6 C(O)OR a6 , C(=NRe6 )NR c6 Rd6 , NRc6 C(=NR e6 )NR c6 Rd6 , S(O)Rb6 , S(O)NRc6 Rd6 , S(O) b6 , NR c6 S(O) b6 , NRc6 S(O) c6 Rd6 , and S(O) c6 Rd6 , wherein said C 2R 2NR 2NR 1-6 alkyl, C3-7 cycloalkyl, 4- 7 membered heterocycloalkyl, C6-10 aryl, and 5-6 membered heteroaryl are optionally tuted by 1, 2, or 3 substituents independently selected from halo, CN, ORa6 , SRa6 , C(O)Rb6 , C(O)NR c6 Rd6 , C(O)ORa6 , OC(O)Rb6 , OC(O)NRc6 Rd6 , NRc6 Rd6 , NRc6 C(O)R b6 , NR c6 C(O)NR c6 Rd6 , NRc6 C(O)OR a6 , C(=NRe6 )NR c6 Rd6 , NRc6 C(=NR e6 )NR c6 Rd6 , S(O)Rb6 , S(O)NR c6 Rd6 , S(O) b6 , NRc6 S(O) b6 , NRc6 S(O) c6 Rd6 , and S(O) c6 Rd6 ; 2R 2R 2NR 2NR or any Rc5 and Rd5 together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered cycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from C1-6 alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, C6-10 aryl, 5-6 membered heteroaryl, C1-6 kyl, halo, CN, ORa6 , SRa6 , C(O)Rb6 , C(O)NRc6 Rd6 , C(O)OR a6 , OC(O)Rb6 , OC(O)NRc6 Rd6 , NRc6 Rd6 , NRc6 C(O)R b6 , NRc6 C(O)NR c6 Rd6 , NR c6 C(O)OR a6 , C(=NRe6 )NR c6 Rd6 , NRc6 C(=NR e6 )NR c6 Rd6 , S(O)Rb6 , S(O)NRc6 Rd6 , S(O) b6 , NR c6 S(O) b6 , NRc6 S(O) c6 Rd6 , and S(O) c6 Rd6 , wherein said C 2R 2NR 2NR 1-6 alkyl, C3-7 cycloalkyl, 4- 7 membered heterocycloalkyl, C6-10 aryl, and 5-6 membered heteroaryl are optionally substituted by 1, 2, or 3 tuents independently selected from halo, CN, ORa6 , SRa6 , C(O)Rb6 , C(O)NR c6 Rd6 , C(O)ORa6 , OC(O)Rb6 , OC(O)NRc6 Rd6 , NRc6 Rd6 , NRc6 C(O)Rb6 , NR c6 C(O)NR c6 Rd6 , NRc6 C(O)OR a6 , C(=NRe6 )NR c6 Rd6 , NRc6 C(=NR e6 )NR c6 Rd6 , S(O)Rb6 , S(O)NR c6 Rd6 , S(O) b6 , NRc6 S(O) b6 , NRc6 S(O) c6 Rd6 , and S(O) c6 Rd6 ; 2R 2R 2NR 2NR each Re, Re2 , Re3 , Re4 , and Re5 is independently selected from H, C1-4 alkyl, CN, ORa6 , SR b6 , S(O) b6 , C(O)Rb6 , S(O) c6 Rd6 , and C(O)NRc6 Rd6 ; 2R 2NR each Ra6 , Rb6 , Rc6 , and Rd6 is independently selected from H, C1-4 alkyl, C1-4 haloalkyl, C2-4 alkenyl, and C2-4 l, wherein said C1-4 alkyl, C2-4 alkenyl, and C2-4 alkynyl are ally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C1-4 alkyl, C1-4 alkoxy, C1-4 alkylthio, C1-4 alkylamino, di(C1-4 amino, C1-4 haloalkyl, and C1-4 haloalkoxy; or any Rc6 and Rd6 together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 tuents independently selected from OH, CN, amino, halo, C1-6 alkyl, C1-4 alkoxy, C1-4 alkylthio, C1-4 alkylamino, di(C1-4 alkyl)amino, C1-4 haloalkyl, and C1-4 haloalkoxy; and each Re6 is independently selected from H, C1-4 alkyl, and CN.
2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R2 is halo.
3. The nd of claim 1, or a pharmaceutically able salt thereof, wherein R2 is fluoro.
4. The compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein R5 is halo.
5. The compound of any one of claims 1 to 3, or a ceutically acceptable salt thereof, n R5 is fluoro.
6. The compound of any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, wherein R6 is H.
7. The compound of any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein R10 and R11 together with the carbon atom to which they are attached form a 3-, 4-, 5-, 6-, or 7-membered cycloalkyl group.
8. The compound of any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein R10 and R11 together with the carbon atom to which they are attached form a cyclopropyl group.
9. The compound of any one of claims 1 to 8, or a ceutically able salt thereof, wherein R7 and R8 are each independently selected from H, C1-6 alkyl, -C(O)RA, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, (5- 10 membered heteroaryl)-C1-4 alkyl, or (4-10 membered heterocycloalkyl)-C1-4 alkyl, wherein said C1-6 alkyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-C1-4 alkyl, and (4-10 membered heterocycloalkyl)- C1-4 alkyl are each optionally tuted with 1, 2, 3, 4, or 5 substituents ndently selected from R7a .
10. The nd of any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, wherein R7 and R8 are each independently selected from H, oxypropyl, -C(O)OCH 3, 3-fluorophenyl, cyclopropyl, cyclobutyl, 3,3-difluorocyclobutyl, cyclopentyl, cyclohexyl, 4-hydroxycyclohexyl, methyl, 1-methyl-1H-pyrazolyl, pyridinyl, N- methylpiperidinyl, tetrahydro-2H-pyranyl, tetrahydrofuranyl, ylethyl, (1-methyl- 1H-pyrazolyl)methyl, 2-morpholinoylethyl, pyridinylmethyl, N-methylpiperazin ylethyl, and tetrahydrofuranylmethyl.
11. The compound of any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, wherein one of R7 and R8 is H.
12. The compound of any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, wherein R7 and R8 are each H.
13. The compound of claim 1 selected from: 2'-(2,6-difluoro-3,5-dimethoxyphenyl)-6'-[(2-morpholinylethyl)amino]-1',2'-dihydro- 3' H-spiro[cyclopropane-1,4'-[2,7]naphthyridin]-3'-one; 6'-amino-2'-(2,6-difluoro-3,5-dimethoxyphenyl)-1' H-spiro[cyclopropane-1,4'- [2,7]naphthyridin]-3'(2' ; 2'-(2,6-difluoro-3,5-dimethoxyphenyl)-6'-(methylamino)-1',2'-dihydro-3' H- spiro[cyclopropane-1,4'-[2,7]naphthyridin]-3'-one; 2'-(2,6-difluoro-3,5-dimethoxyphenyl)-6'-(tetrahydro-2H-pyranylamino)-1',2'-dihydro- 3' H-spiro[cyclopropane-1,4'-[2,7]naphthyridin]-3'-one; (S)-2'-(2,6-difluoro-3,5-dimethoxyphenyl)-6'-(2-hydroxypropylamino)-1' H- spiro[cyclopropane-1,4'-[2,7]naphthyridin]-3'(2' H)-one; 2'-(2,6-difluoro-3,5-dimethoxyphenyl)-6'-(pyridinylmethylamino)-1' H- cyclopropane-1,4'-[2,7]naphthyridin]-3'(2' H)-one; (S)-2'-(2,6-difluoro-3,5-dimethoxyphenyl)-6'-(tetrahydrofuranylamino)-1' H- spiro[cyclopropane-1,4'-[2,7]naphthyridin]-3'(2' H)-one; 2'-(2,6-difluoro-3,5-dimethoxyphenyl)-6'-(2-(4-methylpiperazinyl)ethylamino)-1' H- spiro[cyclopropane-1,4'-[2,7]naphthyridin]-3'(2' ; methyl 2'-(2,6-difluoro-3,5-dimethoxyphenyl)-3'-oxo-2',3'-dihydro-1' H- spiro[cyclopropane- 2,7]naphthyridine]-6'-ylcarbamate; 2'-(2,6-difluoro-3,5-dimethoxyphenyl)-6'-(pyridinylamino)-1' H-spiro[cyclopropane- 1,4'-[2,7]naphthyridin]-3'(2' H)-one; 2'-(2,6-difluoro-3,5-dimethoxyphenyl)-6'-(3-fluorophenylamino)-1' H- spiro[cyclopropane-1,4'-[2,7]naphthyridin]-3'(2'H)-one; 6'-(cyclopentylamino)-2'-(2,6-difluoro-3,5-dimethoxyphenyl)-1'H-spiro[cyclopropane- 1,4'-[2,7]naphthyridin]-3'(2' H)-one; -(2,6-difluoro-3,5-dimethoxyphenyl)-6'-((tetrahydrofuranyl)methylamino)-1' H- spiro[cyclopropane-1,4'-[2,7]naphthyridin]-3'(2' H)-one; 6-difluoro-3,5-dimethoxyphenyl)-6'-(1-methyl-1H-pyrazolylamino)-1'H- spiro[cyclopropane-1,4'-[2,7]naphthyridin]-3'(2'H)-one; 2'-(2,6-difluoro-3,5-dimethoxyphenyl)-6'-((1-methyl-1H-pyrazolyl)methylamino)-1'H- spiro[cyclopropane-1,4'-[2,7]naphthyridin]-3'(2'H)-one; (R)-2'-(2,6-difluoro-3,5-dimethoxyphenyl)-6'-(1-phenylethylamino)-1'H- spiro[cyclopropane-1,4'-[2,7]naphthyridin]-3'(2'H)-one; clohexylamino)-2'-(2,6-difluoro-3,5-dimethoxyphenyl)-1'H-spiro[cyclopropane- 1,4'-[2,7]naphthyridin]-3'(2'H)-one; 2'-(2,6-difluoro-3,5-dimethoxyphenyl)-6'-(trans hydroxycyclohexylamino)-1'H- spiro[cyclopropane-1,4'-[2,7]naphthyridin]-3'(2'H)-one; 6'-(cyclopropylamino)-2'-(2,6-difluoro-3,5-dimethoxyphenyl)-1'H-spiro[cyclopropane- 1,4'-[2,7]naphthyridin]-3'(2'H)-one; 6'-(cyclobutylamino)-2'-(2,6-difluoro-3,5-dimethoxyphenyl)-1'H-spiro[cyclopropane- 1,4'-[2,7]naphthyridin]-3'(2'H)-one; 2'-(2,6-difluoro-3,5-dimethoxyphenyl)-6'-(3,3-difluorocyclobutylamino)-1'H- spiro[cyclopropane-1,4'-[2,7]naphthyridin]-3'(2'H)-one; and 2'-(2,6-difluoro-3,5-dimethoxyphenyl)-6'-(1-methylpiperidinylamino)-1'H- spiro[cyclopropane-1,4'-[2,7]naphthyridin]-3'(2'H)-one, or a pharmaceutically acceptable salt of any of the aforementioned.
14. The compound of claim 1, wherein the compound is 2'-(2,6-difluoro-3,5- dimethoxyphenyl)-6'-[(2-morpholinylethyl)amino]-1',2'-dihydro-3' H-spiro[cyclopropane-1,4'- [2,7]naphthyridin]-3'-one, or a pharmaceutically acceptable salt thereof.
15. The compound of claim 1, wherein the nd is 2'-(2,6-difluoro-3,5- dimethoxyphenyl)-6'-(2-(4-methylpiperazinyl)ethylamino)-1' H-spiro[cyclopropane-1,4'- [2,7]naphthyridin]-3'(2' H)-one, or a pharmaceutically able salt thereof.
16. The compound of claim 1, wherein the compound is (S)-2'-(2,6-difluoro-3,5- dimethoxyphenyl)-6'-((tetrahydrofuranyl)methylamino)-1' H-spiro[cyclopropane-1,4'- [2,7]naphthyridin]-3'(2' H)-one, or a pharmaceutically acceptable salt thereof.
17. A pharmaceutical composition comprising a compound of any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
18. Use of a compound of any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for ting an FGFR enzyme.
19. Use of a compound of any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of cancer in a patient.
20. The use of claim 19 wherein said cancer is selected from r cancer, breast cancer, cervical cancer, colorectal cancer, endometrial cancer, gastric cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, prostate cancer, esophageal cancer, gall bladder cancer, pancreatic cancer, thyroid cancer, skin cancer. leukemia, multiple a, chronic lymphocytic lymphoma, adult T cell leukemia, B-cell lymphoma, acute myelogenous leukemia, Hodgkin’s or non-Hodgkin’s ma, Waldenstrom's Macroglubulinemia, hairy cell lymphoma, t's lymphoma, glioblastoma, ma, and rhabdosarcoma.
21. Use of a compound of any one of claims 1 to 16, or a pharmaceutically acceptable salt f, in the manufacture of a ment for the treatment of a myeloproliferative disorder in a t.
22. The use of claim 21 wherein said myeloproliferative disorder is selected from polycythemia vera, ial thrombocythemia, and primary myelofibrosis.
23. Use of a nd of any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a skeletal or chondrocyte disorder in a patient.
24. The use of claim 23 n said skeletal or chondrocyte disorder is selected from achrondroplasia, hypochondroplasia, dwarfism, ophoric dysplasia (TD), Apert syndrome, Crouzon syndrome, Jackson-Weiss syndrome, Beare-Stevenson cutis gyrate syndrome, Pfeiffer syndrome, and craniosynostosis syndrome.
25. Use of a compound of any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, in the manufacture of a ment for the treatment of a hypophosphatemia disorder in a t.
26. The use of claim 25 wherein said hypophosphatemia disorder is X-linked hypophosphatemic rickets, autosomal recessive hypophosphatemic rickets, autosomal dominant hypophosphatemic rickets, or tumor-induced osteromalacia.
NZ713074A 2013-04-19 2014-04-18 Bicyclic heterocycles as fgfr inhibitors NZ713074B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ752422A NZ752422B2 (en) 2013-04-19 2014-04-18 Bicyclic heterocycles as fgfr inhibitors

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361813782P 2013-04-19 2013-04-19
US61/813,782 2013-04-19
PCT/US2014/034662 WO2014172644A2 (en) 2013-04-19 2014-04-18 Bicyclic heterocycles as fgfr inhibitors

Publications (2)

Publication Number Publication Date
NZ713074A NZ713074A (en) 2020-09-25
NZ713074B2 true NZ713074B2 (en) 2021-01-06

Family

ID=

Similar Documents

Publication Publication Date Title
AU2020250201B2 (en) Bicyclic heterocycles as fgfr inhibitors
US11667635B2 (en) Bicyclic heterocycles as FGFR4 inhibitors
WO2016064960A1 (en) Bicyclic heterocycles as fgfr4 inhibitors
NZ713074B2 (en) Bicyclic heterocycles as fgfr inhibitors
NZ752422B2 (en) Bicyclic heterocycles as fgfr inhibitors